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Abstract
Chronic oxidative stress and oxidative damage has become one of the most convincing 
theories in ageing pathology. NADPH oxidase 2 (Nox2) is a reactive oxygen species 
(ROS) generating enzyme expressed constitutively in the vasculature and the central 
nervous system, however the role of this enzyme in ageing-related cardiovascular 
dysfunction and neurodegenerative diseases remains unclear. Therefore, the overall 
aim of this PhD research project is to investigate the role of Nox2-induced oxidative 
stress in ageing-associated metabolic syndrome, endothelial dysfunction and 
neurodegeneration using age-matched littermates of wild-type (WT) versus Nox2 null 
(Nox2‘^  ) mice on a C57BI/6 background at young (3-4 months), middle aged (10-12 
months) and ageing (20-22  months).
Compared to young mice, there were ageing-related increases in bodyweight and 
fasting insulin levels along with impaired glucose tolerance, hyperlipidaemia and 
hypertension in WT ageing mice (p<0.05). These metabolic syndrome risk factors were 
accompanied by significant increases in aortic ROS production and Nox2 expression 
and a significant decrease in the endothelium-dependent relaxation to acetylcholine 
(Emax 75 % for young and 64 % for ageing, p<0.05). ). However, all these ageing- 
related metabolic and endothelial abnormalities were significantly reduced in Nox2'^' 
ageing mice. We then examined the role of Nox2 in ageing-related neurodegeneration 
and found that compared to young mice, there was a significantly reduced locomotor 
activity and dopaminergic neuron firing frequency accompanied by increased brain 
ROS production in WT but not in Nox2'^' mouse brain. Ageing-associated increases in 
brain ROS production was further confirmed using human post-mortem brain tissues.
In conclusion, Nox2-derived oxidative stress plays an important role in ageing- 
associated metabolic syndrome, vascular dysfunction, and neurodegeneration. 
Targeting Nox2 represents a valuable therapeutic strategy to treat these ageing- 
related diseases.
11
Published Abstracts
1. S Cahill-Smith, JM Li, A crucial role of Nox2-derived oxidative stress in ageing- 
associated metabolic disorders and vascular dysfunction. Heart, 99, A98, 2013
2. S Cahill-Smith, JM Li, Oxidative stress and vascular dysfunction in ageing: The role of 
Nox2, Proceedings o f the British Pharmacological Society, 2012
3. S Cahill-Smith, JM Li, Cardiovascular oxidative stress, insulin resistance and lipid 
metabolic disorders in ageing. Heart, 98, AS, 2012
4. S Cahill-Smith, JM Li, The role of reactive oxygen species and oxidative stress in the 
development of endothelial dysfunction and hypertension in the ageing vasculature. 
Proceedings of the British Pharmacological Society, 2011
5. S Cahill-Smith, JM Li, The role of oxidative stress in the development of endothelial 
dysfunction and hypertension in ageing. Heart, 97, e8 , 2011
111
Conference Presentations
Oral Presentations
1.17^^ Annual ECCR M eeting, Nice, France, October 2013
The role o f  Nox2-derived oxidative stress in ageing-associated m etabolic  
disorders and vascular dysfunction -  Young Investigator Prize Winner
2. University o f Surrey Postgraduate Research Conference, Guildford, February 2012
Oxidative stress, vascular dysfunction and ageing
Poster Presentations
1. University o f Surrey FHMS Festival o f Research, Guildford, July 2013
A crucial role o f Nox2-derived oxidative stress in ageing-associated m etabolic  
disorders and vascular dysfunction
2. BAS/BCS/BSCR Joint Spring M eeting, London, June 2013
A crucial role o f Nox2-derived oxidative stress in ageing-associated m etabolic  
disorders and vascular dysfunction
3. BPS W inte r M eeting, London, December 2012
Oxidative stress and vascular dysfunction in ageing: The role o f  Nox2
4. University o f Surrey FHMS Festival o f Research, Guildford, July 2012
Cardiovascular oxidative stress, insulin resistance and lip id  m etabolic disorders 
in ageing
5. BAS/BCS/BSCR Joint Spring Meeting, Manchester, May 2012
Cardiovascular oxidative stress, insulin resistance and lip id  m etabolic disorders 
in ageing
6. BPS W in te r M eeting, London, December 2011
The role o f reactive oxygen species and oxidative stress in the developm ent o f  
endothelia l dysfunction and hypertension in the ageing vasculature
7. Research in to Ageing Grantholders' Conference, Nottingham , September 2011
The role o f oxidative stress in the development o f endothelia l dysfunction and  
hypertension in ageing
8. BSCR Autum n M eeting, London, September 2011
The role o f  oxidative stress in the development o f endothelia l dysfunction and  
hypertension in ageing
IV
Contents
Acknowledgements.................................................................................................................. i
Abstract.......................................................................................................................................ii
Published abstracts.................................................................................................................. iii
Conference presentations................................................................................................ ...... iv
Contents..................................................................................................................................... v
List of abbreviations................................................................................................................ xi
List of figures............................................................................................................................. xiv
List of tables.............................................................................................................................. xvii
Chapter 1 General introduction
1.1 Ageing and ageing-related diseases............................................................................. 1
1.1.1 Cardiovascular disease and ageing......................................................................1
1.1.2 Neurodegenerative diseases and ageing.......................................................... 2
1.1.3 Ageing population...................................................................................................2
1.1.4 Theories of ageing.................................................................................. ................. 3
1.1.5 Free radical theory of ageing............................................................................... 4
1.2 Reactive oxygen species (ROS)...................................................................................... 5
1.2.1 Species of ROS..........................................................................................................5
1.2.2 Sources of ROS.........................................................................................................7
1.2.3 Mitochondria............................................................................................................ 7
1.2.4 Xanthine oxidase..................................................................................................... 9
1.2.5 Nitric oxide synthase.............................................................................................. 10
V
1.2.6 NADPH oxidases  ............................................................................................ 12
1.2.7 Structure of NADPH oxidase.................................................................................. 13
1.2.8 gp91^^°^ homologues and their expression........................................................15
1.2.9 Mechanism of activation of NADPH oxidase......................................................18
1.2.9.1 Nox2...................................................................................................... 18
1.2.9.2 Nox2 homologues..............................................................................21
1.3 Role of ROS in physiology and pathology..................................................................... 22
1.3.1 Host defence..............................................................................................................22
1.3.2 Signalling pathways..................................................................................................23
1.3.3 Regulation of vascular tone....................................................................................23
1.3.4 Oxidative damage.....................................................................................................24
1.3.5 Redox homeostasis and antioxidants..................................................................25
1.4 Ageing-related oxidative stress and metabolic syndrome........................................26
1.4.1 Obesity and hyperlipidaemia.................................................   27
1.4.2 Hyperglycaemia and insulin resistance............................................................... 28
1.4.3 Hypertension..........................................................................  29
1.5 Ageing-related oxidative stress and vascular dysfunction........................................31
1.5.1 Endothelial dysfunction..............................................................   31
1.5.2 Arterial stiffness....................................................................................................... 32
1.6 Ageing-related oxidative stress and neurodegeneration.......................................... 33
1.6.1 Dopamine in the ageing brain.............................................................................34
1.7 Understanding and ameliorating ageing-related oxidative stress.......................... 34
1.8 Hypothesis and aim................   35
VI
Chapter 2 Materials and methods
2.1 Animals.................................................................................................................................. 37
2.2 Human tissue....................................................................................................................... 38
2.3 Genotyping........................................................................................................................... 38
2.4 Food intake and bodyweight measurement................................................................41
2.5 Tail-cuff blood pressure measurement............................................ ,........................... 42
2.6 Locomotor activity measurement.................................................................................. 43
2.7 Fasting glucose and intraperitoneal glucose tolerance test (IPGTT)......................44
2.8 Euthanasia and tissue collection.....................................................................................45
2.9 Separation of blood............................................................................................................46
2.10 Ex-vivo assessment of vascular function.................................................................... 46
2.11 Neuron firing by extracellular electrophysiology......................................................52
2.12 Insulin ELISA...................................................................................................................... 57
2.13 Lipid measurement..........................................................................................................58
2.14 Griess assay to detect nitric oxide.....................   58
2.15 Preparation of aorta for sectioning............................................................................. 59
2.16 Preparation of aorta and brain homogenates.......................................................... 59
2.17 Bradford protein assay.................................................................................................... 59
2.18 Lucigenin chemiluminescence assay for detection of superoxide....................... 60
2.19 DHE staining for detection of superoxide................................................................... 61
2.20 Western blotting...................................................   62
2.21 Immunofluorescence.......................................................................................................66
2.22 Verhoeff-Van Gieson Staining....................................................................................... 68
Vll
2.23 Statistics..............................................................................................................................68
2.24 Appendix table I: Details of materials and reagents................................................ 70
Chapter 3 The role of Nox2 in the development of metabolic syndrome with ageing
3.1 Introduction......................................................................................................................... 73
3.1.1 Aims and objectives.................................................................................................75
3.2 Results................................................................................................................................ 76
3.2.1 The effect of ageing on food intake, bodyweight and fat weight and the 
role of Nox2..........................................................................................................................76
3.2.2 The effect of ageing on glucose and insulin levels and the role of Nox2„. 80
3.2.3 The effect of ageing on glucose tolerance and the role of Nox2.................83
3.2.4 The effect of ageing on cholesterol levels and the role of Nox2.................86
3.2.5 The effect of ageing on non-esterified fatty acid and triglyceride levels and 
the role of Nox2................................................................................ ..................................89
3.2.6 The effect of ageing on blood pressure and the role of Nox2.......................92
3.3 Discussion..............................................................................................................................95
Chapter 4 The roie of Nox2-derived oxidative stress in ageing-reiated vascuiar 
dysfunction
4.1 Introduction.................................................... .................................................................... 98
4.1.1 Aims and objectives.................................................................................................100
4.2 Results....................................................................................................................................101
4.2.1 The role of Nox2 on vascular function in young mice....................................101
4.2.2 The role of Nox2 on vascular function in middle aged mice.........................104
viii
4.2.3 The role of Nox2 on vascular function in ageing mice.....................................107
4.2.4 The effect of ageing on vascular function in WT and Nox2'^' mice...............110
4.2.5 The effect of L-NAME on vascular relaxation with ageing in WT mice 114
4.2.6 The effect of L-NAME on vascular relaxation with ageing in Nox2‘ “^ mice 117
4.2.7 The effect of ageing and the role of Nox2 on aortic ROS production detected 
by DHE fluorescence...........................................................................................................120
4.2.8 The effect of ageing and the role of Nox2 on aortic ROS production detected 
by lucigenin chemiluminescence.....................................................................................123
4.2.9 The effect of ageing on Nox2 expression in the aorta detected by 
immunofluorescence and western blotting.................................................................128
4.2.10 The effect of ageing and the role of Nox2 on nitric oxide levels..................131
4.2.11 The effect of ageing on the morphology of the aorta.................................... 132
4.3 Discussion............................................................................................................................133
Chapter 5 The effect of ageing and the role of Nox2-derived oxidative stress on 
locomotor activity and dopaminergic neuron firing
5.1 Introduction..........................................................................................................................138
5.1.1 Aims and objectives.................................................................................................140
5.2 Results....................................................................................................................................141
5.2.1 The role of Nox2 on diurnal horizontal activity with ageing.......................... 141
5.2.2 The role of Nox2 on diurnal vertical activity with ageing................................144
5.2.3 The role of Nox2 on total horizontal and vertical activities with ageing ...147
5.2.4 The effect of ageing and the role of Nox2 on brain weight........................... 150
5.2.5 The role of Nox2 on firing of dopaminergic neurons with ageing................ 151
ix
5.2.6 The role of Nox2 on ROS production in the ageing brain detected by lucigenin 
chemiluminescence............................................................................................................154
5.2.7 The role of Nox2 on ROS production in the ageing human brain detected by
lucigenin chemiluminescence.......................................................................................... 159
5.3 Discussion............................................................................................................................162
Chapter 5 General discussion and future work
6.1 Discussion..............................................................................................................................166
6.2 Future work......................................................................................................................... 172
References ...........................................................................................................................173
X
List of abbreviations
8-OHdg 8 -hydroxyguanine
ACh Acetylcholine
aCSF Artificial cerebrospinal fluid
AGE Advanced glycation end product
AMPA 2-amino-3-(3-hydroxy-5-methyl-isoxazol-4-yl)propanoic acid
ANOVA Analysis of variance
ATP Adenosine triphosphate
BH4 Tetrahydrobiopterin
BSA Bovine serum albumin
CGD Chronic granulomatous disease
CHD Coronary heart disease
CVD Cardiovascular disease
DA Dopamine
DBP Diastolic blood pressure
DHE Dihydroethidium
DPI Diphenyleneiodonium
ELISA Enzyme-linked immunosorbent assay
Emax Maximum vessel relaxation
eNOS Endothelium nitric oxide synthase
FAD Flavin adenine dinucleotide
H2O2 Hydrogen peroxide
HBSS Hanks' balanced salt solution
XI
HDL High-density lipoprotein
HOCI Hypochlorous acid
iNOS Inducible nitric oxide synthase
IPGTT Intraperitoneal glucose tolerance test
LDL Low-density lipoprotein
L-NAME Nw-Nitro-L-arginine methyl ester
MLU Mean light unit
NADPH Nicotinamide adenine dinucleotide phosphate
NEFA Non-esterified fatty acids
nNOS Neuronal nitric oxide synthase
NO Nitric oxide
NOS Nitric oxide synthase
Nox NADPH oxidase
Nox2'/' Nox2 null
O2 Superoxide
OCT Optimum cutting temperature compound
OH Hydroxyl radical
ONOO Peroxynitrite
Oxy Oxypurinol
PBl Phox and Beml
PBS Phosphate buffered saline
PCR Polymerase chain reaction
PE Phenylephrine
PVDF Polyvinylidene difluoride
Xll
PX Phox homology
ROS Reactive oxygen species
SBP Systolic blood pressure
SH3 Src homology 3
SN Substantia nigra
SNP Sodium nitroprusside
SOD Superoxide dismutase
TAE Tris-acetate EDTA
TAG Triglycerides
TBS Tris-buffered saline
TBST Tris-buffered saline with Tween
TChol Total cholesterol
TMB 3,3',5,5'-tetramethylbenzidine
TPR Tetratricopeptide repeat
VPR Volume-pressure recording
VTA Ventral tegmental area
WT Wild-type
XDH Xanthine dehydrogenase
XO Xanthine oxidase
XOR Xanthine oxidoreductase
X lll
List of figures
Figure 1.1 Young and ageing population statistics in the UK..........................................3
Figure 1.2 Schematic of the electron transport chain.................................................... 8
Figure 1.3 Oxidation of hypoxanthine to uric acid via xanthine.................................... 10
Figure 1.4 The nitric oxide synthase reaction.................................................................... 11
Figure 1.5 Structure of gp91^^° .^.............................................................................................14
Figure 1.6 Schematic representation of the activated Nox2 enzyme complex 19
Figure 1.7 Schematic representation of the activation of the Nox2 enzyme and
subsequent superoxide production utilising NADPH as an electron donor................ 20
Figure 2.1 Representative image of an electrophoresis gel............................................41
Figure 2.2 Equipment for blood pressure measurement and illustration of how the
mice were restrained...............................................   43
Figure 2.3 Motility chamber used for measuring locomotor activity in mice 44
Figure 2.4 Schematic diagram showing rings cut from the thoracic aorta and
suspended in an organ bath.........................................................   48
Figure 2.5 Representative image of the response of an aortic ring to KCI followed by
a series of washes...................................................................................................................... 49
Figure 2.6 Representative image of the response of an aortic ring to increasing
concentrations of phenylephrine (PE)..................................................................................50
Figure 2.7 Representative images of the response of an aortic ring to increasing 
concentrations of acetylcholine (Ach) or sodium nitroprusside (SNP) after pre­
contraction with phenylephrine (PE)..................................................................   51
Figure 2.8 Preparation of the brain for extracellular electrophysiology......................54
XIV
Figure 2.9 Image of the electrophysiology setup with a close up view of a coronal
section in the recording chamber perfused with oxygenated aCSF..............................55
Figure 2.10 Representative image of the recording of a neuron firing under basal
conditions and in response to AMPA or dopamine stimulation.................................... 57
Figure 3.1 The effect of ageing on food intake, bodyweight and fat weight in WT
and Nox2'^' mice......................................................................................................................... 78
Figure 3.2 The effect of ageing on glucose and insulin levels in WT and Nox2'' ‘^
mice.............................................................................................................................................. 81
Figure 3.3 The effect of ageing on glucose tolerance in WT and Nox2‘'^ ' mice...........84
Figure 3.4 The effect of ageing on cholesterol in WT and Nox2'^' mice.......................87
Figure 3.5 The effect of ageing on non-esterified fatty acid and triglyceride levels in
WT and Nox2'^' mice..................................................................................................................90
Figure 3.6 The effect of ageing on blood pressure in WT and Nox2" ‘^ mice................ 93
Figure 4.1 The role of Nox2 on vascular function in young mice..............................102
Figure 4.2 The role of Nox2 on vascular function in middle aged mice........................ 105
Figure 4.3 The role of Nox2 on vascular function in ageing mice............................. 108
Figure 4.4 The effect of ageing on vascular function in WT and Nox2'^' mice............ I l l
Figure 4.5 The effect of L-NAME on vascular relaxation with ageing in WT mice..... 115
Figure 4.6 The effect of L-NAME on vascular relaxation with ageing in Nox2" "^
mice.......................................................................................... ...................................................118
Figure 4.7 The effect of ageing and the role of Nox2 on aortic ROS production
detected by DHE fluorescence...............  121
Figure 4.8 The effect of ageing and the role of Nox2 on aortic superoxide production
detected by lucigenin chemiluminescence..........................................................................125
XV
Figure 4.9 The effect of ageing on Nox2 expression in the aorta detected by
immunofluorescence and western blotting........................................................................129
Figure 4.10 The effect of ageing and the role of Nox2 on nitric oxide levels 131
Figure 4.11 The effect of ageing on the morphology of the aorta.................................132
Figure 5.1 The role of Nox2 on diurnal horizontal activity with ageing...................   141
Figure 5.2 The role of Nox2 on diurnal vertical activity with ageing......................  144
Figure 5.3 The role of Nox2 on total horizontal and vertical activity with
ageing.......................................................................................................  147
Figure 5.4 The effect of ageing and the role of Nox2 on brain weight......................... 149
Figure 5.5 The role of Nox2 on firing of dopaminergic neurons with ageing............. 151
Figure 5.6 The role of Nox2 on ROS production in the mouse brain at different ages
detected by lucigenin chemiluminescence .......................................  155
Figure 5.7 The role of Nox2 on ROS production in the human brain at different ages 
detected by lucigenin chemiluminescence ............................................................ ....... 159
XVI
List of tables
Table 1.1 Location, length, sequence identity and tissue expression of the seven
NADPH oxidase isoforms................  17
Table 2.1 Tail lysis buffer.........................................................................................................39
Table 2.2 Sequence of primers for PCR................................................................................ 39
Table 2.3 PCR mix......................................................................................................................40
Table 2.4 Thermal cycling parameters for PCR...................................................................40
Table 2.5 Krebs-Henseleit Buffer.......................................................................................... 47
Table 2.6 Concentrations of PE and ACh doses..................................................................49
Table 2.7 Concentrations of SNP doses................................................................................51
Table 2.8 Sucrose Buffer............................................  .53
Table 2.9 Artificial cerebrospinal fluid (aCSF).....................................................................54
Table 2.10 3X Sample Buffer.................................................................................................. 63
Table 2.11 Gel and buffer recipes..........................................................................................63
Table 2.12 TBS and PBS buffer recipes................................................................................ 65
Table 2.13 List of antibodies used in western blotting.....................................................65
Table 2.14 List of antibodies used in immunofluorescence ................................... 67
Table 2.15 Verhoeff and Van Gieson solutions  68
xvii
Chapter 1 
General Introduction
1.1 Ageing and ageing-related diseases
The mean longevity of humans has increased significantly during the 20*  ^century from 
approximately 33 years to approximately 80 years and can be attributable to a 
decrease in infant mortality, discovery of vaccines and antibiotics, improved nutrition 
and improved hygiene (Vina et al., 2007). The consequence of this improved longevity 
is that we now have an increasingly ageing population with the prevalence of ageing- 
related diseases such as cardiovascular and neurodegenerative diseases increasing.
1.1.1 Cardiovascular disease and ageing
Cardiovascular diseases (CVD) are the leading cause of death globally, and in Europe 
alone CVD are responsible for over 4.3 million deaths each year, which is almost half 
(48%) of all deaths (Rayner et al., 2009). The two main causes are coronary heart 
disease (CHD) and stroke which are responsible for 1.92 million and 1.24 million deaths 
respectively each year in Europe (Rayner et al., 2009). Worldwide an estimated 17.3 
million people died from CVD in 2008 with 7.3 million due to CHD and 6.2 million due 
to stroke (WHO, 2013a).The number of deaths worldwide due to CVD is expected to 
increase to a staggering 23.3 million deaths by 2030 (WHO, 2013a). The burden of CVD 
can be measured not only in terms of mortality but also in terms of cost to society. The 
total cost of CVD to the UK is an estimated £30 billion with 60 % due to health-care 
costs alone (Scarborough et al., 2011).
1.1.2 Neurodegenerative diseases and ageing
Neurodegenerative diseases are a group of diseases characterised by the progressive 
loss of structure and function of neurons leading to dysfunction of the central nervous 
system and include Alzheimer's disease and Parkinson's disease. Alzheimer's disease is 
the most common form of dementia and makes up 62 % of all cases (AgeUK, 2013). 
Dementia is one of the main causes of disability in later life and affects 1 in 6 people 
over the age of 80 with an estimated 36 million people affected worldwide (AgeUK, 
2013). This figure is expected to increase to 65.7 million by 2030 and to 115.4 million 
by 2050 (WHO, 2012). Parkinson's disease is another age-related neurodegenerative 
disorder and is estimated to affect 7 to 10 million people worldwide (Parkinson's 
Disease Foundation, 2013). The annual UK economic burden to society is estimated to 
be between £449 million and £3.3 billion for Parkinson's disease and £23 billion for 
Alzheimer's Disease (AgeUK, 2013; Findley, 2007).
1.1.3 Ageing population
Ageing is a major risk factor for both cardiovascular and neurodegenerative diseases 
and prevalence of these disease increases enormously with age. Currently the ageing 
population in the UK is rapidly increasing which in turn is increasing the burden of 
these age-related diseases. In 1971 the percentage of the population over 65 years of 
age was 13.2%, whereas in 2009 the figure had risen to 16.3% with projected figures 
for 2031 reaching as high as 22.3%, see figure 1.1 (ONS, 2011). Not only is the ageing 
population increasing but the young population is decreasing; in 1971 the percentage
of the population under 16 years of age was 25.5%, in 2009 the figure was 18.7% and 
the projected figure for 2031 is 18% (ONS, 2011).
30
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Figure 1.1 Young and ageing population statistics in the UK: estimates (1971-2009) and 
projections (2011-2031). Data from office for National Statistics (ONS, 2011)
1.1.4 Theories of ageing
There are many theories of ageing and generally they fall into two main subgroups, 
either programmed theories or damage-based theories. The programmed theories 
suggest that ageing is predetermined and follows an intrinsic biological clock whereas 
damage-based theories suggest that damage accumulates throughout the lifespan 
causing ageing (Jin, 2010). The shortening of telomeres is a popular programmed 
theory of ageing which proposes that telomeres, which are DNA sequences located at 
the ends of chromosomes, get gradually shorter with every cell division until 
eventually the cell can no longer proliferate and becomes senescent (Takahashi et al., 
2000). Another programme based ageing theory that has attracted a lot of attention is 
the developmental-genetic theory which postulates that there are specific ageing-
3
related genes that play a major role in ageing and longevity such as klotho (Kuro-o et 
al., 1997), sirtuins (Kanfi et al., 2012), mTOR (Johnson et al., 2013; Passtoors et al., 
2013), p6 6 Shc (Tomilov et al., 2010; Trinei et al., 2009), Foxos (Wilicox et al., 2008) and 
heat shock proteins (Tower, 2009). However one of the most prominent and well 
established theories of ageing is the damage-based free radical theory of ageing which 
has extensive experimental support and has been a popular theory of ageing for over 
50 years.
1.1.5 Free radical theory of ageing
In 1956 Denham Harman proposed the free radical theory of ageing which suggested 
that accumulation of free radical-induced oxidative damage to biomolecules such as 
lipids, proteins and DNA results in organismal ageing (Harman, 1956). This theory has 
over the years been expanded to an oxidative stress theory of ageing as it is not only 
free radicals that can cause oxidative damage but also other reactive oxygen species 
(ROS) such as hydrogen peroxide and peroxynitrite. This oxidative damage results in a 
progressive loss in biological function leading to an ageing phenotype. There is 
extensive experimental evidence in support of the oxidative stress theory of ageing 
and numerous studies have found increases in ROS with ageing in various organ tissues 
especially in the cardiovascular and central nervous systems (Oudot et al., 2006; Quick 
et al., 2008; Rodriguez-Mafias et al., 2009; Sasaki et al., 2008). An increase in biological 
markers of oxidative stress have also been seen with ageing in both humans and in 
animal models including protein carbonyls to detect protein oxidation (Smith et al., 
1991; Wu et al., 2007), malondialdehyde to detect lipid peroxidation (Dei et al., 2002;
Inal et al., 2001) and 8 -hydroxyguanine (8 -OHdg) to detect DNA oxidation (Clausen et 
al., 2 0 1 0 ).
The oxidative stress theory can be linked to other theories of ageing and in many long- 
lived animal models reduced oxidative stress has been strongly correlated with 
increased longevity. In the widely used caloric restriction method to improve longevity 
caloric restriction was found to be correlated with reduced oxidative stress in both 
animals and humans (Buchowski et al., 2012; Qiu et al., 2010). In another longevity 
model, the extended lifespan of mice with deletion of the p6 6 Shc gene has also been 
seen to be related to reduced levels of oxidative stress (Tomilov et al., 2010). In 
relation to the telomere theory of ageing a very strong correlation has been found 
between oxidative stress and telomere shortening in human and sheep fibroblasts 
(Richter and Zglinicki, 2007). This supports that the oxidative stress theory of ageing is 
a sound theory not just by itself but also as a key to linking together several other 
theories and mechanisms of ageing.
1.2 Reactive oxygen species (ROS)
1.2.1 Species of ROS
Reactive oxygen species (ROS) are highly reactive oxygen containing molecules and 
include both free radicals e.g. superoxide (O2 '), and the hydroxyl radical (OH ) as well 
as non-radicals e.g. hydrogen peroxide (H2O2). ROS can be produced by a number of 
different means including, mitochondria (Starkov, 2008), uncoupled NO synthases 
(Porasuphatana et al., 2003), xanthine oxidases (Kelley et al., 2010), and most 
importantly NADPH oxidases (Grandes et al., 2010). The primary function of NADPH
oxidases is the production of ROS, which is quite unique as all other methods produce 
ROS only as a by-product. Superoxide is considered as the 'primary' ROS and can react 
with several different molecules to form other reactive oxygen species such as 
hydrogen peroxide (H2O2), the hydroxyl radical (OH ), hypochlorous acid (HOCI) and 
peroxynitrite (ONOO ).
Superoxide can be dismutated to hydrogen peroxide by the enzyme superoxide 
dismutase (SOD) following the reaction 2 O2 ' + 2H^ H2O2 + O2. Hydrogen peroxide 
can then be removed by catalase which converts hydrogen peroxide to water and 
oxygen (2 H2O2 2 H2O + O2) or by glutathione peroxidase which converts hydrogen 
peroxide to water during oxidation of the tripeptide glutathione (GSH) (2GSH + H2O2 
GSSG + 2 H2O) (Valko et al., 2006). The hydroxyl radical can be created from hydrogen 
peroxide by either the Fenton reaction (Fe^  ^ + H2O2 ^  Fe^^  + OH + OH ) or by the 
Haber-Weiss reaction which combines the Fenton reaction with the reduction of Fe^  ^
by superoxide (Fe^  ^+ O2 ' "> Fe^^  + O2) to give the overall reaction O2 ' + H2O2 - > 0 2  + 
OH + OH' (Fenton, 1894; Haber and Weiss, 1934). Hypochlorous acid (HOCI) is created 
by a haem protein released by phagocytes called myeloperoxidase by using hydrogen 
peroxide to oxidize chloride (H2O2 + Cl' + H  ^ ^  HOCI + H2O) (Bergt et al., 2004). 
Peroxynitrite is formed from the reaction between superoxide and nitric oxide (O2 ' + 
NO "> ONOO ), which is 6 times faster than the dismutation of superoxide by SOD 
(Guzik et al., 2002).
1.2.2 Sources of ROS
NADPH oxidases are arguably one of the major sources of ROS however there are also 
several other mechanisms that produce ROS as a by-product. These include 
mitochondria, xanthine oxidase and nitric oxide synthases, which are discussed in 
more detail below.
1.2.3 Mitochondria
Oxidative phosphorylation occurs in the mitochondria to produce energy in the form of 
adenosine triphosphate (ATP). This process involves an electron transport chain which 
consists of the following: complex I (NADH-ubiquinone oxidoreductase), complex II 
(succinate-ubiquinone oxidoreductase), complex III (ubiquinol-cytochrome c 
reductase), complex IV (cytochrome c oxidase), coenzyme Q (ubiquinone) and 
cytochrome c (Balaban et al., 2005; Madamanchi et al., 2005).
The process begins at either complex I where NADH is oxidised to NAD* or at complex 
II where FADHz is oxidised to FAD (see figure 1.2). The electrons from NADH and FADHi 
are then transferred to coenzyme Q and at complex I energy is dissipated by the 
ejection of protons into the intermembrane space (Balaban et al., 2005). There is no 
ejection of protons from complex II because the transfer of electrons from FADH2 is 
not associated with a significant decrease in free energy (Cooper, 2000). The electrons 
are then transferred from coenzyme Q to  complex III, where more protons are ejected, 
then onto cytochrome c and lastly onto complex IV where they are used to reduce 
molecular oxygen to water, with a final ejection of protons into the intermembrane 
space.
FADH2 FAD M atrix H+
NADH NAD+
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Figure 1.2 Schematic of the electron transport chain (I: NADH-ubiquinone 
oxidoreductase, II: succinate-ubiquinone oxidoreductase, III: ubiquinol-cytochrome c 
reductase, IV: cytochrome c oxidase, V: ATP synthase, CoQ: coenzyme Q, Cyt: 
cytochrome c)
The movement of protons into the intermembrane space by complexes I, III and IV 
creates a chemiosmotic or electrochemical gradient across the mitochondrial inner 
membrane, which drives the production of ATP. The potential energy stored in this 
proton gradient, which originates from the oxidation and reduction reactions in the 
electron transport chain, is released when the protons flow back into the matrix via 
the Fo subunit of ATP synthase (complex V) (Feniouk et al., 2005). At the Fi subunit of 
ATP synthase, ADP is phosphorylated to ATP in a spontaneous manner and the energy 
released from proton flow is used in the dissociation of ATP from the Fi subunit (Boyer 
et al., 1973; Cross, 2004). The NAD* and FAD are reduced back to NADH and FADHz in 
the citric acid cycle and the electron transport chain can begin again.
At various points along the electron transport chain electrons can directly react with
molecular oxygen to produce superoxide and other reactive oxygen species (ROS). The
2 major sites for ROS production are believed to be at complex I and complex III 
(Balaban et al., 2005).
1.2.4 Xanthine oxidase
Xanthine oxidoreductase (XOR) is a molybdoflavin enzyme and exists in 2 different 
forms, xanthine oxidase (XO) and xanthine dehydrogenase (XDH). In vivo most XOR 
exists in the XDH form but can be converted reversibly or irreversibly to XO. XDH is 
reversibly converted to XO by sulfhydryl oxidation which oxidises thiol groups at 
cysteine residues Cys535 and Cys992 (Berry, 2004; Nishino, 1994). XDH is reproduced 
from XO by treatment with thiol compounds. In the presence of proteases (trypsin, 
chymotrypsin, pancreatin) XDH is converted to XO irreversibly by proteolysis (Berry, 
2004). Significant conformational changes occur around the FAD binding site when 
XDH is converted to XO resulting in different affinities to the electron acceptors NAD* 
and O2 (Nishino, 1994). XDH will reduce both NAD* and O2 with a preference for NAD* 
whereas XO does not interact with NAD* and will only reduce O2 leading to the 
formation of either O2 ' or H2O2 (Enroth et al., 2000).
The active form of XDH is a homodimer with catalytically independent subunits each 
consisting of 2 iron-sulphur (Fe2-S2) centres at the N-terminal, a flavin adenine 
dinucleotide (FAD) domain in the centre and a molybdopterin (Mo) binding domain at 
the C-terminal (Enroth et al., 2000). This enzyme catalyses the oxidation of 
hypoxanthine to xanthine and xanthine to uric acid (figure 1.3), which are the final 2 
stages in the purine degradation pathway. The mechanism involves donation of 
electrons from either hypoxanthine or xanthine to the Mo cofactor. The electrons are
then transferred via the iron-sulphur centres onto the FAD domain where reduction of 
either NAD* or 0% occurs depending on which form the enzyme exists in (XDH or XO) 
(Kelley et al., 2010). The FAD can be divalently oxidised by 0% to produce H2O2 or 
univalently oxidised in 2 stages to produce 2O2" (Galbusera et al., 2006).
0
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Xanthine Uric Acid
Figure 1.3 Oxidation of hypoxanthine to uric acid via xanthine
1.2.5 Nitric oxide synthase
Nitric oxide synthase (NOS) is a heme-containing monooxygenase which produces
nitric oxide (NO ) during the oxidation of L-arginine to L-citrulline (Porasuphatana et
al., 2003). NOS is functionally active as a homodimer and has 3 isozymes: NOS I
(constitutive in neuronal tissue and so termed nNOS), NOS II (inducible by cytokines
and bacterial endotoxins and so termed iNOS), and NOS III (constitutive in vascular
endothelial cells and so termed eNOS) (Knowles and Moncada, 1994; Porasuphatana
et al., 2003). Each monomer of nitric oxide synthase contains binding sites for FAD,
F IVIN and NADPH at the reductase domain and binding sites for haem (iron
protoporphyrin IX), the substrate (L-arginine) and tetrahydrobiopterin (BH4) at the
oxygenase domain (Sun et al., 2010). Both nNOS and eNOS require calcium ions for
activation whereas iNOS activation is calcium independent (Knowles and Moncada,
1994). In the activation of nNOS and eNOS calcium ions bind to calmodulin which in
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turn binds to NOS activating the transfer of electrons, donated by NADPH, from the 
reductase domain of one monomer to the oxygenase domain of the other monomer 
allowing oxygenation of the substrate (Covers and Rabelink, 2001; Sun et al., 2010).
The nitric oxide synthase reaction, shown in figure 1.4, is a 2-step reaction which 
converts L-arginine to L-citrulline and nitric oxide via the intermediate species N^- 
hydroxy-L-arginine (Huang et al., 2001).
coo
L-arginine
NH NHg
N^-hydroxy-L-arginine
NH _NH2
V
L-citrulline
NADPH
VjNADPH
NH NHz
" N = 0
Figure 1.4 The nitric oxide synthase reaction (modified from (Huang et al., 2001))
When levels of BH4 or L-arginine are low, nitric oxide synthase produces superoxide 
instead of nitric oxide (Bevers et al., 2006). This is caused by 'NOS uncoupling' which is 
when the reduction of molecular oxygen by NADPH becomes uncoupled from L-
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arginine oxidation and nitric oxide synthesis (Fukai, 2007; Katusic, 2001). 
Tetrahydrobiopterin is the major factor for NOS uncoupling as it facilitates electron 
transfer from the reductase domain to the oxidase domain and also helps the enzyme 
stay in its active form as a homodimer (Fukai, 2007). Tetrahydrobiopterin is easily 
oxidised to dihydrobiopterin (BHz) which, although binds to NOS with equal affinity, 
will not prevent NOS uncoupling (Crabtree et al., 2008).
1.2.6 NADPH oxidase
NADPH oxidases are an important source of reactive oxygen species which produce 
superoxide as their primary function. NADPH oxidase was first found in phagocytes, 
where it produces superoxide during phagocytosis, but is also present in many 
nonphagocytic cells. It plays a vital role in nonspecific host defence and mutations in 
the subunits that make up the enzyme lead to the rare genetic disease chronic 
granulomatous disease (CGD) where patients suffer from recurrent infections, 
formation of granulomas and premature death (see section 1.3.1). The ROS produced 
by the enzyme NADPH oxidase is not only an essential part of immune defence but 
also plays an important role in redox signalling in several cellular processes such as cell 
growth, apoptosis, migration and extracellular matrix remodelling (see section 1.3.2) 
(Li and Shah, 2003). In nonphagocytic cells NADPH oxidases have low constitutive 
activity but can be activated by various stimuli including growth factors, cytokines, and 
mechanical stress (see section 1.2.9). Cells also have a defence against over production 
of ROS including antioxidants such as uric acid, vitamin C, vitamin E and antioxidant 
enzymes such as superoxide dismutase and catalase (see section 1.3.5). When the level
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of ROS production increases to a level which outweighs the antioxidant capability the 
excess ROS can lead to oxidative stress (see section 1.3.4).
1.2.7 Structure of NADPH oxidase
NADPH oxidase is a multi-component enzyme consisting of a membrane-bound 
catalytic core called flavocytochrome bsss, and a group of cytosolic regulatory subunits. 
Flavocytochrome bsss, so called due to the haem maximum absorbance peak at 558 
nm in the reduced form, consists of gp9l' '^ °^  ^ (|3 subunit) and p22"^ °^^  (a subunit) (Rae et 
al., 1998). The gp91^^°^ subunit is a large glycoprotein of 570 amino acids with a mass 
of 91 kDa in its mature form, due to heavy glycosylation, and a mass of 65 kDa in its 
immature form, pre-glycosylation (MeischI and Roos, 1998). It is encoded by the gene 
CYBB which is located on the short arm of the X chromosome (Patino et al., 1999). This 
subunit contains 6 transmembrane helices with 2 bound haems (in transmembrane 
helices III and V) in the N-terminal half and in the C-terminal region the FAD and 
NADPH binding domains reside (Takeya and Sumimoto, 2003), see figure 1.5. Both 
COOH and NHz termini are situated in the cytoplasm (Bedard and Krause, 2007).
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Figure 1.5 Structure of gpSl^^^’^ : The six transmembrane helices are located in the 
membrane and the two haems are located between helices three and five. The FAD 
and NADPH binding regions are situated towards the C-terminus and both the NH2- 
and COOH- terminal tails are situated in the cytoplasm (modified from (Bedard and 
Krause, 2007)).
The p22’^ °^^  subunit is a small protein of 195 amino acids with a mass of 22 kDa 
(MeischI and Roos, 1998). It is encoded by the gene CYBA which is located on the long 
arm of chromosome 16 (San José et al., 2008). This protein has 2 transmembrane 
helices and is the docking site for the cytosolic subunits containing a proline rich region 
in the C-terminal cytoplasmic tail which is involved in interactions with Src homology 3 
(SH3) domains (Keith et al., 2009).
The cytosolic subunits of NADPH oxidase are p47^^°^ p67^^°^ p40'^ °^  ^and Racl or Rac2. 
The p47^^°  ^subunit is a protein of 390 amino acids with a mass of 47 kDa (MeischI and
14
Roos, 1998). It is encoded by the gene NCFl which is located on chromosome 7 
(Chanock et al., 2000). The N-terminal region of this subunit contains a PX (phox 
homology) domain, the middle region of the amino acid sequence contains 2 SH3 
domains and the C-terminal is rich in serine residues (phosphorylation sites) and has a 
proline rich region (El-Benna et al., 2009). The p67"^ °^^  subunit is a protein of 526 amino 
acids with a mass of 67 kDa (MeischI and Roos, 1998). It is encoded by the gene NCF2 
which is located on chromosome 1 (Koker et al., 2009). This subunit contains 2 SH3 
domains, a PBl (phox and Bem 1) domain and an N-terminal domain comprising 4 
tetratricopeptide repeats (TPR) motifs (Maehara et al., 2010). The p40"^ °^^  subunit is a 
protein of 339 amino acids with a mass of 40 kDa (MeischI and Roos, 1998). It is 
encoded by the gene NCF4 which is located on chromosome 22 (MeischI and Roos, 
1998). This subunit contains a PX domain at the N-terminus, an SH3 domain and a PBl 
domain (Honbou et al., 2007). The Racl subunit is encoded by a gene on chromosome 
7, whereas the Rac2 subunit is encoded by a gene on chromosome 22 (Matos et al.,
2000). Racl and Rac2 differ in just 14 of 92 residues making them 92% identical. At the 
N-terminus of these subunits reside 2 'switch' regions which change conformation 
according to the type of nucleotide (GDP or GTP) which is bound to the amino acid 
residues also present at the N-terminus. At the C-terminus a geranylgeranyl group can 
be attached by a thioether linkage to a cysteine residue (Vignais, 2002).
1.2.8 homologues and their expression
In the last 15 years new homologues of gp9l'^^°’^ have been identified; Noxl (Banfi et 
al., 2000; Sub et al., 1999), Nox3 (Cheng et al., 2001; Kikuchi et al., 2000), Nox4 (Geiszt 
et al., 2000; Shiose et al., 2001), Nox5 (Banfi et al., 2001; Cheng et al., 2001) and Duoxl
15
and 2 (De Deken et al., 2000; Dupuy et al., 1999) with the original gp91^^°^ being 
renamed Nox2. Noxl, 3 and 4 share a similar structure with Nox2 and are expressed in 
a variety of tissues, see table 1.1. Nox5, also present in a wide variety of tissues, shares 
the same basic structure with Noxl-4 but with an additional calmodulin-like Ca^* 
binding domain at the N-terminus (Bedard and Krause, 2007; Dworakowski et al.,
2006). The Duox proteins also share the same basic structure with Noxl-4 however 
they also contain a Ca^* binding domain (like Nox5) as well as a peroxidise homology 
domain at the N-terminal (Dworakowski et al., 2006).
In research investigating both the cardiovascular and central nervous systems the most 
relevant and highly expressed Nox isoforms are Noxl, Nox2, Nox4 and Nox5. Nox2 
expression has been found to be increased with ageing in the brain, heart, stomach 
and ischemic muscles and also very recently in the aorta (Dugan et al., 2009; Roos et 
al., 2013; Salles et al., 2005; Turgeon et al., 2012; Wang et al., 2010). This Nox isoform 
therefore may play an important role in the development of ageing-related diseases 
such as cardiovascular disease and neurodegenerative diseases through its increased 
expression and subsequent increased ROS production and oxidative damage.
16
s
i
•scc
oo
en"
cg Een
"ôj
(J
"ên [gw _ru(U "oîe_a 3U
3
O
• 3
(U C
3 e/T 3en 3en eu+ j
en
%! "Ô;i_
(U
3 u
JC eu _g+-» ej
O ru
2
en
3
E
s:OüO
c
0
1
I
î r<U o
O)
Q.cuo
o  u  c
(U
1 1
00c
(U
(/)
■D
"0
ro
Oc
E
m
- a
cri
£T- =  CO_ "O
I  I  6
ClOo
en
eu
O
=  CD
Si
O
c_o
5
eo
LD
eoun
'ôT
1  I (Ntî o rN
§ i
crX
_i i_.c
s s
; g
enJÇ
O
CD
en
O)
2
tnro
e/Tc
2
3
euc
(U eu
O
T3c
eu
bjoo
en
O)
&
eu
O
O
O
un
rHfNj
Q.
X
o en
Q.
dû
i t
:  I
eu
3
en
C
'eu
J3
(Uc
g
(Uo
eoun
enUDun
eû
(N
unrMcrUD
o
o
_T mro ooeu rsi
<u
o 3JZ (T5
o
: (D
oB HL: o
T5 enceu OO
IV (N
dû
O
en
_ro
Si
O
=  ^  
S ^
ro =
O)_c
4-»O
• 3
C
(U
en
(U
&O
tnnj
en
C
2
3
euc
>-
euc
■D
Le:
enro
00
un
T—4 
fNcr
fN
o
00 fo 5P <N
(U =  O
eu% u 
—ro O  
% °  
4= eu
CQ_ ro ro
g
_g "03
3
U 4->en O
m "3> C
en 0)
3
■3 e/T
O "03 en
C u *05
JO _g U
Q. u
E en3
E
en" _c3
3
4->
oo
3 E
C
(U_0J
Q.en
CN
uneûun
m
rvi
(NŒen
o
o  en o  en o  en
enfD
2ucfd
Q.
dûc
3
en T5 ■3_e^ en
’+-» 2 2en
m "rü >•_c
>•
_c
OU h- 1 -
ro
in
unin
rNcrun
Xo
3
O
c _r %!
en
(D
2uc
ru
Q.
00TTun
CMcr
rô
unT—4 
O"in
(N
Xo
3
Q
Oen
(Uen
ru
" 3
Xo
n:
CL
Q<
Z
C
eu
><uen
(V
Cg
I
3
3
■3
C
(U
>-
c
(U
3
U
CO)
3
3"
3en
dû
C_g
cg
'+ ->
ruuO
_g
ru
1.2.9 Mechanism of activation of NADPH oxidase
A wide variety of physiological and pathological stimuli can increase the activity of 
NADPH oxidase including 1) G protein-coupled receptor agonists such as angiotensin II 
and endothelin-1; 2) cytokines such as tumour necrosis factor alpha (TNFa), 
transforming growth factor beta (TGFP) and interleukin 1 (IL-1); 3) growth factors such 
as vascular endothelial growth factor (VEGF), insulin and thrombin; 4) metabolic 
factors such as oxidised low-density lipoprotein (oxLDL), non-esterified fatty acids 
(NEFA) and advanced glycation end products (AGE); 5) hypoxia-reoxygenation and 
ischaemia-reperfusion; and 6 ) mechanical stimuli such as oscillatory shear stress 
(Dworakowski et al., 2006; ü and Shah, 2004). In the presence of these stimuli NADPH 
oxidase is activated via a number of mechanistic steps, detailed below, to produce 
superoxide.
1.2.9.1 Nox2
The Nox2 subunit is constitutively associated with p22"^ °^^  to form a stable 
heterodimer, however the Nox2 enzyme is not constitutively active and requires 
interaction with its cytosolic subunits to become activated. This activation occurs 
through a number of mechanisms starting with the phosphorylation of p47^^°’‘ at 
multiple serine residues, which causes a conformational change (Takeya and 
Sumimoto, 2003). Non-phosphorylated p47^^°  ^ has an autoinhibitory region (AIR) 
formed by the interaction of the Src homology 3 (SH3) domains with the C-terminal 
region (El-Benna et al., 2009). Upon phosphorylation the SH3 and PX domains become 
accessible and p47 '^^°’‘ translocates to the membrane taking with it p67^ *^ °^  and p40"^ °^^ .
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Interactions then occur between the SH3 domain of with the proline rich
regions at the C-terminal of p22^^°^ between the PX domain of p47^^°’^ with membrane 
phospholipids and between the proline rich region of the p47^ °^'  ^with the SH3 domain 
of p67'^ °^  ^ (figure 1.6) (Bedard and Krause, 2007). The small G protein Rac, is also 
involved in the translocation of the cytosolic subunits and has been shown to 
translocate p67"^ °^^  to the membrane even in the absence of p47*^ °^^  (Vignais, 2002). in 
its inactive form Rac is bound with the nucleotide GDP with its geranylgeranyl tail 
bound to GDI (GDP dissociation inhibitor) (Brandes and Kreuzer, 2005). Rac is activated 
by GEF proteins (GDP/GTP exchange factors) that catalyse the exchange of GDP for 
GTP to give the active form of Rac (Vignais, 2002). The activated GTP-bound Rac 
interacts with tetratricopeptide repeats (TPR) at the N-terminal of p67^^°  ^ and 
interacts with the membrane via its prenylated tail. On translocation to the membrane 
p67phox binds with gp91^^°’^ (Nox2), via its activation domain, and p47^^°^ acts as an 
adaptor protein which helps to stabilise the interaction (Brandes and Kreuzer, 2005).
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Figure 1.6 Schematic representation of the activated Nox2 enzyme complex
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Once activated the NADPH oxidase complex can begin to generate superoxide by a 
series of electron transfer reactions. Electrons are first donated by NADPH which 
becomes reduced (NADP^) and the electrons are transferred to FAD (flavin adenine 
dinucleotide). In the next step an electron is transferred from the reduced FAD (FADH2) 
to the first haem and then onto the second haem. The second electron can only be 
transferred from the partially reduced FADH to the first haem after the first electron 
has already been transferred to the second haem, as the iron center in the haem can 
only accommodate one electron at a time (Bedard and Krause, 2007). From the second 
haem the electrons are transferred to molecular oxygen producing 2 molecules of 
superoxide. The overall pathway of electrons is NADPH FAD hem el heme2
0 :
Oo
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g p 9 1 P * i(H  p 2 2 P h o *
p4Qphox
gp91Phox p22Phox
p47Phox
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Figure 1.7 Schematic representation of the activation of the Nox2 enzyme and 
subsequent superoxide production utilising NADPH as an electron donor.
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1.2.9.2 Nox2 homologues
The activation mechanism for Noxl is similar to that of Nox2 and depends on the 
expression of p2 2 ^^ °^  to form a stable heterodimer and to allow superoxide production 
(Ambasta et al., 2004; Takeya et al., 2003). Noxl superoxide generation also relies on 
the presence of cytosolic subunits such as p47"^ °^^  and p67'^ °^ *^ however these subunits 
are not found in high quantities in the colon where Noxl is predominantly expressed. 
Therefore homologues of these subunits were found and identified as Nox organiserl 
(NoxOl) for p47'’ °^’^  and Nox activatorl (NoxAl) for p67 '^^°^ both of which are found in 
high levels in the colon epithelium (Banfi et al., 2003). It has also been found that Racl 
can activate Noxl as well as Nox2 and that a decreased Rac expression can lead to 
lower Noxl dependent ROS production (Cheng et al., 2006). Nox3 dependent 
superoxide generation is known to depend on the expression of p2 2 '^ °^^  and to 
increase with involvement of the cytosolic subunits p47'^^°  ^ NoxOl, p67^^°^ NoxAl, 
and Rac (Cheng et al., 2004; Ueno et al., 2005; Ueyama et al., 2006). Nox4 dependent 
superoxide generation is known to depend on the expression of p22"^ °^^  (Ambasta et 
al., 2004) however it does not require any cytosolic subunits or Rac for activation but is 
constitutively active (Martyn et al., 2006). The activation of NoxS NADPH oxidase is 
quite different from that of Noxl-4, it does not require cytosolic subunits but 
generates superoxide in response to intracellular calcium (Banfi et al., 2004b). Duoxl 
and Duox2 do not require cytosolic subunits to be activated but do require maturation 
factors DuoxAl and DuoxA2, which allow the dual oxidases to undergo maturation to 
acquire their active conformation. Once matured, Duoxl and Duox2 are activated by 
intracellular calcium (Rigutto et al., 2009).
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1.3 Role of ROS in physiology and pathology
1.3.1 Host defence
Phagocytic cells are an essential part of the body's innate immune system that 
circulate in the blood and can migrate into tissues where they search for invading 
pathogens such as bacteria and any other foreign particles or cellular debris which 
they engulf and destroy. NADPH oxidase is a fundamental enzyme present in 
phagocytes which is required for the 'respiratory burst' that involves conversion of 
molecular oxygen to superoxide which is responsible for destroying any invading 
pathogens. Phagocytes lacking NADPH oxidase activity are unable to destroy 
pathogens effectively and chronic granulomatous disease (CGD) is a rare genetic 
disorder where this phenomenon occurs. CGD results from mutations in the genes 
which encode for the protein subunits which constitute NADPH oxidase. Patients with 
CGD are immunodeficient and suffer from chronic and recurrent, often fatal infections. 
There are a number of variations of this disease depending on the defective gene but 
the most common form, affecting approximately 70 % of CGD patients, is mutations in 
the CYBB gene which encodes for the gp9l"^ °^  ^ subunit (Heyworth et al., 2003). Other 
less common forms include mutations in the CYBA, NCFl and NCF2 genes which 
encode for p22' '^ °^  ^ p47^^°  ^ and p67"^ °^^  respectively (Heyworth et al., 2003). More 
recently it has been found that mutations in a fifth gene, NCF4 which encode for the 
p4 0 Phox leads to a very rare form of CGD (Matute et al., 2009).
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1.3.2 Signalling pathways
Reactive oxygen species can activate redox-sensitive signalling pathways by oxidation 
of cysteine residues on proteins such as transcription factors, kinases and 
phosphatases (Bolisetty and Jaimes, 2013). The most common down-stream targets of 
Nox2-derived ROS are mitogen-activated protein kinases (MARK) such as the 
extracellular signal-regulated kinase (ERK), c-Jun N-terminal kinase (JNK) and p38MAPK 
(Fan et al., 2009; Li et al., 2005; Teng et al., 2012; Tickner et al., 2011); protein kinase B 
(Du et al., 2013; Flingtgen et al., 2006; Liu et al., 2013; Thakur et al., 2010), 
phosphoinositide 3-kinase (Bae et al., 2000), nuclear factor kappa B (NFkB) (Li et al.,
2009); TNFa receptor associated factor 4 (Li et al., 2005); and signalling molecules 
involved in cell apoptosis such as p21*^ '^  ^ and p53 (Li et al., 2007). Activation of these 
redox sensitive pathways can result in both physiological and pathological cellular 
responses such as oxygen sensing, endothelial dysfunction and permeability, 
migration, proliferation, inflammation, apoptosis and senescence (Frey et al., 2009; Li 
and Shah, 2004).
1.3.3 Regulation of vascular tone
Reactive oxygen species also play an important physiological role in the regulation of 
vascular tone. Nitric oxide is an endothelium-derived relaxing factor (EDRF) which 
plays a vital role in vasodilation of blood vessels and reduced bioavailability of NO can 
lead to hypertension (see section 1.4.3). Another species of ROS that plays a role in 
vasodilation is hydrogen peroxide which is an endothelium-derived hyperpolarising
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factor (EDHF) that contributes to flow-induced dilation of human coronary arterioles 
(Miura et al., 2003; Thengchaisri and Kuo, 2003).
1.3.4 Oxidative damage
Reactive oxygen species play important roles in mammalian cell biology, as previously 
mentioned, however excess production of ROS results in oxidative stress, which 
involves damage to cellular components such as lipids, proteins, and nucleic acids and 
leads to the loss of biological function. ROS can attack polyunsaturated fatty acid 
residues of phospholipids, resulting in the production of carbon-centred radicals which 
can then react with molecular oxygen to form peroxyl radicals (Marnett, 1999). These 
radicals can go on to produce a variety of compounds including malondialdehyde, 
hydroxynonenal and F2-isoprostanes, which can be used as biomarkers for lipid 
peroxidation and oxidative stress (Gil Del Valle, 2010). Damage to DNA by ROS can 
cause base and nucleotide modifications as well as breaks in the DNA strand (Bennett,
2001). The oxidised DNA product 8 -hydroxyguanine (8 -OFIdg), produced from ROS 
attack on guanine, is a good biomarker for DNA damage and oxidative stress (Wiseman 
and Flalliwell, 1996). The oxidised forms of DNA can cause errors in transcription and 
translation and lead to the synthesis of abnormal proteins, which are more susceptible 
to oxidation. Protein oxidation can occur at the protein polypeptide backbone by 
attack from the hydroxyl radical, and on the side chains of all amino acid residues of 
proteins of which methionine and cysteine residues are the most vulnerable 
(Stadtman, 2004). The extent of protein oxidation by ROS is most commonly 
determined by the quantity of protein carbonyl groups, which are produced in many 
protein oxidation mechanisms.
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1.3.5 Redox homeostasis and antioxidants
Redox homeostasis involves maintaining a balance between the rate of production and 
rate of removal of reactive oxygen species (ROS). Optimal ROS levels are critical for 
normal functioning of physiological processes and antioxidants are an important 
defence mechanism which helps to keep ROS levels in check. There are a wide variety 
of antioxidants including both antioxidant compounds and antioxidant enzymes which 
are discussed in further detail below.
Superoxide dismutase (SOD) which was identified as an antioxidant enzyme in 1969 
catalyses the dismutation of superoxide to hydrogen peroxide and molecular oxygen 
(McCord and Fridovich, 1969). There are 2 forms of SOD found inside the cell; Cu/Zn- 
SOD which is found in the cytoplasm and Mn-SOD which is found in the inner 
mitochondrial matrix (Landis and Tower, 2005). The third form of SOD, extracellular 
SOD (EC-SOD) is found in the extracellular matrix (Fukai, 2002). Another predominant 
antioxidant enzyme is glutathione peroxidase (GPx) which acts in conjunction with the 
tripeptide antioxidant molecule glutathione (GSH) to convert hydrogen peroxide and 
lipid peroxides to water and lipid alcohols respectively (Wassmann et al., 2004). During 
this reaction glutathione is oxidised to glutathione disulphide (GSSG) but can be 
regenerated by glutathione reductase (GR) (Nordberg and Arnér, 2001). The 
antioxidant catalase, located primarily in cell peroxisomes, reduces hydrogen peroxide 
to water with one of the highest turnover rates of all enzymes (Valko et al., 2006). 
Peroxiredoxins (Prx) are a family of antioxidants which can reduce a wide range of 
organic hydroperoxides including hydrogen peroxide and peroxynitrite and there have
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been at least 6 isoforms of PRx identified in mammalian cells (Prxl-PrxVI) (Wood et al.,
2003).
Vitamin C (ascorbic acid) is a powerful antioxidant compound which donates an 
electron to free radicals to become the ascorbate radical which is a relatively 
unreactive free radical that can be reduced back to ascorbic acid by enzyme systems 
(Buettner and Jurkiewicz, 1996). a-Tocopherol (most biologically active isoform of 
vitamin E) is another powerful antioxidant compound which can be reduced to the a- 
tocopherol free radical by donation of a labile hydrogen to a lipid or lipid peroxyl free 
radical (Valko et al., 2006). The relatively innocuous a-tocopherol free radical can 
subsequently be reduced back to a-tocopherol by ascorbic acid (Valko et al., 2006). 
Uric acid is an antioxidant compound which donates an electron to free radicals to 
neutralise them becoming a radical itself, however the uric acid free radical is much 
more stable than oxygen based radicals and can be easily reduced back to uric acid by 
ascorbic acid (Becker, 1993).
1.4 Ageing-related oxidative stress and metabolic syndrome
Several different organisations have released clinical criteria for the diagnosis of 
metabolic syndrome including the world health organisation and the national 
cholesterol education program adult treatment panel III and each have similar but 
varying criteria. Generally metabolic syndrome is present when at least 3 of the 
following criteria are true: abdominal obesity, hyperlipidaemia, hypertension and 
insulin resistance (Grundy et al., 2004; Kassi et al., 2011). The prevalence of metabolic 
syndrome increases with advancing age and is strongly associated with increased
26
production of reactive oxygen species (ROS), in particular Nox2-derived ROS and 
oxidative stress.
1.4.1 Obesity and hyperlipidaemia
Obesity is defined as a BMI greater than or equal to 30 and hyperlipidaemia is a 
condition where the concentration of lipids such as cholesterol, triglycerides and fatty 
acids in the blood are elevated (WHO, 2013b). Obesity and hyperlipidaemia have been 
seen to be increased with advancing age and are strong risk factors for the 
development of atherosclerosis and other cardiovascular diseases. Total cholesterol 
and low-density lipoprotein (LDL) cholesterol were found to be significantly increased 
in ageing subjects compared to young subjects, however there was no difference 
found between levels of triglycerides or high-density lipoprotein (HDL) cholesterol 
(James et al., 2006; Singh et al., 2002). Oxidative stress is associated with obesity and 
hyperlipidaemia and in diabetic mice increases in body weight, cholesterol and 
triglycerides were found alongside increases in superoxide production and 
malondialdehyde (lipid peroxidation marker) (Pannirselvam et al., 2005). In particular 
NADPH oxidase is an important source of ROS and oxidative stress with ageing, and 
recently increases in bodyweight, total cholesterol and triglyceride levels in old rats 
compared to young controls were found in association with increased NADPH oxidase 
activity, effects which were further exacerbated by treatment with high-fat diet (Erdos 
et al., 2011). Increased Nox-derived superoxide evidenced by increased nitrotyrosine 
levels and increased expression of p47^*’°^  has also been seen in ageing human subjects 
(55-78 years) compared with young subjects (18-30 years) and is accompanied by 
increases in bodyweight, total cholesterol, LDL cholesterol and triglycerides (Donato et
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al., 2007). Increased expression of the Nox2 isoform in particular has been linked with 
increased total cholesterol levels and superoxide production (Judkins et al., 2010) and 
elimination of Nox2 results in reduced levels of superoxide production and attenuated 
high-fat diet induced obesity, hyperlipidaemia, hypertension and endothelial 
dysfunction (Du et al., 2013).
1.4.2 Hvperglvcaemia and insulin resistance
Insulin resistance occurs when cells become less sensitive and less responsive to the 
hormone insulin which subsequently leads to increased insulin production by beta 
cells. However when beta cells are no longer able to compensate for the reduced 
sensitivity to insulin, levels of glucose in the blood become elevated resulting in 
hyperglycaemia. ROS and oxidative stress have been widely shown to induce insulin 
resistance which in turn can lead to further increases in ROS (Ando and Fujita, 2009; 
Evans et al., 2003). With ageing the prevalence of insulin resistance and 
hyperglycaemia increase in association with increased superoxide and oxidative stress 
(Cha et al., 2010; Petersen et al., 2003; Wu et al., 2009). NADPH oxidase activity and 
expression is associated with insulin resistance (Fortuno et al., 2009) and increased 
angiotensin II levels resulted in insulin resistance alongside increased expression of 
racl, p67 '^^°  ^ p22"^ °^^  and Nox2 and increased NADPH oxidase derived ROS (Wei et al.,
2007). Apocynin, a Nox inhibitor, has been shown to ameliorate hyperglycaemia and 
insulin resistance in mice fed a high-fat diet by reducing oxidative stress (Meng et al., 
2011). Insulin resistance and Nox2 activation are strongly related to endothelial 
dysfunction and in an in vivo model of insulin resistance inhibition or knockout of Nox2 
resulted in reduced oxidative stress and improved endothelial function (Sukumar et al.,
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2013). Knockout of Nox2 in a high-fat diet mouse model also resulted in reduced levels 
of superoxide production and attenuated high-fat diet induced hyperglycaemia, 
impaired glucose tolerance and endothelial dysfunction (Du et al., 2013).
1.4.3 Hypertension
There is substantial evidence supporting that ageing is strongly associated with an 
increase in blood pressure. Data published from the Framingham heart study, for 
example, demonstrated a linear rise in systolic blood pressure between ages 30 and 84 
years (Franklin et al., 2001, 1997). Ageing-related hypertension is primarily associated 
with structural changes in the arteries in particular wall thickness and artery stiffness 
(see section 1.52) but is also closely linked to changes in levels of nitric oxide, 
angiotensin II and endothelin-1 (Francia et al., 2004; Van Guilder et al., 2007; Wang et 
al., 2003).
Nitric oxide is important in the vasculature not just due to its function in relaxation of 
blood vessels but also its inhibition of platelet aggregation and adhesion, reduced 
expression of cell adhesion molecules, inhibition of leucocyte adhesion, prevention of 
endothelial cell apoptosis, inhibition of vascular smooth muscle proliferation, 
stimulation of angiogenesis and activation of endothelial progenitor cells (Forstermann 
and Sessa, 2012; Gewaltig, 2002). Nitric oxide bioavailability decreases with ageing 
(van der Loo et al., 2000) but the mechanisms behind this remain largely unclear with 
conflicting results in the literature. The endothelial NOS (eNOS) has been found to be 
increased, (Cernadas et al., 1998) unchanged (Francia et al., 2004; Yang et al., 2009) 
and decreased (Rippe et al., 2010; Tanabe et al., 2003) in ageing. Flowever there is
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more agreement that the inducible NOS (iNOS) increases with ageing (Csiszar, 2002; 
Francia et al., 2004; Zanetti et al., 2010) and taken with the evidence that superoxide 
and peroxynitrite (Francia et al., 2004; Rodriguez-Mahas et al., 2009) also increase with 
ageing suggests that the reduced nitric oxide bioavailability in ageing is not caused by 
reduced production of nitric oxide but rather by scavenging of the molecule by 
increased levels of superoxide. This scavenging is most likely due to Nox2-derived 
superoxide which has been strongly linked with decreased nitric oxide bioavailability 
(Jung et al., 2004).
Angiotensin II induces the contraction of blood vessels and plays a key role in vascular 
homeostasis along with numerous roles in cell signalling including activation of NADPFI 
oxidase (Mehta and Griendling, 2007). NADPH oxidase-derived ROS stimulated by 
angiotensin II infusion in vivo plays a pivotal role in hypertension and both p47^^°  ^
knockout mice and mice treated with a Nox inhibitor (gp91ds-tat) have been shown to 
be protected against angiotensin II induced increases in superoxide production and 
hypertension (Landmesser et al., 2002; Rey et al., 2001). The expression of angiotensin 
II and angiotensin converting enzyme has been shown to be increased with ageing 
(Wang et al., 2003) which further increases the risk for NADPH oxidase linked 
hypertension. Angiotensin II induced hypertension can also be linked to decreased 
nitric oxide bioavailabilty and increased peroxynitrite formation due to the increased 
levels of NADPH-derived superoxide present.
Overall these findings suggest that increased levels of superoxide from NADPH oxidase 
is a key contributor to the ageing related metabolic syndrome risk factors such as 
obesity, hyperlipidaemia, hyperglycaemia, insulin resistance and hypertension.
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1.5 Ageing-related oxidative stress and vascular dysfunction
With increasing age the vasculature undergoes structural and functional changes, in 
particular vascular remodelling and alterations in endothelial function. The exact 
mechanisms behind this vascular ageing are not fully elucidated but numerous findings 
support a major role for increased superoxide production and oxidative stress, in 
particular arising from NADPH oxidase.
1.5.1 Endothelial dysfunction
Ageing is a major risk factor for the progressive increase in endothelial dysfunction 
which is a precursor for many cardiovascular diseases such as hypertension and 
atherosclerosis (Herrera et al., 2010). The mechanisms behind ageing-related 
endothelial dysfunction are not fully elucidated but increasing evidence supports a role 
for increased superoxide production and reduced bioavailability of nitric oxide. An age- 
related decline in endothelial function as assessed by aortic relaxation to acetylcholine 
has been shown in mice (Francia et al., 2004) and rats (van der Loo et al., 2000) and is 
associated with an increased production of superoxide and a subsequent decreased 
nitric oxide bioavailability due to the combination of the two radicals to form 
peroxynitrite. Ageing related endothelial dysfunction associated with increased 
oxidative stress has also been found in humans as evidenced by reduced endothelium 
dependent dilation in older healthy males (55-78 years) compared with young healthy 
males (18-30 years) (Donato et al., 2007). A more recent study measuring endothelium  
dependent relaxations in arteries from young and ageing men and women has further 
demonstrated that endothelial dysfunction associated with increased oxidative stress
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occurs with advancing age (Rodriguez-Manas et ah, 2009). Rodriguez-Manas et al. 
(2009) found increased levels of superoxide in ageing arteries, along with increased 
expression of NADPH oxidase and discovered that both apocynin (NADPH oxidase 
inhibitor) and uric acid (peroxynitrite scavenger) improved endothelium dependent 
vasodilation, thus supporting a role for NADPH-oxidase derived superoxide and 
peroxynitrite in ageing-related endothelium dysfunction.
Research linking NADPH-oxidase and endothelium dysfunction has also been carried 
out in knock-out mice such as p47"^ °^^  knockout mice which were found to be 
protected against angiotensin II induced endothelial dysfunction and Nox2 knockout 
mice which were protected against high-fat diet induced endothelial dysfunction (Du 
et al., 2013; Li et al., 2004). Insulin resistance-induced impairment of endothelial 
function in association with increased superoxide production can also be attenuated 
by knockout of Nox2 (Sukumar et al., 2013). On the other hand in mice with 
endothelium specific overexpression of Nox2, angiotensin II induced endothelial 
dysfunction is exacerbated (C E Murdoch et al., 2011).
1.5.2 Arterial stiffness
Increased arterial stiffness is a major cause of age-associated hypertension and occurs 
due to structural remodelling in the intima, media and adventitia of the artery caused 
by increased collagen, decreased elastin and accumulation of advanced glycation end 
products (AGE) which cross-link proteins throughout the artery (Fleenor, 2013). 
Studies have shown that oxidative stress plays an important role in arterial stiffness 
(Plantinga et al., 2007; Wykretowicz et al., 2007) and recent data supports a role for
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NADPH oxidase-derived ROS. It has been shown that an ageing-related decrease in 
elastin and increase in collagen and AGEs resulting in large elastic artery stiffness is 
associated with increased levels of superoxide, reduced nitric oxide bioavailability, 
increased nitrotyrosine levels, increased expression of the nox subunit p67^^°  ^ and 
increased Nox activity (Donato et al., 2013; Fleenor et al., 2013, 2012). Apocynin, a nox 
inhibitor, was found to prevent increased ROS and subsequent arterial stiffness in 
hypertensive rats providing further support for a major role of Nox-derived ROS in 
arterial stiffness (Chen et al., 2013).
1.6 Ageing-related oxidative stress and neurodegeneration
Neurodegeneration involves the progressive loss of structure or function of neurons 
leading to dysfunction of the central nervous system and ageing is a major risk factor. 
Ageing related neurodegenerative diseases include Alzheimer's disease, Parkinson's 
disease and amyotrophic lateral sclerosis. Although the exact mechanisms behind the 
damage and loss of neurons with ageing remain unknown evidence has suggested that 
an ageing-associated increase in reactive oxygen species (ROS) production causes 
central nervous system oxidative stress and neuronal damage. There are numerous 
studies that document increases in oxidative stress with ageing in the brain including 
evidence of increased ROS (Park et al., 2007; Quick et al., 2008) and increased levels of 
oxidative stress biomarkers. Protein carbonyls a marker of protein oxidation (Jolitha et 
al., 2006; Perluigi et al., 2010; Smith et al., 1991), malondialdehyde a marker of lipid 
peroxidation (Dei et al., 2002; Jolitha et al., 2006; Leutner et al., 2001) and 8 -OHdg a 
marker of DNA oxidation have all been investigated in the ageing brain (Clausen et al., 
2010; Nicolle et al., 2001).
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Nox2 is a major source of oxidative stress in the brain and has been shown to play an 
important role in ageing-related cerebrovascular impairment, mild-cognitive 
impairment, Alzheimer's disease and Parkinson's disease (Ansari and Scheff, 2011; 
Park et al., 2007; Wu et al., 2003). Additionally, increased Nox2 expression and activity 
and subsequent increased superoxide production were found in the brain of ageing 
mice in association with cognitive decline (Dugan et al., 2009).
1.6.1 Dopamine in the ageing brain
Dopamine is a neurotransmitter which plays a vital role in locomotor movement, 
motivation, reward, learning and memory. It is produced primarily by dopaminergic 
neurons in the ventral tegmental area and the substantia nigra. Age-related decreases 
in dopamine and dopamine markers such as Di and Dz receptors and dopamine 
transporters (DAT) have been seen throughout the brain including the striatum, frontal 
cortex, temporal cortex, parietal cortex and occipital cortex, hippocampus, amygdala 
and thalamus (Backman et al., 2006). This ageing-related decline in dopamine is 
strongly associated with a decline in episodic (long-term) memory (Morcom et al.,
2010) and a decline in locomotor activity (Salvatore et al., 2009). The molecular 
mechanisms underlying the ageing-related decline in dopamine are unknown but may 
be caused by oxidative damage to dopaminergic neurons.
1.7 Understanding and ameliorating ageing-related oxidative stress
Numerous clinical trials have been carried out to investigate the role of antioxidants on 
cardiovascular risk and mortality and there have been mixed responses with studies 
showing no effects, beneficial effects and even adverse effects (Kris-Etherton et al.,
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2004). However the majority of studies have not shown beneficial effects and coupled 
with the risk of possible adverse effects means the use of antioxidants as a therapy to 
reduce oxidative stress and CVD risk is not justified.
Understanding and ameliorating ageing-related oxidative stress by targeting the 
enzymes responsible for the production of reactive oxygen species such as NADPH 
oxidase is perhaps a better alternative. In this regard several inhibitors of NADPH 
oxidase have been developed but only few have shown to be specific for NADPH 
oxidase such as the peptide inhibitor gp91ds-tat (Rey et al., 2001) and the small 
molecule inhibitors VAS2870 and VAS3947 (Tegtmeier et al., 2005). However even 
these superior inhibitors do not appear to be isoform specific (Grandes, 2003; Wind et 
al., 2010), which is a challenging trait considering the high-degree of homology 
between the 7 Nox isoforms. Therefore knockout mouse models such as Nox2 and 
p4 7 Phox indispensible model to use to help further understand the mechanisms
behind ageing-related oxidative stress.
1.8 Hypothesis and aim
Nox2 null (Nox2‘'^ ‘) mice have been widely used to investigate the role of Nox2 in 
various disease pathologies in particular in cardiovascular diseases (Chan and 
Baumbach, 2013; Chen et al., 2004; Du et al., 2013; Turgeon et al., 2012). However the 
role of Nox2 in ageing-associated cardiovascular and neurodegenerative diseases is not 
fully elucidated. Therefore the aim of this PhD research project is to investigate the 
role of Nox2-derived oxidative stress in ageing-associated metabolic syndrome, 
endothelial dysfunction and neurodegeneration. To do this the mouse strain C57BI/6
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which have been proven as a good ageing mouse model will be used in this project as 
they are long-lived, they breed well and are a good and popular background strain for 
many transgenic mice (The Jackson Laboratory, 2013). The mouse age groups which 
will be used are comparable with human ageing with young mice aged 3-4 months 
comparable to a 20-25 year old 'young' adult human, middle aged mice aged 10-12 
months comparable to a 40-45 year old middle aged human and ageing mice aged 20- 
22 months comparable to a >60 year old elderly human (Flurkey et al., 2007).
The hypothesis of this thesis is that Nox2-derived superoxide is increased with 
advancing age which causes an accumulation of oxidative stress and leads to the 
development of metabolic syndrome, endothelial dysfunction and neurodegeneration.
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Chapter 2 
Materials and Methods
For a comprehensive list of materials and reagents used in this study please see 
Appendix table I at the end of this chapter. All equipment used is detailed in the text 
including, where appropriate, the company and model.
2.1 Animals
All animal studies and procedures were approved by the Home Office and were 
performed in accordance with the Animals (Scientific Procedures) Act 1986. Inbred 
male Nox2 null C'^ ') mice on a C57BL/6 background at young (3-4 month), middle age 
(10-12 month) and ageing (20-22 month) were investigated alongside their wild-type 
(WT) controls. Nox2'^' mice were generated by Pollock et al. by insertion of a neomycin 
resistant gene into exon 3 of the Cybb (Nox2) gene which encodes the 91
kD subunit of the oxidase cytochrome b (Pollock et al., 1995).
All mice were originally obtained from The Jackson Laboratory and were subsequently 
bred at the University of Surrey animal unit. Male Nox2'^' hemizygous and female 
Nox2^ "^ ' heterozygous mice were mated to produce male WT and Nox2'^' littermates 
which were genotyped by PCR amplification of tail lysates followed by gel 
electrophoresis separation (see section 2.3). Nox2'" '^ mice were also routinely 
outcrossed with WT to keep the colony healthy.
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All mice were housed at 18-23°C and 45-55 % humidity in a 12:12 hour light dark cycle 
with lights on at 7am and food and water available ad libitum. Nox2 ^^' mice are 
immunodeficient and so were kept in sterile cages with irradiated food and bedding 
and autoclaved water.
2.2 Human tissue
Edinburgh brain bank kindly donated human post-mortem brain tissue for use in this 
study. Frozen samples from the ventral tegmental area (VTA) region of the mid brain 
were grouped into 3 age groups young (25-38 years), middle age (46-60 years) and 
ageing (75-76 years).
2.3 Genotvping
Genotyping was carried out on 10-15 day old mice by polymerase chain reaction (PCR) 
and gel electrophoresis to identify Nox2'^' hemizygous male mice for scientific use. 
Each mouse was tail marked with permanent marker for later identification and a tail 
tip (2-3 mm) was cut and placed in a pre-labelled DNase-free 1.5 ml microcentrifuge 
tube. Each tail tip was digested overnight with 150 pi of tail lysis buffer (table 2.1) in a 
water bath at 55°C with gentle agitation. The next morning the samples were heated 
at 95°C for 5 minutes to deactivate proteinase K. The samples were then briefly mixed 
by a vortex mixer before being centrifuged at 13000 x g for 5 minutes to pellet the 
debris. The supernatant containing genomic DNA was used for PCR analysis.
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Table 2.1 Tail lysis buffer
Reagent Concentration
KCI 50 mM
MgClz 1.5 mM
Tris HCI (pH 7.5) 10 mM
Gelatin 0.01 %
Nonidet P-40 0.45 %
Tween-20 0.45 %
Proteinase K 200 pg/ml
A common forward primer, a wild-type reverse primer and a mutant (Nox2'^') reverse 
primer (table 2.2) designed to amplify the areas of interest were synthesised by 
Eurofins MWG Operon.
Table 2.2 Sequence of primers for PCR
Primer Sequence
Common Forward 5'-AAG AGA AAC TCC TCT GCT GTG AA-3'
Wild-type Reverse 5'-CGC ACT GGA ACC CCT GAG AAA GG-3'
Mutant (Nox2‘/‘) Reverse 5'-GTT CTA ATT CCA TCA GAA GCT TAT CG-3'
The PCR mix was made according to table 2.3 and 10 pi was added to PCR tubes with 2 
pi of DNA sample from the digested tail tissue. PCR was run on a PCR thermal cycler 
(Applied Biosystems, USA) according to the thermal cycling parameters in table 2.4.
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Table 2.3 PCR mix
Reagent Concentration
GoTaq Flexi Buffer Ix
MgClz 2.5 mM
dNTP mix 0.2 mM
Common Forward Primer Ip M
WT Reverse Primer Ip M
Mutant Reverse Primer Ip M
GoTaq Hot Start Polymerase 0.3 Units
Table 2.4 Thermal cycling parameters for PCR
Step Temperature Time Comments
1 94°C 3 min
2 94°C 20 sec
3 64°C 30 sec -0.5°C per cycle
4 72°C 35 sec Repeat steps2-4 for 12 cycles
5 94°C 20 sec
6 58°C 30 sec
7 72°C 35 sec Repeat steps 5-7 for 25 cycles
8 72°C 2 min
9 10°C Hold
After PCR had amplified the genes of interest, gel electrophoresis was used to separate 
the bands which were identified according to a DNA marker. A 3 % agarose gel was 
made up in a glass duran bottle by adding 3 g of agarose to 100 ml tris-acetate-EDTA 
(TAE) buffer, composed of 40 mM Tris-acetate and 1 mM ethylenediaminetetraacetic 
acid (EDTA), and heating in a microwave until fully dissolved. The agarose solution was 
allowed to cool before addition of 5 pi ethidium bromide (10 mg/ml). The gel was
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poured into a gel rack and after it had set was transferred to an electrophoresis 
chamber (Fisher Scientific, UK) with chilled TAE buffer.
The samples and a 100 bp DNA ladder were loaded onto the gel and electrophoresis 
was carried out at 120 V for around 45 minutes. The bands were visualised and 
captured using a GeneGenius bio imaging system (Syngene, UK) with GeneSnap 
(Syngene, UK) software. The presence of a 240 base pair (bp) band in the gel 
represents the wild-type allele and a 195 bp band represents the mutated (Nox2) 
allele. Heterozygote mice were identified by the presence of both bands (figure 2.1).
Lane 1 2 3 - 4  5 6 7
240 bp (wild-type)--------- ►
195 bp (Nox2 ' ’)--------- *■
Lane 8 9 10 11 12 13
240 bp (wild-type) ►
195 bp (Nox2'^‘)---------
Figure 2.1 Representative image of an electrophoresis gel with separated bands 
representing wild-type and knock-out alleles
2.4 Food intake and bodvweight measurement
Mice were individually housed when food intake measurements were carried out. The 
food was weighed every 24 hours using a 1 decimal place balance for at least 3 days
41
and the average daily intake per mouse was calculated. The bodyweight of each mouse 
was measured every month using a 1 decimal place balance.
2.5 Tail-cuff blood pressure measurement
Systolic and diastolic blood pressure was measured on conscious mice by tail-cuff 
plethysmography using a non-invasive blood pressure system (Kent Scientific 
Corporation, USA). This system works by inflation of the volume-pressure recording 
(VPR) cuff to remove blood from the tail, the occlusion cuff then inflates to prevent 
blood flow back into the tail and then gradually deflates. The systolic blood pressure is 
taken as the pressure at which the blood volume in the tail increases after deflation of 
the occlusion cuff and the diastolic blood pressure is the pressure at which the blood 
flow into and out of the tail equalizes (Feng et al., 2008).
All mice were habituated in a restrainer on a heated platform for 15 minutes per day 
for at least 4 days prior to taking the measurement. Mice were handled gently and, to 
minimise stress, were not forced to enter the restrainer. Once in the restrainer the tail 
of the mouse was threaded through the occlusion cuff and VPR cuff (see figure 2.2). 
The body temperature of the mice was recorded with an infra-red thermometer (La 
Crosse Technology, USA) to ensure that the body temperature remained stable. At a 
high temperature the mice overheat and become stressed and at a low temperature 
blood flow to the tail is impaired.
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Figure 2.2 Equipment for blood pressure measurement and illustration of how the 
mice were restrained
On the day of measurement mice were habituated in the restrainer with both cuffs on 
the tail for 5-10 minutes until they remained calm and still and the blood pressure was 
recorded using Coda6 V2.5 software (Kent Scientific Corporation, USA). All 
measurements were taken between 9 am and 12 pm and the average of at least 5 
successful recordings was calculated.
2.6 Locomotor activity measurement
The horizontal and vertical activity of the mice was measured by the use of motility 
chambers (figure 2.3) of length 40 cm, width 20 cm and height 20 cm (Linton 
Instrumentation, UK). Each chamber had 2 sets of 16 photocells located at right angles 
to each other, projecting horizontal infrared beams 2.5 cm apart and 1 and 6 cm above 
the cage floor. The lower beams at 1 cm measure the horizontal activity and the upper 
beams at 6 cm measure the vertical 'rearing' activity.
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Figure 2.3 Motility chamber used for measuring locomotor activity in mice
Horizontal and vertical activities were defined as the activity from measurement of 
sequential infrared beam breaks, recorded in 30 minute bins on AmonLite activity 
monitoring software (MJS Technology, UK). Recording began immediately after placing 
the animals in the cage, which was 3 hours before the beginning of the dark cycle, and 
continuing over a period of 42 hours. The mice were housed in individual chambers at 
18-23°C and 45-55 % humidity in a 12:12 hour light dark cycle with lights on at 7am 
and food and water available ad libitum.
2.7 Fasting glucose and intraperitoneal glucose tolerance test (IPGTT)
Mice were fasted overnight with free access to water and a blood sample was taken by 
cutting the tip of the tail. The fasting glucose was measured (time = 0) from a small 
drop of blood from the mouse tail using a glucose meter (Accu-Chek, UK). The mice 
were weighed and a 20 % glucose solution was made up with sterile saline (1 g in 5 ml). 
Syringes were prepared with 10 pi of glucose solution per gram of bodyweight for each 
mouse and an intraperitoneal injection of glucose (2 g/kg) was given. Blood glucose 
levels were then measured at 15, 30, 60 and 120 minutes after injection by removing
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the blood clot gently from the tip of the tail and collecting a small drop of blood onto 
the glucose meter strip.
2.8 Euthanasia and tissue collection
Mice were euthanised by an intraperitoneal injection of sodium pentobarbital (100 
mg/kg) and the body was sprayed with 70 % ethanol to disinfect the skin and fur. Using 
forceps the skin below the ribs was lifted and a small cut was made through the skin 
with scissors. Closed scissors were inserted into the cut made and then opened and 
this was repeated until the skin was separated from the abdominal and thoracic 
cavities. The skin was then cut along the midline of the body up to the neck and down 
towards the hind legs. The abdominal cavity was cut open along the midline and across 
the body below the ribs to open up the abdominal region. The intestines were gently 
pushed to the side until the inferior vena cava was clearly visible. A 25 gauge needle 
was carefully inserted into the vein and blood was slowly drawn into a syringe and 
transferred to a 1.5 ml centrifuge tube with no anticoagulant. The blood was left to 
clot at 4°C until ready for serum collection (see section 2.9). After blood collection the 
stomach and intestines were removed and the epididymal fat pads, pancreas, spleen, 
liver and kidneys were collected. The rib cage was then removed by cutting along the 
sternum towards the head, through the ribs down to the diaphragm and through the 
diaphragm to give access to the heart and lungs which were collected. The aorta was 
then collected from the heart down to the iliac bifurcation, by cutting the connective 
tissue underneath the vessel. The brain was collected by cutting and peeling away the 
skull and then gently lifting out with a thin spatula (NB When doing electrophysiology 
experiments the brain was collected immediately after the blood). The muscle from
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around the legs was collected by cutting through the femur close to the pelvis and 
then pulling the leg free allowing the muscle to be easily removed. All organs not used 
for physiological experiments were fixed or frozen for future use by the research 
group. The aortas and brains used for physiological experiments were collected and 
prepared as described in sections 2.10 and 2.11. The weight of the brain and the 
epididymal fat pads were measured using a 4 decimal place balance.
2.9 Separation of blood
Blood was collected as described in section 2.8 and was separated by centrifugation at 
6000 rpm for 15 minutes at 4°C. The serum was collected and transferred into small 
eppendorf tubes and kept at -80°C until required for analysis of fasting insulin, lipid 
and nitric oxide levels.
2.10 Ex-vivo assessment of vascular function
The aorta was excised as described in section 2.7 and immersed in ice cold Krebs- 
Henseleit buffer (table 2.5). The aorta was pinned at either end in a petri dish filled 
with ice cold Krebs-Henseleit buffer. Connective tissue and fat were carefully removed 
under a dissection microscope (GT Vision, UK) with fine scissors and forceps and the 
thoracic aorta was cut into 3-4 mm wide rings.
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Table 2.5 Krebs-Henseleit buffer
Reagent Concentration (m M)
NaCl 118
KCI 4.7
MgS04 1.2
KH2PO4 1.2
NaHCOs 25
CaCb 2.5
D(+)-Glucose 12
Vascular function of mouse thoracic aortas was assessed ex vivo using a tissue organ 
bath system (ML0146/C-V, AD Instruments Ltd, UK), The aortic rings were each 
mounted on 2 parallel horizontal hooks, made of stainless steel wire (ISO pi diameter), 
in a water-jacketed organ bath chamber (figure 2.4). Each chamber contained 10 ml 
Krebs-Henseleit solution continuously oxygenated with 95 % O2/5  % CO2 and 
maintained at 37°C. The upper hook was attached to an isometric force displacement 
transducer and the lower hook was fixed to a support leg attached to the organ bath. 
The isometric force was measured digitally on a computer with the software 
programme PowerLab Chart 5.0 (AD Instruments, UK).
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Figure 2.4 Schematic diagram showing rings cut from the thoracic aorta and suspended 
in an organ bath
All rings were equilibrated in the organ bath with no tension for 45 minutes with the 
buffer being replenished every 15 minutes. Gradually the tension was manually 
increased until a passive tension of 0.3 g was reached and was left for 15 minutes 
(Russell and Watts, 2000; Scotland et al., 2005). All subsequent measurements 
throughout the experiment represent tension generated above this baseline. After 15 
minutes the tension was checked and adjusted if necessary to ensure it was at 0.3 g. 
The viability of the rings was then tested by addition of 250 pi 2 M KCI (50 mM final 
concentration in 10 ml) for 10 minutes, and any rings which did not contract were 
rejected at this point. The rings were then flushed with Krebs-Henseleit buffer 3 times 
with 10 minutes between each wash to remove the KCI and allow the rings to return to 
baseline tension (figure 2.5).
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Figure 2.5 Representative image of the response of an aortic ring to KCI followed by a 
series of washes
To assess the contractile response of the rings, phenylephrine (PE), an al-adrenergic 
receptor agonist which causes smooth muscle cell contraction by releasing intracellular 
calcium, was added in increasing concentrations (table 2.6) to create a dose response 
curve (figure2.6).
Table 2.6 Concentrations of PE and ACh doses
Dose Stock
Concentration
(M)
Volume of 
Stock Added
(W)
Cumulative
Concentration
(M)
Cumulative
Concentration
(-logM)
1 1 X 10'® 1 0 1 X 10'^ 9
2 1 X 10'® 2 0 3 X 10'^ 8.5
3 1 X 10® 70 1 X 10'® 8
4 1 X 10'® 2 0 3 X 10'® 7.5
5 1 X 10® 70 1 X 10'^ 7
6 1 X 10'"^ 2 0 3 X 10'^ 6.5
7 1 X 10'"^ 70 1 X 10® 6
8 1 X 10'® 2 0 3 X 10® 5.5
9 1 X 10'® 70 1 X 10® 5
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Figure 2.6 Representative image of the response of an aortic ring to increasing 
concentrations of phenylephrine (PE)
The integrity of the aortic endothelium was assessed by relaxation to acetylcholine 
(ACh) (figure 2.7), an endothelium dependent vasodilator which binds to muscarinic 
receptors on the endothelium to stimulate the production of NO by eNOS which 
causes smooth muscle cell relaxation. Rings were first pre-contracted to 70-80 % of the 
maximal phenylephrine contraction by using the appropriate concentration (normally 
either 0.3 x 10'® or 1 x 10’® M) and were then relaxed by adding increasing 
concentrations of acetylcholine (table 2.6).
The endothelium independent relaxation (figure 2.7) was assessed by relaxation to 
increasing concentrations of the nitric oxide donor sodium nitroprusside (SNR) (table 
2.7) after pre-contraction to 70-80 % of the maximal phenylephrine contraction.
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Table 2.7 Concentrations of SNP doses
Dose Stock
Concentration
(M)
Volume of 
Stock Added
(W)
Cumulative
Concentration
(M)
Cumulative
Concentration
(-logM)
1 1 X 10'^ 10 1 X 10'^° 10
2 1 X 10'^ 20 3 X 10'^° 9.5
3 1 X 10'^ 70 1 X 10'^ 9
4 1 X 10'^ 20 3 X 10'^ 8.5
5 1 X 10'^ 70 1 X 10'^ 8
6 1 X 10'^ 20 3 X 10'^ 7.5
7 1 X 10'^ 70 1 X 10'^ 7
8 1 X lO  "^ 20 3 X 10'^ 6.5
9 1 X 10'"^ 70 1 X 10"® 6
PE
Dose ACh 
1 2 3 4 5 6 7 8 9
Dose SNP
PE 1 2 3 4 5 6 7  8 9
S
Figure 2.7 Representative images of the response of an aortic ring to increasing 
concentrations of acetylcholine (ACh) or sodium nitroprusside (SNP) after pre­
contraction with phenylephrine (PE)
Experiments were also carried out in the presence of the endothelial nitric oxide 
synthase (eNOS) inhibitor Nw-Nitro-L-arginine methyl ester (L-NAME). Rings were 
incubated with 300 pM L-NAME for 30 minutes before endothelial relaxation by 
acetylcholine, as described above, was assessed. The aortic rings were washed
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between each dose response curve 3 times with Krebs-Henseleit buffer with 10 
minutes between each wash until the tension returned to the baseline tension (0.3 g).
The results were analysed manually on the PowerLab Chart 5.0 (AD Instruments, UK) 
software by taking the plateaued tension reading after each addition of either PE, ACh 
or SNP. All dose response curves were generated in GraphPad Prism 6.0 software using 
four parameter variable slope nonlinear regression curve fitting and the EC50 and Emax 
were determined. The PE contraction results were expressed in grams of tension and 
the ACh and SNP relaxation results were expressed as a percentage of the pre­
contraction to PE.
2.11 Neuron firing by extracellular electrophvsioiogy
The neuron firing was investigated by extracellular electrophysiology which uses a 
borosilicate glass electrode inserted into fresh brain tissue to detect and record the 
firing of nearby neurons. Mice were euthanised by intraperitoneal injection of sodium 
pentobarbital (100  mg/kg) and the whole brain was immediately excised and 
immersed in ice cold sucrose buffer (table 2.8) (Gartside et al., 2007) oxygenated with 
95 % O2/5  % CO2.
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Table 2.8 Sucrose Buffer
Reagent Concentration (m M)
Sucrose 200
HEPES 10
NaHCOs 25
MgS04 7
D(+)-Glucose 10
KCI 2.5
NaHzP04 1.2
CaCl2 0.5
The edges of the brain were cut away to form a square cube (figure 2.8 A) containing 
the midbrain which was mounted with cyanoacrylic glue to a stainless steel stage. The 
brain was transferred to the tissue chamber of a vibratome (VT1200, Leica, Germany) 
containing ice cold oxygenated sucrose solution (figure 2.8 B). Coronal slices (300 pm) 
were cut and 3 slices containing the substantia nigra (SN) and ventral tegmental area 
(VTA) were harvested and each slice was cut in half with a scalpel to give 6 half brain 
slices containing the SN and VTA. The coronal slices were incubated in oxygenated 
artificial cerebrospinal fluid (aCSF) (table 2.9) (Chen et al., 2005) at 28°C for 1 hour 
(figure 2.8 C).
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Figure 2.8 Preparation of the brain for extracellular electrophysiology. (A) Trimming of 
the brain before mounting on a vibratome. (B) Cutting of coronal sections using a 
vibratome. (C) Incubation of coronal half brain sections in aCSF.
Table 2.9 Artificial cerebrospinal fluid (aCSF)
Reagent Concentration (m M)
NaCI 123
NaHCOs 22
NaH2P04 1.25
KCI 3.75
MgS04 1.2
D(+)-Glucose 10
CaCb 2.5
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For electrophysiological recordings, one brain slice was placed in the recording 
chamber (see figure 2.9) which was continuously perfused with oxygenated aCSF at 
32°C with a flow rate of 2 ml/min. The VTA was visually identified as a grey area medial 
to the SN and the medial lemniscus (a white fibre tract). Borosilicate glass 
microelectrodes with a tip of approximately 1 pm were pulled on a P-67 Flaming 
Brown micropipette puller (Sutter Instrument Company, USA) and were filled with 
aCSF to give an impedence of 3-6 MQ. The electrode was lowered into the VTA region 
and extracellular recordings of spontaneous action potentials from a single cell was 
recorded in the AC mode and amplified 1000 times. Signals were digitised using a 
CED1401 Micro Mark 2 (Cambridge Electronic Design Ltd, UK) and were recorded in 10 
second bins with Spike 2 Software Version 5.2 (Cambridge Electronic Design Ltd, UK).
Figure 2.9 Image of the electrophysiology setup with a close up view of a coronal 
section in the recording chamber perfused with oxygenated aCSF.
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Dopaminergic neurons in the VTA were distinguished by well-defined 
electrophysiological characteristics: a firing frequency of 0.5-4 Hz and an action 
potential waveform of approximately 2.5-3 milliseconds in duration. Dopaminergic 
neurons also exhibit inhibition of firing in response to 50 pM dopamine perfusion. 
Non-dopaminergic neurons exhibit high firing frequencies (>4 Hz), short action 
potentials (<2 milliseconds) and no inhibition of firing in response to dopamine 
perfusion.
A baseline firing frequency of each dopaminergic neuron was recorded for 5-10 
minutes, then 0.5 pM AMPA (2-amino-3-(3-hydroxy-5-methyl-isoxazol-4-yl)propanoic 
acid), a glutamate agonist, was perfused with aCSF, which increased the firing of the 
neuron. The firing was recorded for roughly 6 minutes. The AMPA was then washed 
out and firing frequency was left to return to its basal rate. After 10-15 minutes 50 pM 
dopamine was perfused with aCSF, which blunted firing of the neuron and confirmed 
that the neuron was dopaminergic. The dopamine was washed out with aCSF to allow 
firing to return to normal and to ensure that blunting of the signal was due to the 
dopamine perfusion. Figure 2.10 is a representative image of the recording of a neuron 
which has been stimulated with both AMPA and dopamine. The results were analysed 
manually on the Spike 2 Software by taking the firing frequency reading for basal firing 
and for the AMPA stimulated firing peak.
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Figure 2.10 Representative image of the recording of a neuron firing under basal 
conditions and in response to AMPA or dopamine stimulation.
2.12 Insulin ELISA
Fasting insulin levels were measured in mouse serum samples using an enzyme-linked 
immunosorbent assay (ELISA) kit (Mercodia, Sweden). The kit uses a direct sandwich 
technique where two monoclonal antibodies are directed against separate antigenic 
determinants on the insulin molecule. Insulin in the mouse serum sample reacts with 
anti-insulin antibodies bound to the bottom of the microplate wells and with 
peroxidase-conjugated anti-insulin antibodies. The insulin bound peroxidase-conjugate 
is detected by reaction with its substrate 3,3%5,5'-tetramethylbenzidine (TMB) which 
produces a blue reaction product. The reaction is then stopped by adding acid which 
gives a colorimetric endpoint with a yellow reaction product that can be measured by 
spectrophotometry at 450 nm.
Calibrators and samples (10 pi) were added in duplicate to a 96 well plate coated with 
anti-insulin antibodies and 100 pi of enzyme conjugate solution was added to each
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well. The plate was incubated at room temperature for 2 hours with orbital shaking 
(800 rpm). The plate was then washed 6 times with 300 pi of wash buffer before 200 pi 
of the substrate TMB was added to each well. The plate was incubated for 15 minutes 
at room temperature and then 50 pi of stop solution containing 0.5 M H2SO4 was 
added. The plate was briefly placed back on a shaker to ensure mixing before the 
optical density was measured at 450 nm using a spectrophotometer (MBA 2000, 
Perkin Elmer). The concentration of insulin was calculated in GraphPad Prism 6.0 using 
cubic spline regression.
2.13 Lipid measurement
Mouse serum triglyceride (TAG), total cholesterol (TChol), high-density lipoprotein 
(HDL) cholesterol and non-esterified fatty acid (NEFA) concentrations were analysed in 
duplicate using an I Lab 650 Clinical Chemistry System (Instrumentation Laboratory, UK) 
at the University of Surrey. The I Lab uses photometry for in vitro quantification of 
analytes in biological fluid. The low-density lipoprotein (LDL) cholesterol was calculated 
using the Friedewald equation: LDL (mmol/L) = TChol-HDL-TAG/2.17.
2.14 Griess assay to detect nitric oxide
Production of nitric oxide levels in the fasting serum was assessed by measuring the 
concentration of its breakdown product nitrite using a Griess assay kit and 
measurements were carried out according to the manufacturer's instructions. Briefly, 
calibrators and serum samples were added to a 96 well plate with Griess reagent and 
distilled water. The plate was then incubated for 30 minutes at room temperature 
before the absorbance was measured at 540 nm using a spectrophotometer (MBA
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2000, Perkin Elmer). The concentration of nitrite (nitric oxide) in fasting serum samples 
was calculated from the standard curve.
2.15 Preparation of aorta for sectioning
Freshly excised aortas were cleaned of any adherent fat and connective tissue and 
were cut into 2-3 mm long rings. Aortas were arranged upright in optimum cutting 
temperature (OCT) compound on cork discs with 3 rings per disc. Isopentane was 
cooled by liquid nitrogen until the edges of the solution began to turn into a white 
solid. The OCT embedded aorta sample was slowly immersed in the cold isopentane 
until the OCT solidified. The sample was stored at -80°C until ready for sectioning.
2.16 Preparation of aorta and brain homogenates
Aorta and brain (mouse and human) samples from the -80°C freezer were ground with 
a chilled pestle and mortar into a fine powder and an appropriate volume of chilled 
HBSS buffer, with 50 mM NaF and IX  concentration protease inhibitor cocktail, was 
added. The samples were then lysed by homogenisation on ice for 1 min twice with a 
hand held polytron PT1200E homogeniser (VWR, UK) and by sonication on ice for 10 
seconds 3 times with a VC130PB ultrasonic processor (Sonics and Materials, USA) at 
half of maximal amplitude. Tissue homogenates were then analysed to determine 
protein concentrations (section 2.17).
2.17 Bradford protein assay
The protein concentration in aorta and brain (mouse and human) homogenates was 
measured by the Bradford protein assay. This assay is a colorimetric dye-binding assay
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in which a colour change occurs in response to the binding of coomassie brilliant blue 
G-250 with protein resulting in a shift in the absorbance peak from 470 nm to 595 nm.
The dye reagent was prepared by a 1:5 dilution of Bio-Rad dye concentrate with water 
and 2 pi of tissue homogenate was added to 1 ml of the dye reagent and was 
thoroughly mixed using a vortex. The mixture was then transferred to a 1 cm cuvette 
and the absorbance was measured at 595 nm wavelength using a spectrophotometer 
(Perkin Elmer, UK). The protein concentration was calculated from the absorbance 
value using a standard curve created using known concentrations of bovine serum 
albumin. Tissue homogenates were then used for lucigenin chemiluminescence 
(section 2.18) and for western blotting (section 2.20).
2.18 Lucigenin chemiluminescence assay for detection of superoxide
Superoxide production in aorta and brain (mouse and human) homogenates was 
measured using lucigenin chemiluminescence. Lucigenin (bis-N-methylacridinium) is 
first reduced by one electron to produce the lucigenin cation radical. Superoxide then 
reduces this cation radical to produce lucigenin dioxetane, which decomposes creating 
two molecules of N-methylacridone, one of which is in the excited state and emits light 
as it relaxes to its ground state (Guzik and Channon, 2005).
Tissue homogenates were prepared as stated in (section 2.16) and an appropriate 
volume of each homogenate containing 50 pg of protein was added to a 96 well plate. 
HBSS buffer with 50 mM NaF and IX  concentration protease inhibitor cocktail was 
added to each well to make the volume up to 140 pi. Prior to measurement, solutions 
of lucigenin (25 pM) and NADPH (1 mM) were made up using HBSS buffer with 1.8 mM
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CaClz and 0.8 mM MgCl2. All measurements were run on a luminometer (BMG Labtech, 
Germany) which was set to 37°C.
The 96 well plate was inserted into the luminometer and 40 pi of lucigenin was 
injected into each well using the auto-dispenser function to give a final concentration 
of 5 pM. To obtain a basal reading, omitted light expressed as relative light units (RLU) 
was recorded for 10 cycles with 3 second intervals per well. NADPH (20 pi) was then 
added manually to each well using an auto-pipette to give a final concentration of 100 
pM and NADPH dependent superoxide production was measured for 20 cycles with 3 
second intervals per well. To confirm specificity for superoxide, further measurements 
were taken in the presence of 20 mM tiron, a superoxide scavenger.
To investigate the enzymatic sources of superoxide utilising NADPH as a substrate, 50 
pg of tissue homogenates were incubated in a 96 well plate with the following 
inhibitors: 100 pM NOS inhibitor Nw-Nitro-L-arginine methyl ester (L-NAME), 100 pM  
xanthine oxidase inhibitor oxypurinol, 20 pM flavoprotein inhibitor 
diphenyleneiodonium, and 20 mM superoxide scavenger tiron. After a 10 minute 
incubation period lucigenin chemiluminescence was performed as described above.
2.19 DHE staining for detection of superoxide
Dihydroethidium (DHE) staining was carried out to determine intracellular superoxide 
levels in aorta. DHE is cell-permeable and reacts with superoxide inside the cell to 
produce a red fluorescent product 2-hydroxyethidium which intercalates with DNA 
(Gudot et al., 2006; Zhao et al., 2003). Frozen samples of aorta were prepared as in
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section 2.15 and sections of aorta (6 pm) were cut on a cryostat (Bright Instrument 
Company, UK) and thaw mounted onto superfrost plus slides (VWR, UK).
The slides were washed with 100 pi of DHE buffer (HBSS with 50 pM MgClz) per section 
and dried by tapping off the excess buffer and wiping edges with tissue. Then 20 pi of 
DHE buffer was added to each section and the slide was incubated at 37°C for 10 
minutes. Finally 10 pi of DHE stain (0.5 pM in DHE buffer) was added to each section 
and was incubated at 37°C for 5 minutes in the dark. Sections were immediately 
viewed under an Olympus BX61 fluorescent microscope (Olympus, UK) (excitation 530- 
560 nm and emission 575-650 nm) and images were taken at 20x magnification with at 
least 10 images taken per section and 3 sections per mouse. Images were quantified 
using Simple PCI imaging software (Hamamatsu, USA).
2.20 Western blotting
Investigation into the relative expression of proteins of interest in mouse aorta was 
carried out by western blotting. This technique involves the separation of proteins by 
gel electrophoresis followed by blotting of proteins onto a membrane, which can be 
detected by antibodies.
Aorta homogenates were prepared as previously described (section 2.16) and protein 
concentration was measured by the Bradford assay (section 2.17). Western blotting 
samples with 3 pg/pl protein concentration were prepared with 3X sample buffer 
(table 2.10) and were boiled at 95°C for 5 minutes.
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Table 2.10 3X Sample Buffer
Reagent Volume/Weight
1 M Tris-HCI pH 6.8 30 ml
SDS 6g
Glycerol 30 ml
H2O 40 ml
Bromophenol blue 50 mg
Vt 100 ml
Add 60 pi 2-Mercaptoethanol to 940 pi buffer before use
Mini-gels were prepared for sodium dodecyl suphate polyacrylamide gel 
electrophoresis (SDS-PAGE) using the Bio-Rad Mini-protean II apparatus (Bio-Rad, UK). 
A 10 % resolving gel was prepared (table 2.11 A) and allowed to set before a 5 % 
stacking gel (table 2.11 B) was overlaid. A rainbow protein marker was loaded into the 
first well of the gel and 10 pi of protein samples were loaded into subsequent wells. 
The gel was run at 80 V for 30 minutes and then 110 V for about 90-120 minutes in 
running buffer (table 2.11 C) until the loading dye was at the end of the resolving gel.
Table 2.11 Gel and buffer recipes
A. Resolving Gel B. Stacking Gel
Reagent Volume for 2 gels Reagent Volume for 2 gels
40 % Acrylamide 2.5 ml 40 % Acrylamide 625 pi
1.5 M Tris pH 8.8 2.5 ml 1 M Tris pH 6.8 630 pi
10% SDS 100 pi 10% SDS 50 pi
H2O 4.8 ml H2O 3.64 ml
10 % APS 100 pi 10 % APS 50 pi
TEMED 4 pi TEMED 5 pi
Vt 10 ml Vt 5 ml
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c. Running Buffer D. Transfer Buffer
Reagent Volume/Weight Reagent Volume/Weight
Tris 6g Tris 3.75 g
Glycine 29 g Glycine 18 g
10 % SDS 10 ml Methanol 250 ml
Vt Up to 1 L with H2O Vt Up to 1 L with H2O
The separated proteins were transferred from the gel onto a Millipore Immobilon-P 
Polyvinylidene Difluoride (PVDF) membrane using a Bio-Rad Semi-Dry Transfer Cell 
(Bio-Rad, UK). Filter papers were soaked in transfer buffer (table 2.11 D) for 10 
minutes and the PVDF membrane was soaked in methanol for 15 seconds then in 
water for 2 minutes and finally in transfer buffer for 10 minutes. The transfer 
'sandwich' was prepared by stacking the PVDF membrane with the resolving gel on top 
between two layers of rectangular filter papers (four either side). The semi-dry transfer 
process was run at 15 V for 1 hour then the PVDF membrane containing the 
transferred proteins was blocked with 5 % non-fat milk in TBST buffer (1 X TBS (table 
2.12) with 0.1 % Tween 20) for 1 hour at room temperature with orbital shaking. The 
membrane was then incubated with primary antibody diluted to its optimal 
concentration (table 2.13) with 2.5 % non-fat milk in 1 X PBS (table 2.12) at 4°C 
overnight with orbital shaking. The following day the membrane was left shaking at 
room temperature for 1 hour before being washed with 1 x TBST for 10 minutes then 1 
X TBS for 10 minutes and finally 1 X PBS for 10 minutes. The membrane was then 
incubated with horseradish peroxidase (HRP)-conjugated secondary antibody diluted 
to its optimal concentration (table 2.13) with 2.5 % non-fat milk in 1 X PBS (table 2.12) 
for 90-120 minutes at room temperature with orbital shaking. Following another set of
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10 minute washes with TBST, TBS and PBS the membrane was exposed to Clarity 
Western ECL Substrate made up following the manufacturer's instructions. Detection 
of bands was carried out using a BioSpectrum AC Imaging System (UVP, UK). All results 
were compared against the housekeeping protein alpha-tubulin detected in the 
membrane.
Table 2.12 TBS and PBS buffer recipes
lOXTris Buffered Saline (TBS) lOX Phosphate Buffered Saline (PBS)
Reagent Weight Reagent Weight
Tris/Base 30 g NaCI 80 g
NaCI 88 g KCI 2 g
KCI 2 g Na2HP04 14.4 g
Vt Up to 1 L with H2O KH2PO4 2.4 g
pH to 7.4 Vt Up to 1 L with H2O
pH to 7.4
Table 2.13 List of antibodies used in western blotting
Antibody Dilution Company
Nox2-Rabbit 1:1000 Santa Cruz
p22Phox_Rabbit 1:1000 Santa Cruz
Alpha-tubulin-Mouse 1:5000 Sigma
Anti-Rabbit IgG HRP 1:4000 Sigma
Anti-Mouse IgG HRP 1:4000 Sigma
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2.21 Immunofluorescence
The relative expression and location of proteins of interest in mouse aorta was 
investigated by immunofluorescence, which uses fluorescent-labelled antibodies to 
detect the proteins of interest in sections of biological tissue.
Frozen samples of aorta were prepared as in section 2.15 and sections of aorta (10 
pM) were cut on a cryostat (Bright Instrument Company, UK) and thaw mounted onto 
superfrost plus slides (VWR, UK). The sections were fixed in chilled 50 % methanol/50 
% acetone solution for 15 minutes at room temperature and then fan dried for 10 
minutes before being stored at -80°C until ready for further use.
Slides were removed from the -80°C freezer and were fan dried at room temperature 
for 10-15 minutes. Sections were then washed in ice cold 1 X PBS (table 2.12) prior to 
blocking in 50 pi 2 % bovine serum albumin (BSA) in 1 X PBS with 0.5 % Triton X-100 for 
30 minutes at room temperature. After blocking, the sections were washed twice in ice 
cold 1 X PBS and then incubated with 30 pi primary antibody, diluted 1:100 in 0.2 % 
BSA in 1 X PBS, for 1 hour at room temperature. The antibody was drained from the 
slides which were then rinsed and washed 3 times in ice cold 1 X PBS. Sections were 
then incubated with 30 pi biotin-conjugated secondary antibody, diluted 1:250 in 0.2 % 
BSA in 1 X PBS, for 30 minutes at room temperature. The secondary antibody was 
drained from the slides which were then rinsed and washed 3 times in ice cold 1 X PBS.
The rest of the experiment was carried out in the dark. Sections were incubated with 
30 pi streptavidin-CY3, diluted 1:500 in 0.2% BSA in 1 X PBS, for 30 minutes at room 
temperature. The streptavidin-CY3 was drained from the slides which were then rinsed
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and washed 3 times in ice cold 1 X PBS. The procedure above was repeated using a 
second primary antibody, second biotin-conjugated secondary antibody and 
extravidin-FITC. In the last 5 minutes of the extravidin-FITC incubation 30 pi of 1 X DAPI 
was added to each section and incubated for the remaining 5 minutes. The extravidin- 
FITC and DAPI was drained from the slides which were then rinsed and washed 3 times 
in ice cold 1 X PBS. Slides were then briefly immersed in distilled water to wash away 
any salt and were fan dried for 10 minutes. Then 50 pi antifade solution (9:1 Mowiol : 
0.1 % p-phenylenediamine) was added to each section and a coverslip was gently 
placed over the top. Slides were stored at 4°C overnight and images were taken the 
next day.
Fluorescent labelled antigens were visualised using an Olympus BX61 fluorescent 
microscope (Olympus, UK) equipped with an argon UV lamp to investigate CY3 
(excitation/emission: 530-560/575-650 nm), FITC (excitation/emission: 470-495/510- 
550 nm) and DAPI (excitation/emission: 360-370/420-460 nm) fluorescence. Images 
were captured at 20x magnification using Simple PCI imaging software (Hamamatsu, 
USA).
Table 2.14 List of antibodies used in immunofluorescence
Antibody Dilution Company
Nox2-Rabbit 1:100 Santa Cruz
CD31-Goat 1:100 Santa Cruz
Anti-Goat biotin conjugated 1:250 Sigma
Anti-Rabbit biotin conjugated 1:250 Sigma
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2.22 Verhoeff-Van Gieson staining
Frozen samples of aorta were prepared as in section 2.15 and sections of aorta (6 pm) 
were cut on a cryostat (Bright Instrument Company, UK) and thaw mounted onto 
superfrost plus slides (VWR, UK). The sections were immersed in 4 % 
paraformaldehyde for 10 minutes and were then stained with Verhoeffs solution for 
40 minutes at room temperature. Slides were then rinsed with water 3 times before 
the tissue was differentiated in 2 % ferric chloride for 4 minutes. Slides were rinsed 
with water 5 times and then treated with 5 % sodium thiosulphate for 5 minutes. 
Slides were then washed in running water for 5 minutes before staining with Van 
Gieson solution for 4 minutes. Samples were dehydrated with ethanol and then 
immersed in xylene for 3 minutes. Coverslips were then mounted onto the samples 
using mounting medium and images were taken using an EVOS xl core transmitted 
light microscope (Peqlab,UK).
Table 2.15 Verhoeff and Van Gieson solutions
Verhoeff Solution Van Gieson Solution
Reagent Volume Reagent Volume
5 % Alcoholic Haematoxylin 40 ml 1 % Aqueous Acid Fuchsin 5 ml
10 % Ferric Chloride 16 ml Saturated Picric Acid 95 ml
Weigerts Iodine Solution 16 ml
2.23 Statistics
Comparisons were made by either a one-way or two-way ANOVA followed by a 
Bonferroni post-hoc test or by an unpaired student's f-test where appropriate using
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GraphPad Prism 6.0 software. Data are expressed as mean ± SEM with p<0.05 denoting 
statistical significance. For the in vivo animal work a number of at least 5 mice per 
group were used, for the ex vivo organ bath work a number of at least 8 mice per 
group was used and for the ex vivo electrophysiology experiments a number of at least 
3 mice were used. Sample size and details of which statistical method was used are 
presented in the figure legends of each figure.
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2.24 Appendix table I: Details of materials and reagents
Reagent Catalogue No. Supplier
100 bp DNA ladder G2101 Promega
2-Mercaptoethanol M7154 Sigma
Acetone A/0606/17 Fisher Scientific
Acetylcholine A6625 Sigma
Acid Fuchsin F8129 Sigma
Acrylamide BPE1410-1 Fisher Scientific
Agarose BP1356-500 Fisher Scientific
Ammonium Persulfate (APS) A9164 Sigma
AMPA 0254 Tocris Bioscience
Bio Rad Protein Assay Reagent 500-0006 Bio-Rad
Borosilicate glass capillaries G150F-3 Warner Instruments
Bovine Serum Albumin A3059 Sigma
Bromophenol blue 161-0404 Bio-Rad
CaCl2 C5670 Sigma
Clarity Western ECL Substrate 170-5061 Bio-Rad
Cyanoacrylic glue 16704 Loctite
D (+) Glucose G-7021 Sigma
DAPI D9542 Sigma
Dihydroethidium (DHE) D11347 Invitrogen
Diphenyleneiodonium Chloride D2926 Sigma
dNTP mix (dATP, dGTP, dCTP, dTTP) U120A, U121A, 
U122A, U123A
Promega
Dopamine Hydrochloride H8502 Sigma
EDTA D/0700/53 Fisher Scientific
ELISA Kit 10-1247-01 Mercodia
Ethanol E/0650DF/17 Fisher Scientific
Ethidium Bromide E8751 Sigma
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Extravidin-FITC E2761 Sigma
Ferric Chloride 451649 Sigma
Gelatin G1393 Sigma
Glycerol G5516 Sigma
Glycine G /0800/60 Fisher Scientific
GoTaq Green Flexi Buffer M891A Promega
GoTaq Hot Start Polymerase M500A Promega
Griess Assay Kit G-7921 Invitrogen
Haematoxylin H9627 Sigma
HBSS Buffer 14175-137 Invitrogen
HEPES 7365-45-9 ACROS Organics
Isopentane P/1030/17 Fisher Scientific
KCI P3911 Sigma
KH2PO4 P/4800/53 Fisher Scientific
L-NAME N5751 Sigma
Lucigenin B49203 Sigma
Methanol M /4056/17 Fisher Scientific
MgCl2 M8266 Sigma
MgSÛ4 M7506 Sigma
PVDF membrane P2813 Sigma
Mowiol 4-88 81381 Sigma
Na2HP04 S/4520/53 Fisher Scientific
NaCI S/3120/65 Fisher Scientific
NADPH N7785 Sigma
NaF S7920 Sigma
NaH2P04 71500 Sigma
NaHCOg S5761 Sigma
Non-fat milk - Marvel
Nonidet P-40 - Sigma
OCT Compound KMA-OIOO-OOA CellPath
Oxypurinol 04502 Sigma
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Paraformaldehyde P6148 Sigma
Phenylephrine Hydrochloride P6126 Sigma
Picric Acid P6744 Sigma
P-phenylenediamine P6001 Sigma
Protease Inhibitor Cocktail P8340 Sigma
Protein marker 161-0374 Bio-Rad
Proteinase K 03 115 836 001 Roche
Rotenone R8875 Sigma
Sodium dodecyl sulphate (SDS) 71725 Sigma
Sodium nitroprusside dihydrate S/5720/48 Fisher Scientific
Pentoject (Sodium pentobarbital) 57-33-0 Animalcare
Sodium Thiosulphate 72049 Sigma
Streptavidin-CY3 S6402 Sigma
D (+) Sucrose S/8600/60 Fisher Scientific
TEMED 87689 Sigma
Tiron 89460 Sigma
Tris Acetate T1258 Sigma
Tris Base T/3710/60 Fisher Scientific
Tris HCI T5941 Sigma
Triton X-100 XlOO Sigma
Tween-20 BPE337 Fisher Scientific
Weigert's Solution 03979 Sigma
Xylene 534056 Sigma
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Chapter 3 
The role of Nox2 in the development of metabolic syndrome 
with ageing
3.1 Introduction
Metabolic syndrome is diagnosed when a subject has 3 or more of the following 
cardiovascular disease risk factors: abdominal obesity, hyperlipidaemia, hypertension 
and insulin resistance. The likelihood of developing these conditions and hence the 
prevalence of metabolic syndrome is increased with advancing age and is associated 
with increased reactive oxygen species (ROS) production. The enzyme NADPH oxidase 
2 (Nox2) is a major source of ROS in the vascular system and produces superoxide by 
the one electron reduction of molecular oxygen. Excess ROS can cause oxidative stress 
to biomolecules and contributes to the pathology of metabolic syndrome and 
cardiovascular diseases.
Several studies have demonstrated ageing-related increases in various metabolic 
syndrome risk factors in association with increased oxidative stress. For example, an 
ageing-associated increase in blood glucose levels in rats between 6 and 33 months of 
age have been found along with increased ROS production (Wu et al., 2009) and in 
ageing mice (22 months) development of insulin resistance and increases in 
bodyweight and fat mass associated with increased oxidative stress were shown (Cha 
et al., 2010). Increases in metabolic syndrome risk factors have also been 
demonstrated in humans with insulin resistance and increased fat accumulation in
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muscle and liver in elderly humans (61-84 years) in comparison with young controls 
(18-39 years) (Petersen et al., 2003) and elevated cholesterol levels in aging human 
subjects (>60 years) (James et al., 2006). Hypertension with ageing has also been well 
established and data showing a linear rise in systolic blood pressure in human subjects 
between ages 30 and 84 years was published from the Framingham heart study 
(Franklin et al., 2001,1997).
Although it is well known that ageing causes an increase in oxidative stress and is a 
prominent risk factor for developing cardiovascular diseases, the exact mechanisms 
behind ageing-related oxidative stress and the development of metabolic syndrome 
are not fully elucidated. However accumulating evidence supports a role for NADPH 
oxidase derived superoxide. An increase in bodyweight, cholesterol and mean arterial 
blood pressure was seen in ageing rats (26 months) compared to young controls (5 
months) associated with increased NADPH oxidase activity and increased expression of 
the cytosolic subunits and p67*^ °^^  (Erdos et al., 2011). Increases in bodyweight,
cholesterol, systolic blood pressure and fasting blood glucose in ageing human subjects 
(55-78 years) compared to young controls (18-30 years) has also been associated with 
increased oxidative stress and increased p47"^ °^^  expression (Donato et al., 2007). 
These findings strongly support a role for NADPH oxidase derived oxidative stress in 
ageing-related metabolic syndrome, however further evidence is still needed to 
identify which isoform of NADPH oxidase is primarily involved and to what extent it 
plays a role. As p47^ *^ °^  and p67^^°^ which are found increased in ageing, are important 
subunits of the Nox2 isoform and as Nox2 is highly expressed in the cardiovascular 
system this study focuses on identifying the role of Nox2 in ageing related metabolic
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disorders. Therefore in this chapter groups of young (3-4 months), middle aged (10-12 
months) and ageing (20-22 months) wild-type (WT) mice were assessed for metabolic 
risk factors to investigate the development of metabolic syndrome with ageing and to 
uncover the role of Nox2 these risk factors were also assessed in Nox2 null (Nox2’^ ') 
mice at corresponding ages.
3.1.1 Aims and objectives
The aim of this chapter was to uncover the role of Nox2 in the development of 
metabolic syndrome with ageing and therefore the objectives were to investigate 
whether elimination of Nox2 may protect against the ageing-related development of:
1. Obesity by measuring food intake, bodyweight and fat weight
2. Insulin resistance by determining fasting glucose and insulin levels and 
assessing glucose tolerance
3. Dyslipidemia by determining cholesterol, fatty acids and triglyceride levels
4. Hypertension by determining diastolic and systolic blood pressure
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3.2 Results
3.2.1 The effect of ageing on food intake, bodyweight and fat weight and 
the role of Nox2
The food intake of the mice was measured throughout their lifetime to investigate the 
effect of ageing on food intake and the role of Nox2. There was no significant 
difference in food intake between the young (3-4 months) and ageing (20-21 months) 
WT mice (3.9 ± 0.2 versus 3.4 ± 0.1 grams per day p>0.05) or between any other of the 
WT age groups. There was also no significant difference in food intake between the 
young (3-4 months) and ageing (20-21 months) Nox2 '^ ' mice (3.8 ± 0.1 versus 3.7 ± 0.1 
grams per day p>0.05) or between any other of the Nox2'^' age groups. No significant 
difference was seen between WT and Nox2'^' ageing mice (20-21 months) (3.4 ± 0.1 
versus 3.7 ± 0.1 grams per day p>0.05) or between the two genotypes at any other age 
group.
The bodyweight of the mice was measured every month throughout their lifetime to 
investigate the effect of ageing on bodyweight and the role of Nox2. There was a 
significant increase in bodyweight between the young (4 months) and ageing (21 
months) WT mice (25 ± 0.9 versus 36 ± 1.9 grams *p<0.05). In fact there was a 
significant increase in bodyweight from 6 months of age which increased further with 
ageing. In contrast there was no significant difference in bodyweight between the 
young (4 months) and ageing (21 months) Nox2'^' mice (27± 0.5 versus 29 ± 0.5 grams 
p>0.05). The bodyweight of the Nox2'^' mice remained stable at all age groups and a 
significant difference was seen in the bodyweight between the WT and Nox2'^' mice
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from 9 months of age (35 ± 1.0 versus 29 ± 0.6 grams *^p<0.05) through to 21 months of 
age (36 ± 1.9 versus 29 ± 0.5 grams ^p<0.05).
The epididymal fat pad weight of the mice was measured to investigate the effect of 
ageing on fat mass and the role of Nox2. Similar to the bodyweight results the fat mass 
also increased with ageing in the WT mice and a significant increase in fat weight was 
seen between both the young (3-4 months) and middle aged (10-12 months) WT mice 
(0.42 ± 0.03 versus 1.01 ± 0.17 grams *p<0.05) and between the young (3-4 months) 
and ageing (20-22 months) WT mice (0.42 ± 0.03 versus 1.13 ± 0.15 grams *p<0.05). 
There was no significant difference in fat weight between the young (3-4 months) and 
middle aged (10-12 months) Nox2 '^ ‘ mice (0.25 ± 0.03 versus 0.50 ±0.02 grams p>0.05) 
or between the young (3-4 months) and ageing (20-22 months) Nox2'^' mice (0.25 ± 
0.03 versus 0.34 ± 0.04 grams p>0.05). Regarding effect of genotype with age, the fat 
weight was significantly higher in middle aged WT mice compared with middle aged 
Nox2 '^ ' mice (1.01 ± 0.17 versus 0.50 ± 0.02 grams **p<0.05) and in ageing WT mice 
compared with ageing Nox2"' '^ mice (1.13 ± 0.15 versus 0.34 ± 0.04 grams **p<0.05).
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Figure 3.1 The effect of ageing on food intake, bodyweight and fat
weight in WT and Nox2  ^ mice
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Legend to figure 3.1
(A) Daily food intake data of male WT (open bars) and Nox2 '^ ’ (filled bars) C57BI/6 
mice. Food intake was measured throughout the lifetime of the mice in approximately 
3 month intervals. The mean of at least 3 individual 24 hour food intake measurements 
per mouse was calculated. Data are expressed as mean ± SEM with a number of at 
least 5 mice per group. Comparisons were made by two-way ANOVA with bonferroni 
post-hoc test.
(B) Bodyweight measurement of male WT (open circles) and Nox2"' '^ (filled circles) 
C57BI/6 mice with representative photographs of ageing WT and Nox2'^' mice. 
Bodyweight was measured throughout the lifetime of the mice and was recorded 
every month. Data are expressed as mean ± SEM with a number of 8-9 mice per group. 
Comparisons were made by two-way ANOVA with bonferroni post-hoc test. *p<0.05 
versus 3-4 months old mice ^p<0.05 versus age-matched Nox2'^‘ mice.
(C) Epididymal fat pad weight of male WT (open bars) and Nox2'" '^ (filled bars) C57BI/6 
mice. Groups of mice were euthanised at young (3-4 months), middle age (10-12 
months) and ageing (20-22 months) and epididymal fat pad samples were collected. 
The combined weight of both fat pads was measured. Data are expressed as mean ± 
SEM with a number of at least 8 mice per group. Comparisons were made by two-way 
ANOVA with bonferroni post-hoc test. *p<0.05 versus young mice ^p<0.05 versus age- 
matched WT mice.
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3.2.2 The effect of ageing on glucose and insulin levels and the role of 
Nox2
The fasting glucose and insulin levels were measured in the mice at all three age 
groups young (3-4 months), middle age (10-12 months) and ageing (20-22 months) to 
investigate possible insulin resistance with ageing and the role of Nox2. There was no 
significant difference in the fasting glucose levels across all age groups and across both 
WT and Nox2'' ’^ genotypes. However there was an increase in the fasting insulin levels 
between the young and middle aged WT mice (0.8 ± 0.1 versus 1.3 ± 0.3 pg/L p>0.05) 
and an even greater increase between the young and ageing WT mice (0.8 ± 0.1 versus 
2.1 ± 0.3 pg/L *p<0.05). In contrast there was no significant difference in fasting insulin 
levels between the Nox2'^' young and middle aged mice (0.6 ± 0.1 versus 0.8 ± 0.1 pg/L 
p>0.05) or between Nox2'^' young and ageing mice (0.6 ± 0.1 versus 0.8 ± 0.2 pg/L 
p>0.05). In regard to the effect of genotype with age, the insulin levels were 
significantly higher in ageing WT mice compared with ageing Nox2'^’ mice (2.1 ± 0.3 
versus 0.8 ± 0.2 pg/L **p<0.05).
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Figure 3.2 The effect of ageing on glucose and insulin levels in WT and
Nox2^ mice
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Legend to figure 3.2
(A) Fasting blood glucose levels of male WT (open bars) and Nox2'^' (filled bars) 
C57BI/6 mice at young (3-4 months), middle age (10-12 months) and ageing (20-22 
months). Mice were fasted overnight before a blood sample from the tall was taken 
and measured with a blood glucose meter. Data are expressed as mean ± SEM with a 
number of 6-12 mice per group. Comparisons were made by two-way ANOVA with 
bonferroni post-hoc test.
(B) Calibration curve for Insulin measurements. The optical density was measured at 
450 nm for calibrator concentrations of 0, 0.2, 0 .5 ,1 .5 , 3 and 6.5 pg/L Insulin.
(C) Fasting serum Insulin levels of male WT (open bars) and Nox2'^' (filled bars) C57BI/6 
mice at young (3-4 months), middle age (10-12 months) and ageing (20-22 months). 
Mice were fasted overnight and then euthanlsed before a blood sample was taken 
from the Inferior vena cava. The serum was separated by centrifugation and the level 
of Insulin was determined by an ELISA. Data are expressed as mean ± SEM with a 
number of 6-8 mice per group. Comparisons were made by two-way ANOVA with 
bonferroni post-hoc test. *p<0.05 versus young mice ^p<0.05 versus age-matched WT 
mice.
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3.2.3 The effect of ageing on glucose tolerance and the role of Nox2
Glucose tolerance tests were carried out on young (3-4 months), middle aged (10-12 
months) and ageing (20-22 months) mice to further investigate insulin resistance with 
ageing and the role of Nox2. There was no difference in fasting glucose levels between 
the young, middle aged and ageing WT or Nox2'^' mice before administration of 
glucose. After administration of glucose the concentration of glucose in the blood 
increased dramatically and levels peaked at around 15 - 30 minutes. Glucose levels 
then decreased between 30 and 120 minutes at differing rates with some mice 
showing signs of impaired glucose tolerance.
Glucose tolerance was significantly impaired in the ageing WT mice compared to 
young controls with significantly higher glucose levels both at 60 minutes after 
injection (16.4 ±1.0 versus 12.8 ± 0.7 mmol/L *p<0.05) and at 120 minutes after 
injection (11.8 ± 1.0 versus 7.6 ± 0.5 mmol/L *p<0.05). Glucose tolerance was also 
mildly impaired in middle aged mice however this difference was not significant. 
Glucose tolerance in the Nox2'^’ mice with ageing was not significantly different 
between any of the age groups at any time point.
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Figure 3.3 The effect of ageing on glucose tolerance in WT and Nox2
mice
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Legend to figure 3.3
Intraperintoneal glucose tolerance test (IPGTT) of male young (3-4 months), middle 
aged (10-12 months) and ageing (20-22 months) WT and Nox2'^' C57BI/6 mice. Mice 
were fasted overnight and the fasting blood glucose was determined before IP 
injection of glucose (2 g/kg). Blood glucose concentrations were measured at 15, 30, 
60, 90 and 120 minutes after injection to determine glucose tolerance. (A) IPGTT of WT 
mice. Data are expressed as mean ± SEM with a number of 9-11 mice per group. (B) 
IPGTT of Nox2'^' mice. Data are expressed as mean ± SEM with a number of 7-8 mice 
per group. Open circles represent young mice, grey filled circles represent middle aged 
mice and black filled circles represent ageing mice. Comparisons made by one-way 
ANOVA with bonferroni post-hoc test *p<0.05 for ageing mice versus time-point 
matched young mice.
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3.2.4 The effect of ageing on cholesterol levels and the role of Nox2
Total cholesterol and high-density lipoprotein (HDL) cholesterol levels in the fasting 
blood serum of young (3-4 months), middle aged (10-12 months) and ageing (20-22 
months) WT and Nox2’ '^ C57BI/6 mice were measured. Total cholesterol (TChol) levels 
were found to increase with increasing age and there were significant differences 
between the young WT mice compared to middle aged WT mice (2.0 ± 0.1 versus 2.7 ± 
0.1 mmol/L *p<0.05) and compared to ageing WT mice (2.0 ± 0.1 versus 2.7 ± 0.2 
mmol/L *p<0.05). HDL cholesterol followed a similar trend with increased serum 
concentrations with ageing in WT mice. Significant differences were seen between 
young and middle aged mice (1.6 ± 0.1 versus 2.1 ± 0.05 mmol/L *p<0.05) and 
between young and ageing mice (1.6 ± 0.1 versus 2.0 ± 0.1 mmol/L *p<0.05). No 
difference was seen in Nox2'^' ageing mice with cholesterol levels remaining similar 
between young and middle age (TChol: 2.0 ± 0.2 versus 2.1 ± 0.1 mmol/L; HDL:1.6 ± 0.1 
versus 1.7 ± 0.1 mmol/L ) and between young and ageing (TChol: 2.0 ± 0.2 versus 1.8 ± 
0.1 mmol/L; HDL: 1.6 ± 0.1 versus 1.6 ± 0.1 mmol/L). With regard to effect of genotype 
knockout of Nox2 significantly reduced total cholesterol in middle aged (2.7 ± 0.1 
versus 2.1 ± 0.1 mmol/L **p<0.05) and ageing mice (2.7 ± 0.2 versus 1.8 ± 0.1 mmol/L 
**p<0.05). Knockout of Nox2 also reduced HDL-Cholesterol levels but the effect was not 
significant.
Low-density lipoprotein (LDL) cholesterol levels were estimated using the Friedewald 
equation and increases were seen with ageing in WT mice although this was not 
significant. Nox2'^' mice generally had lower LDL cholesterol levels compared with their 
age-matched WT counterparts, however these differences were also not significant.
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Figure 3.4 The effect of ageing on cholesterol in WT and Nox2'^‘ mice
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Legend to figure 3.4
Total cholesterol and HDL-cholesterol levels were measured in male WT and Nox2'^‘ 
C57BI/6 mice with advancing age. Mice were fasted overnight and blood samples were 
collected from the vena cava. The serum was separated by centrifugation and 
cholesterol levels in the serum were determined using an I Lab 650 clinical chemistry 
system.
(A) Total cholesterol in male WT (open bars) and Nox2'^' (filled bars) C57BI/6 mice at 
young (3-4 months), middle age (10-12 months) and ageing (20-22 months). Data are 
expressed as mean ± SEM with a number of at least 8 mice per group. Comparisons 
were made by two-way ANOVA with bonferroni post-hoc test *p<0.05 versus young 
mice ^p<0.05 versus age-matched WT mice.
(B) High-density lipoprotein (HDL) cholesterol in male WT (open bars) and Nox2'^' 
(filled bars) C57BI/6 mice at young (3-4 months), middle age (10-12 months) and 
ageing (20-22 months). Data are expressed as mean ± SEM with a number of at least 8 
mice per group. Comparisons were made by two-way ANOVA with bonferroni post-hoc 
test *p<0.05 versus young mice.
(C) Low-density lipoprotein (LDL) cholesterol levels in male WT (open bars) and Nox2'^‘ 
(filled bars) C57BI/6 mice at young (3-4 months), middle age (10-12 months) and 
ageing (20-22 months) were estimated using the Friedewald equation:
LDL cholesterol = Total cholesterol -  HDL cholesterol - Triglycerides/2.17 (mmol/L)
Data are expressed as mean ± SEM with a number of at least 8 mice per group. 
Comparisons were made by two-way ANOVA with bonferroni post-hoc test.
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3.2.5 The effect of ageing on non-esterified fatty acid and triglyceride 
levels and the role of Nox2
Non-esterified fatty acid (NEFA) and triglyceride (TAG) levels in the fasting blood serum 
of young (3-4 months), middle aged (10-12 months) and ageing (20-22 months) WT 
and Nox2'^' C57BI/6 mice were determined. There was no significant difference in 
NEFA levels in the fasting blood serum across any of the age groups or between the 
two genotypes. There was however a significant decrease in TAG levels with ageing 
which was seen in both the WT mice (0.7 ± 0.04 versus 0.54 ± 0.05 mmol/L *p<0.05) 
and Nox2" '^ mice (0.6 ± 0.05 versus 0.34 ± 0.04 mmol/L *p<0.05). Differences were also 
seen between the two genotypes with a significant decrease in TAG between the WT 
and Nox2"' '^ mice at middle age (0.71 ± 0.04 versus 0.53 ± 0.04 mmol/L ^p<0.05) and 
ageing (0.54 ± 0.05 versus 0.34 ± 0.04 mmol/L ^p<0.05).
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Figure 3.5 The effect of ageing on non-esterified fatty acid and 
triglyceride levels in WT and Nox2' ‘^ mice
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Legend to figure 3.5
Non-esterified fatty acid (NEFA) and triglyceride (TAG) levels were measured in male 
WT and Nox2'^‘ C57BI/6 mice with advancing age. Mice were fasted overnight and 
blood samples were collected from the vena cava. The serum was separated by 
centrifugation and NEFA and TAG levels in the serum were determined using an ILab 
650 clinical chemistry system.
(A) NEFA in male WT (open bars) and Nox2'^' (filled bars) C57BI/6 mice at young (3-4 
months), middle age (10-12 months) and ageing (20-22 months). Data are expressed as 
mean ± SEM with a number of at least 8 mice per group. Comparisons were made by 
two-way ANOVA with bonferroni post-hoc test.
(B) TAG in male WT (open bars) and Nox2‘^ ' (filled bars) C57BI/6 mice at young (3-4 
months), middle age (10-12 months) and ageing (20-22 months). Data are expressed as 
mean ± SEM with a number of at least 8 mice per group. Comparisons were made by 
two-way ANOVA with bonferroni post-hoc test *p<0.05 versus young mice *p<0.05 
versus age-matched WT mice.
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3.2.6 The effect of ageing on blood pressure and the role of Nox2
The blood pressure of the mice was measured throughout their lifetime to investigate 
the effect of ageing on blood pressure. There was a significant increase in both systolic 
and diastolic blood pressure between the young (3-4 months) and ageing (20-21 
months) wild-type (WT) mice (systolic: 126 ± 3 versus 148 ± 4 mmHg *p<0.05; diastolic: 
99 ± 3 versus 117 ± 4 mmHg *p<0.05). In fact there was already a significant difference 
in both systolic and diastolic blood pressure between the young and middle aged (11- 
12 months) mice which then increased further with ageing.
In contrast to this there was no difference in either systolic or diastolic blood pressure 
between the young (3-4 months) and ageing (20-21 months) Nox2‘ '^ mice (systolic: 130 
± 1 versus 126 ± 3 mmHg p>0.05; diastolic: 105 ± 1 versus 100 ± 2 mmHg p>0.05). The 
blood pressure of the Nox2'^' mice remained stable at all age groups.
There was a significantly higher blood pressure in the WT ageing mice (20-21 months) 
compared to the Nox2'^" ageing mice (20-21 months) (systolic: 148 ± 4 versus 126 ± 3 
mmHg ^p<0.05; diastolic: 117 ± 4 versus 100 ± 2 mmHg ^p<0.05). This difference was 
again seen from middle age (11-12 months) and continued with ageing.
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Figure 3.6 The effect of ageing on blood pressure in WT and Nox2  ^ mice
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Legend to figure 3.6
Blood pressure was measured throughout the lifetime of the mice in approximately 3 
month intervals. Mice were trained for at least 4 days prior to measurement and blood 
pressure was measured by tail-cuff plethysmography between 9am and 12 pm. The 
mean of at least five successful recordings per mouse was used for result calculation.
(A) Systolic blood pressure (SBP) (B) Diastolic blood pressure (DBP) of male WT (open 
bars) and Nox2‘^ ‘ (filled bars) C57BI/6 mice. Data are expressed as mean ± SEM with a 
number of at least 8 mice per group. Comparisons were made by two-way ANOVA with 
bonferroni post-hoc test. *p<0.05 versus 3-4 months old mice ^p<0.05 versus age- 
matched WT mice.
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3.3 Discussion
In this chapter, the effect of ageing on cardiovascular risk factors and metabolic 
syndrome has been investigated with particular focus on the role of Nox2. Wild-type 
(WT) and Nox2 null (Nox2'" '^) C57BI/6 mice were grouped into young (3-4 months), 
middle age (10-12 months) and ageing (20-22 months) and obesity, glucose tolerance 
and insulin resistance, lipid levels and blood pressure were determined.
In this study WT mice developed hypertension with advancing age (figure 3.6) and in 
particular an increase in systolic and diastolic blood pressure was seen from middle 
age which persisted with ageing until 20-21 months where the blood pressure declined 
slightly. Studies have shown that oxidative stress is a major pathogenic factor in the 
development of hypertension but the primary source of ROS, particularly with ageing is 
still unclear. Elimination of the superoxide generating enzyme Nox2 was found to 
protect against ageing-induced hypertension with both systolic and diastolic blood 
pressure remaining stable throughout all age groups in Nox2'^' mice.
The ageing-related hypertension in WT mice was accompanied by increased 
bodyweight and fat mass which were both significantly increased even by middle age 
and remained elevated in ageing mice. The relationship between obesity and 
hypertension is well established, however the exact mechanisms by which obesity is 
associated with hypertension and ageing is still unclear. Increasing evidence indicates 
that oxidative stress may be an important link as increased ROS is present in both 
obesity and ageing. It has been shown in this study that removal of Nox2 prevents the 
development of hypertension (figure 3.6) and obesity (figure 3.1) with ageing which
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further supports a role for oxidative stress in the development of ageing related 
hypertension and obesity.
The food intake of the mice was measured to investigate whether the obesity in WT 
mice with ageing may be related to an increased caloric intake however there were no 
differences in food intake between the WT and Nox2'^' mice at any age group. The 
difference in bodyweight therefore, may be due to reduced activity of the WT mice 
with ageing which will be investigated and discussed further in chapter 5.
Insulin resistance is one of the major risk factors for metabolic syndrome and 
cardiovascular disease and is strongly associated with obesity and hypertension with 
ageing. Glucose levels in the fasting serum of the mice were assessed and no 
difference was seen with ageing in the WT or Nox2 '^ ' mice (figure 3.2 A). However an 
increase in insulin levels was seen with ageing in the WT mice (figure 3.2 C) indicating 
possible insulin resistance. To further support this result glucose tolerance was 
assessed (figure 3.3) and was found to be impaired in the ageing mice. It is clear from 
these results that insulin resistance occurs with advancing age however not to such an 
extent that hyperglycaemia exists. The high insulin concentrations are still able to 
prevent hyperglycaemia indicating that the mice are not completely insulin resistant. 
In contrast in the Nox2‘ '^ mice there is no evidence of insulin resistance with insulin 
levels remaining stable and glucose tolerance unimpaired.
Increased levels of total cholesterol were found with ageing in the WT mice (figure 3.4)
and interestingly this was accompanied by an increase in high-density lipoprotein
(HDL) cholesterol. This was unexpected as HDL-cholesterol, which is often seen to be
decreased with ageing, is known as the 'good' cholesterol which protects against
96
atherosclerosis and the development of cardiovascular diseases by transporting excess 
cholesterol to the liver to be disposed of. It may be that the increase in HDL- 
cholesterol levels is a protective mechanism in response to the high levels of low- 
density lipoprotein (LDL) cholesterol circulating in the system. LDL-cholesterol levels 
were calculated using the Friedewald equation and, although not significant, were 
increased with ageing in the WT mice. In the Nox2’ ‘^ mice there was no difference in 
any of the cholesterol levels with ageing providing evidence that elimination of Nox2 
protects against ageing-induced hypercholesterolaemia.
Non-esterified fatty acids (NEFA) were investigated with ageing and no difference was 
found between any age group or between the WT and Nox2'^' genotypes (figure 3.5). 
In contrast triglyceride levels were found to decrease with ageing which was 
unexpected as levels are often seen to be increased with ageing and are linked to the 
development of cardiovascular disease. It may be that high triglyceride levels have 
stimulated increased uptake into adipose and/or liver tissue.
Overall these findings have shown that ageing leads to the development of 
hypertension, obesity, insulin resistance and hypercholesterolaemia all of which can be 
prevented by deletion of Nox2. The next chapter will further investigate the role of 
Nox2 and oxidative stress in cardiovascular diseases particularly focusing on 
endothelial dysfunction with ageing which may be associated with ageing-related 
hypertension.
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Chapter 4 
The role of Nox2-derived oxidative stress in ageing-related 
vascular dysfunction
4.1 Introduction
The endothelium is a single layer of cells which lines the interior surface of the entire 
vascular system to form a semi-permeable barrier between the circulating blood and 
surrounding tissues. Endothelial cells can produce and react to cytokines, growth 
factors, adhesion molecules, vasoactive substances and chemokines and therefore play 
a role in a wide variety of processes such as haemostasis and coagulation, immune and 
inflammatory reactions, angiogenesis and regulation of vascular tone (Galley and 
Webster, 2004). Dysfunction of the endothelium contributes to several cardiovascular 
diseases such as atherosclerosis, hypertension and heart failure. Reactive oxygen 
species (ROS) have been shown to be involved in the physiological regulation of the 
endothelium but also, when in excess, can contribute to disease pathology (Li and 
Shah, 2004). Overproduction or imbalance of ROS can cause oxidative stress which 
damages the endothelium and disrupts vascular homeostasis. Ageing is associated with 
increased oxidative stress and is therefore a strong risk factor for the development of 
endothelial dysfunction.
The mechanisms behind vascular ageing and ageing-related endothelial dysfunction 
are not fully elucidated but a large body of evidence supports a role for increased 
superoxide production and reduced bioavailability of nitric oxide (NO). An ageing-
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related impairment in endothelium-dependent relaxation to acetylcholine in mice 
between 6-7 and 17-18 months of age has been associated with increased levels of 
superoxide and oxidative stress and decreased levels of NO (Francia et al., 2004). In 
agreement with this finding a previous study carried out in rats at ages 4-6 months and 
32-35 months also reported a decrease in endothelium-dependent relaxation to 
acetylcholine with ageing along with increased superoxide production and decreased 
NO bioavailability (van der Loo et al., 2000). Data from a human study demonstrating 
increased levels of superoxide and endothelial dysfunction in aged patients further 
supports these findings (Rodriguez-Manas et al., 2009).
Numerous findings implicate the involvement of the NADPH oxidase enzyme in 
oxidative stress mediated endothelial dysfunction. In angiotensin II treated mice 
deletion of p4 ?P^ °^  prevented an increase in superoxide production and protected 
against impaired endothelium-dependent relaxation (Li et al., 2004) and in both high- 
fat diet fed mice and insulin-resistant ESMIRO (endothelial-specific mutated human 
insulin receptor overexpression) mice deletion of Nox2 provided the same protection 
(Du et al., 2013; Sukumar et al., 2013).
Although the exact mechanisms involved in vascular ageing and ageing-related 
endothelial dysfunction are not fully understood increasing evidence suggests that 
Nox2-derived oxidative stress may play a substantial role. More information is needed 
however to further understand the significance of Nox2 and therefore this study 
focuses on identifying the role of Nox2 in vascular ageing and ageing-related 
endothelial dysfunction. Groups of young (3-4 months), middle aged (10-12 months) 
and ageing (20-22 months) Nox2'^' mice and their wild-type (WT) controls were
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assessed for vascular function. Age-related differences in superoxide production, Nox2 
expression, nitric oxide levels and elastin content were also investigated.
4.1.1 Aims and objectives
The aim of this chapter was to uncover the role of Nox2-derived oxidative stress in the 
development of vascular dysfunction with ageing and therefore the objectives were:
1. To investigate the development of endothelial dysfunction with ageing and 
determine whether deletion of Nox2 may be protective
2. To measure the level of superoxide production and Nox2 protein expression 
with ageing and determine the effect of Nox2 deletion
3. To asses nitric oxide bioavailability with ageing and the role of Nox2
4. To determine elastin and collagen content with ageing
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4.2 Results
4.2.1 The role of Nox2 on vascular function in young mice
The vascular function of young (3-4 months) WT and Nox2’ '^ mice was investigated 
using an organ bath. Firstly, the smooth muscle cell contraction to phenylephrine (PE) 
was assessed and no significant difference was seen in the maximum contraction 
(Emax) between the WT and Nox2'^' mice (0.29 ± 0.01 versus 0.26 ±0.01 g p>0.05). 
Secondly, the smooth muscle cell relaxation (endothelium independent) was assessed 
by the nitric oxide donor sodium nitroprusside (SNP) after pre-contraction with PE. No 
significant difference was seen in the maximum vessel relaxation (Emax) to SNP, 
calculated as a percentage of the total PE contraction, between the WT and Nox2'" '^ 
mice (96 ± 2.6 versus 100 ± 2.6 % p>0.05). Finally the endothelium dependent 
relaxation was assessed by acetylcholine (ACh) which stimulates the endothelium to 
produce nitric oxide. There was no significant difference in the maximum vessel 
relaxation (Emax) to ACh, calculated as a percentage of the total PE contraction, 
between the WT and Nox2'^' mice (75 ± 2.4 versus 82 ± 3.6 % p>0.05).
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Figure 4.1 The role of Nox2 on vascular function In young mice
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Legend to figure 4.1
Aortic rings from young (3-4 months) male WT (open circles) and Nox2 '^ ' (filled circles) 
C57BI/6 mice were prepared and hung in an organ bath for measurement of vascular 
function.
(A) Smooth muscle contraction was assessed by adding cumulative concentrations (1 
nM to 10 pM) of phenylephrine (PE). Data are expressed as mean ± SEM with a 
number of 8-12 mice per group. Comparisons of Emax values were made by the 
student's t-test.
(B) Endothelium independent relaxation was assessed by adding cumulative 
concentrations (0.1 nM to 1 pM) of sodium nitroprusside (SNP). Data are expressed as 
mean ± SEM with a number of 10-11 mice per group. Comparisons of Emax values 
were made by the student's t-test.
(C) Endothelium dependent relaxation was assessed by adding cumulative 
concentrations (1 nM to 10 pM) of acetylcholine (ACh). Data are expressed as mean ± 
SEM with a number of 9-10 mice per group. Comparisons of Emax values were made 
by the student's t-test.
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4.2.2 The role of Nox2 on vascular function in middle aged mice
The vascular function of middle aged (10-12 months) WT and Nox2'^" mice was 
investigated using an organ bath. Firstly, the smooth muscle cell contraction to 
phenylephrine (PE) was assessed and no significant difference was seen in the 
maximum contraction (Emax) between the WT and NoxZ '^  mice (0.30 ± 0.01 versus 
0.27 ± 0.01 g p>0.05). Secondly, the smooth muscle cell relaxation (endothelium  
independent) was assessed by the nitric oxide donor sodium nitroprusside (SNP) after 
pre-contraction with PE. No significant difference was seen in the maximum vessel 
relaxation (Emax) to SNP, calculated as a percentage of the total PE contraction, 
between the WT and Nox2'^' mice (95 ± 2.2 versus 101 ± 2.6 % p>0.05). Finally the 
endothelium dependent relaxation was assessed by acetylcholine (ACh) which 
stimulates the endothelium to produce nitric oxide. There was a significant decrease in 
the maximum vessel relaxation (Emax) to ACh, calculated as a percentage of the total 
PE contraction, between the WT and Nox2'^' mice (69 ± 2.4 versus 81 ± 3.3 % *p<0.05).
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Figure 4.2 The role of Nox2 on vascular function In middle aged mice
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Legend to figure 4.2
Aortic rings from middle aged (10-12 months) male WT (open circles) and Nox2'^' (filled 
circles) C57BI/6 mice were prepared and hung in an organ bath for measurement of 
vascular function.
(A) Smooth muscle contraction was assessed by adding cumulative concentrations (1 
nM to 10 pM) of phenylephrine (PE). Data are expressed as mean ± SEM with a 
number of 8-12 mice per group. Comparisons of Emax values were made by the 
student's t-test.
(B) Endothelium independent relaxation was assessed by adding cumulative 
concentrations (0.1 nM to 1 pM) of sodium nitroprusside (SNP). Data are expressed as 
mean ± SEM with a number of 9-10 mice per group. Comparisons of Emax values were 
made by the student's t-test.
(C) Endothelium dependent relaxation was assessed by adding cumulative 
concentrations (1 nM to 10 pM) of acetylcholine (ACh). Data are expressed as mean ± 
SEM with a number of 8-11 mice per group. Comparisons of Emax values were made 
by the student's t-test *p<0.05 WT versus Nox2'^'.
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4.2.3 The role of Nox2 on vascular function in ageing mice
The vascular function of ageing (20-22 months) WT and Nox2'^’ mice was investigated 
using an organ bath. Firstly, the smooth muscle cell contraction to phenylephrine (PE) 
was assessed and no significant difference was seen in the maximum contraction 
(Emax) between the WT and Nox2'^’ mice (0.31 ± 0.02 versus 0.27 ± 0.02 g p>0.05). 
Secondly, the smooth muscle cell relaxation (endothelium independent) was assessed 
by the nitric oxide donor sodium nitroprusside (SNR) after pre-contraction with PE. No 
significant difference was seen in the maximum vessel relaxation (Emax) to SNP, 
calculated as a percentage of the total PE contraction, between the WT and Nox2'^' 
mice (96 ± 2.5 versus 101 ± 1.8 % p>0.05). Finally the endothelium dependent 
relaxation was assessed by acetylcholine (ACh) which stimulates the endothelium to 
produce nitric oxide. There was a significant decrease in the maximum vessel 
relaxation (Emax) to ACh, calculated as a percentage of the total PE contraction, 
between the WT and Nox2'^' mice (64 ± 1.9 versus 80 ± 2.4 % *p<0.05).
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Figure 4.3 The role of Nox2 on vascular function in ageing mice
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Legend to figure 4.3
Aortic rings from ageing (20-22 months) male WT (open circles) and Nox2 '^ ’ (filled 
circles) C57BI/6 mice were prepared and hung in an organ bath for measurement of 
vascular function,
(A) Smooth muscle contraction was assessed by adding cumulative concentrations (1 
nM to 10 pM) of phenylephrine (PE). Data are expressed as mean ± SEM with a 
number of 9-12 mice per group. Comparisons of Emax values were made by the 
student's t-test.
(B) Endothelium independent relaxation was assessed by adding cumulative 
concentrations (0.1 nM to 1 pM) of sodium nitroprusside (SNP). Data are expressed as 
mean ± SEM with a number of 11 mice per group. Comparisons of Emax values were 
made by the student's t-test.
(C) Endothelium dependent relaxation was assessed by adding cumulative 
concentrations (1 nM to 10 pM) of acetylcholine (ACh). Data are expressed as mean ± 
SEM with a number of 11-12 mice per group. Comparisons of Emax values were made 
by the student's t-test *p<0.05 WT versus Nox2'^'.
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4.2.4 The effect of ageing on vascular function in WT and Nox2' '^ mice
The endothelium dependent relaxation of young (3-4 months), middle aged (10-12 
months) and ageing (20-22 months) WT mice was compared to see the effect of ageing 
on endothelium function. The acetylcholine (ACh) Emax was decreased in middle aged 
mice compared to young mice but this effect was not significant (69 ± 2.4 versus 75 ±
2.4 % p>0.05). The ACh Emax was further decreased with advancing age and a 
significant difference between the relaxation in ageing mice compared with young 
mice was found (64 ± 1.9 versus 75 ± 2.4 % *p<0.05). There was also a significant 
difference in the ACh logECso value between the young and ageing mice (7.7 ± 0.1 
versus 7.1 ± 0.1 *p<0.05) however no difference was seen between young and middle 
aged mice (7.7 ± 0.1 versus 7.7 ± 0.1 p>0.05).
The endothelium dependent relaxation of young (3-4 months), middle aged (10-12 
months) and ageing (20-22 months) Nox2'^' mice was compared to investigate the role 
of Nox2 on endothelium function with ageing. There was no significant difference in 
the ACh Emax between the young and middle aged mice (82 ± 3.6 versus 81 ± 3.3 % 
p>0.05) and the young and ageing mice (82 ± 3.6 versus 80 ± 2.4 % p>0.05). There was 
also no significant difference in the ACh logEC50 value between the young and middle 
aged mice (7.7 ± 0.2 versus 7.4 ±0.1 p>0.05) and the young and ageing mice (7.7 ± 0.2 
versus 7.3 ±0.1 p>0.05).
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Figure 4.4 The effect of ageing on vascular function in WT and Nox2
mice
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Legend to figure 4.4
Aortic rings from young (3-4 months), middle aged (10-12 months) and ageing (20-22 
months) male WT and Nox2'^' C57BI/6 mice were prepared and hung in an organ bath 
for measurement of vascular function.
(A) Endothelium dependent relaxation was assessed by adding cumulative
concentrations (1 nM to 10 pM) of acetylcholine (ACh). Aortic relaxation of young 
(open circles), middle aged (grey filled circles) and ageing (black filled circles) WT mice 
were compared. Data are expressed as mean ± SEM with a number of 10-11 mice per 
group. Comparisons of Emax values were made by one-way ANOVA with bonferroni 
post-hoc test *p<0.05 young versus ageing.
(B) Endothelium dependent relaxation was assessed by adding cumulative
concentrations (1 nM to 10 pM) of acetylcholine (ACh). EC50 values were derived from 
a non-linear dose response curve fit for young (open bar), middle aged (grey filled bar) 
and ageing (black filled bar) WT mice. Data are expressed as mean ± SEM with a 
number of 10-11 mice per group. Comparisons of EC50 values were made by one-way 
ANOVA with bonferroni post-hoc test *p<0.05 young versus ageing.
(C) Endothelium dependent relaxation was assessed by adding cumulative
concentrations (1 nM to 10 pM) of acetylcholine (ACh). Aortic relaxation of young 
(open circles), middle aged (grey filled circles) and ageing (black filled circles) Nox2‘^ ‘ 
mice were compared. Data are expressed as mean ± SEM with a number of 10-11 mice 
per group. Comparisons of Emax values were made by one-way ANOVA with 
bonferroni post-hoc test.
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(D) Endothelium dependent relaxation was assessed by adding cumulative 
concentrations (1 nM to 10 pM) of acetylcholine (ACh). EC50 values were derived from 
a non-linear dose response curve fit for young (open bar), middle aged (grey filled bar) 
and ageing (black filled bar) Nox2’ '^ mice. Data are expressed as mean ± SEM with a 
number of 10-11 mice per group. Comparisons of EC50 values were made by one-way 
ANOVA with bonferroni post-hoc test.
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4.2.5 The effect of L-NAME on vascular relaxation with ageing in WT
mice
The endothelium dependent relaxation of young (3-4 months), middle aged (10-12 
months) and ageing (20-22 months) WT C57BI/6 mice in the presence or absence of 
the nitric oxide synthase (NOS) inhibitor Nw-Nitro-L-arginine methyl ester (L-NAME) 
was compared to investigate the role of NOS and nitric oxide in endothelium 
dependent relaxation of the aorta. Due to the nature of the response to ACh in the 
presence of L-NAME a non-linear dose response curve could not be fit to the data and 
so statistical comparisons were made between the relaxation of the vessels using the 
final data point value. The acetylcholine relaxation response was completely impaired 
in young aortas treated with L-NAME compared with the young control aortas (-10.5 ±
3.7 versus 74.8 ± 1.7 % *p<0.05), this effect was also seen in middle aged mice (-4.4 ±
6.1 versus 69.7 ± 3.0 % *p<0.05). In ageing mice the relaxation response was 
significantly impaired (-0.7 ± 5.6 versus 65.0 ± 1.3 % *p<0.05) but not completely 
abolished.
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Figure 4.5 The effect of L-NAME on vascular relaxation with ageing In WT
mice
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Legend to figure 4.5
Aortic rings from young (3-4 months), middle aged (10-12 months) and ageing (20-22 
months) male WT C57BI/6 mice were prepared and hung in an organ bath for 
measurement of vascular function. One set of rings from each age group were 
incubated in 300 pM of the nitric oxide synthase (NOS) inhibitor Nw-Nitro-L-arginine 
methyl ester (L-NAME) for 30 minutes before relaxation to acetylcholine. Endothelium 
dependent relaxation in mice was assessed by adding cumulative concentrations (1 nM 
to 10 pM) of acetylcholine (ACh) to both control (open circles) and L-NAME (filled 
circles) treated aortas.
(A) Endothelium dependent relaxation in young mice. Data are expressed as mean ± 
SEM with a number of 10 mice per group. Comparisons of relaxation were made by the 
student's t-test *p<0.05 control versus L-NAME.
(B) Endothelium dependent relaxation in middle aged mice. Data are expressed as 
mean ± SEM with a number of 10 mice per group. Comparisons of relaxation were 
made by the student's t-test *p<0.05 control versus L-NAME.
(C) Endothelium dependent relaxation in ageing mice. Data are expressed as mean ± 
SEM with a number of 8-11 mice per group. Comparisons of relaxation were made by 
the student's t-test *p<0.05 control versus L-NAME.
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4.2.6 The effect of L-NAME on vascular relaxation with ageing in Nox2'^'
mice
The endothelium dependent relaxation of young (3-4 months), middle aged (10-12 
months) and ageing (20-22 months) Nox2'^‘ C57BI/6 mice in the presence or absence of 
the nitric oxide synthase (NOS) inhibitor Nw-Nitro-L-arginine methyl ester (L-NAME) 
was compared to investigate the role of NOS and nitric oxide in endothelium 
dependent relaxation of the aorta. Due to the nature of the response to ACh in the 
presence of L-NAME a non-linear dose response curve could not be fit to the data and 
so statistical comparisons were made between the relaxation of the vessels using the 
final data point value. The acetylcholine relaxation response was completely impaired 
in young aortas treated with L-NAME compared with the young control aortas (-1.41±
3.8 versus 84.2 ± 4.0 % *p<0.05), this effect was also seen in middle aged mice (-5.7 ±
4.1 versus 80.8 ± 3.1 % *p<0.05) and ageing mice (-0.9 ± 5.5 versus 78.8 ± 2.5 % 
♦p<0.05).
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Figure 4.6 The effect of L-NAME on vascular relaxation with ageing In
Nox2^ mice
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Legend to figure 4.6
Aortic rings from young (3-4 months), middle aged (10-12 months) and ageing (20-22 
months) male Nox2'^’ C57BI/6 mice were prepared and hung in an organ bath for 
measurement of vascular function. One set of rings from each age group were 
incubated in 300 pM of the nitric oxide synthase (NOS) inhibitor Nw-Nitro-L-arginine 
methyl ester (L-NAME) for 30 minutes before relaxation to acetylcholine. Endothelium 
dependent relaxation in mice was assessed by adding cumulative concentrations (1 nM 
to 10 pM) of acetylcholine (ACh) to both control (open circles) and L-NAME (filled 
circles) treated aortas.
(A) Endothelium dependent relaxation in young mice. Data are expressed as mean ± 
SEM with a number of 8-9 mice per group. Comparisons of relaxation were made by 
the student's t-test *p<0.05 control versus L-NAME.
(B) Endothelium dependent relaxation in middle aged mice. Data are expressed as 
mean ± SEM with a number of 6-8 mice per group. Comparisons of relaxation were 
made by the student's t-test *p<0.05 control versus L-NAME.
(C) Endothelium dependent relaxation in ageing mice. Data are expressed as mean ± 
SEM with a number of 6-12 mice per group. Comparisons of relaxation were made by 
the student's t-test *p<0.05 control versus L-NAME.
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4.2.7 The effect of ageing and the role of Nox2 on aortic ROS production 
detected by DHE fluorescence
The reactive oxygen species (ROS) production in aortas of young (3-4 months), middle 
aged (10-12 months) and ageing (20-22 months) WT and Nox2'^' C57BI/6 mice was 
assessed by dihydroethidium (DHE) fluorescence. In WT mice the red DHE fluorescence 
was increased with ageing but was reduced in Nox2'^' mice. This was confirmed by 
quantification of the fluorescent intensities.
There was an increase in fluorescent intensity between the young and middle aged WT 
aortas but this was not significant (70.7 ± 7.7 versus 98.9 ± 6.5 p>0.05). Fluorescent 
intensity increased further with ageing and there was a significant increase in 
fluorescent intensity between the young and ageing WT aortas (70.7 ± 7.7 versus 116.6 
± 8.0 *p<0.05). There was a significant decrease in fluorescent intensities in the Nox2‘ '^ 
aortas compared with the WT aortas at young (43.4 ± 7.4 versus 70.7 ± 7.7 ^p<0.05), 
middle age (66.9 ± 4.5 versus 98.9 ± 6.5 ^p<0.05), and ageing (85.2 ± 4.5 versus 116.6 ±
8.0 ^p<0.05). There was also an increase in fluorescence intensity with ageing in the 
Nox2‘^ ’ aortas with a significant difference between the young and ageing mice (43.4 ±
7.4 versus 85.2 ± 4.5 *p<0.05).
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Figure 4.7 The effect of ageing and the role of Nox2 on aortic ROS
production detected by DHE fluorescence
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Legend to figure 4.7
Frozen sections of aorta (6 pm) from young (3-4 months), middle aged (10-12 months) 
and ageing (20-22 months) male WT and Nox2'^' C57BI/6 mice were incubated with 0.5 
pM of dihydroethidium (DFIE). Intracellular ROS production was detected under a 
fluorescent microscope with a Cy3 filter (excitation: 530-560 nm; emission: 575-650 
nm).
(A) Representative fluorescent images, captured at 20X magnification, of intracellular 
ROS production in aortic sections.
(B) Quantitative analysis of fluorescence intensities of images of aortic sections from 
WT (open bars) and Nox2'^‘ (filled bars) mice. Data are expressed as mean ± SEM with a 
number of 9 sections from 3 mice {>10 images per section). Comparisons were made 
by two-way ANOVA with bonferroni post-hoc test *p<0.05 versus young mice *p<0.05 
versus age-matched WT mice.
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4.2.8 The effect of ageing and the role of Nox2 on aortic ROS production 
detected by lucigenin chemiluminescence
The reactive oxygen species (ROS) production in aortic homogenates of young (3-4 
months), middle aged (10-12 months) and ageing (20-22 months) WT and Nox2'^’ 
C57BI/6 mice was assessed by lucigenin chemiluminescence. There was a significant 
increase in ROS production in ageing WT aortic homogenates compared with young 
WT controls (77.8 ± 4.2 versus 46.7 ± 3.3 MLU *p<0.05). There was also a significant 
increase in ROS production in ageing Nox2‘^ ' aortic homogenates compared with young 
Nox2'^' controls (47.3 ± 7.7 versus 33.0 ± 2.3 MLU *p<0.05). Regarding effect of 
genotype, there was a decrease in ROS production in Nox2'^’ compared with WT aortic 
homogenates at young (33.0 ± 2.3 versus 46.7 ± 3.3 MLU p>0.05) and middle age (30.2 
± 4.8 versus 49.1 ± 5.0 MLU p>0.05) although this was not significant. There was 
however a significant decrease in ROS production in Nox2 '^ ' compared with WT ageing 
aortic homogenates (47.3 ± 7.7 versus 77.8 ± 4.2 MLU ^p<0.05).
To confirm that superoxide is the major type of ROS being produced lucigenin 
chemiluminescence was carried out in the presence or absence of 20 mM of the 
superoxide scavenger tiron. There was a significant decrease in ROS production in the 
WT aortic homogenates in the presence of tiron at young (27.6 ± 5.7 versus 46.7 ± 3.3 
MLU ^p<0.05), middle age (26.5 ± 4.4 versus 49.1 ± 5.0 MLU ^p<0.05) and ageing (24.7 
± 1.8 versus 77.8 ± 4.2 MLU ^p<0.05). There was also a significant decrease in ROS 
production in the Nox2'^' aortic homogenates in the presence of tiron at young (12.5 ±
3.1 versus 33.0 ± 2.3 MLU ^p<0.05), middle age (11.8 ± 2.8 versus 30.2 ± 4.8 MLU 
^p<0.05) and ageing (9.0 ± 1.1 versus 47.3 ± 7.7 MLU ^p<0.05).
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An inhibitor assay was carried out to determine the source of superoxide in young WT 
mice. Aortic homogenates were incubated with either buffer, 100 pM of the nitric 
oxide synthase (NOS) inhibitor Nw-Nitro-L-arginine methyl ester (L-NAME), 100 pM of 
the xanthine oxidase inhibitor oxypurinol (oxy), 20 pM of the NADPH oxidase inhibitor 
diphenyleneiodonium (DPI) or 20 mM of tiron. There was a significant decrease in ROS 
production in the presence of DPI (30.0 ± 2.9 versus 49.7 ± 1.8 MLU *p<0.05) or tiron 
(10.7 ± 4.7 versus 49.7 ± 1.8 MLU *p<0.05) but not in the presence of L-NAME or 
oxypurinol.
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Figure 4.8 The effect of ageing and the role of Nox2 on aortic superoxide 
production detected by lucigenin chemiluminescence
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Legend to figure 4.8
ROS production was detected in aortic homogenates by NADPH-dependant lucigenin 
(5 pM) chemiluminescence.
(A) ROS production in young (3-4 months), middle aged (10-12 months) and ageing 
(20-22 months) male WT (open bars) and Nox2'^" (filled bars) C57BI/6 mice. Data are 
expressed as mean ± SEM with a number of 4-6 measurements from 8-12 mouse 
aortas. Comparisons were made by two-way ANOVA with bonferroni post-hoc test 
*p<0.05 versus young mice ^p<0.05 versus age-matched WT mice.
(B) ROS production in young (3-4 months), middle aged (10-12 months) and ageing (20- 
22 months) male WT C57BI/6 mice in the presence (filled bars) or absence (open bars) 
of 20 mM of the superoxide scavenger tiron. Data are expressed as mean ± SEM with a 
number of 4-6 measurements from 10-12 mouse aortas. Comparisons were made by 
two-way ANOVA with bonferroni post-hoc test *p<0.05 versus young mice **p<0.05 
tiron versus control.
(C) Inhibitor assay in young (3-4 months) WT C57BI/6 mice to confirm source of 
superoxide. Homogenates were incubated with 100 pM L-NAME, 100 pM oxypurinol 
(Oxy), 20 pM diphenyleneiodonium (DPI) or 20 mM tiron for 15 minutes before 
measurement of superoxide production by NADPH-dependant lucigenin 
chemiluminesence. Data are expressed as mean ± SEM with a number of 3 
measurements from 9 mouse aortas. Comparisons were made by one-way ANOVA 
with bonferroni post-hoc test *p<0.05 versus vehicle.
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(D) ROS production in young (3-4 months), middle aged (10-12 months) and ageing 
(20-22 months) male Nox2‘ ‘^ C57BI/6 mice in the presence (filled bars) or absence 
(open bars) of 20 mM of the superoxide scavenger tiron. Data are expressed as mean ± 
SEM with a number of 4-6 measurements from 10-12 mouse aortas. Comparisons 
were made by two-way ANOVA with bonferroni post-hoc test ^p<0.05 tiron versus 
control.
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4.2.9 The effect of ageing on Nox2 expression in the aorta detected by 
immunofluorescence and western blotting
The expression of Nox2 in the endothelium of the aorta in young (3-4 months) and 
ageing (20-22 months) WT and Nox2'^‘ C57BI/6 mice was investigated by 
immunofluorescence. The red fluorescence of the endothelium marker CD31 and the 
blue fluorescence of the nuclear stain DAPI were not changed in any of the groups. 
However in WT mice the green Nox2 fluorescence was increased with ageing and was 
absent in the Nox2'^' mice.
The expression of Nox2 in the aorta in young (3-4 month), middle aged (10-12 months) 
and ageing (20-22 months) WT C57BI/6 mice was confirmed by western blotting. 
Expression of Nox2 in the aorta was increased in middle aged mice compared with 
young controls and was even further increased in ageing mice. The expression of the 
membrane bound Nox2 subunit p22^^°  ^was also increased with ageing. Tubulin which 
was used as a protein loading control was not different at any age group.
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Figure 4.9 The effect of ageing on Nox2 expression in the aorta detected
by immunofluorescence and western blotting
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Legend to figure 4.9
(A) Immunofluorescence images of 10 pM frozen aortic sections from young (3-4 
months) and ageing (20-22 months) male WT and Nox2'^' C57BI/6 mice. Sections are 
stained with Nox2 (green), the nuclear stain DAPI (blue) and the endothelial cell 
marker CD31 (red). Fluorescent labelled antigens were visualised using an Olympus 
BX61 fluorescent microscope equipped with an argon UV lamp to investigate CY3 
(excitation/emission: 530-560/575-650 nm), FITC (excitation/emission: 470-495/510- 
550 nm) and DAPI (excitation/emission: 360-370/420-460 nm) fluorescence.
(B) Detection of Nox2 and p22*^ °^^  proteins in aortic homogenates from young (3-4 
months), middle aged (10-12 months) and ageing (20-22 months) WT mice by western 
blot. Alpha-tubulin was used as a protein loading control.
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4.2.10 The effect of ageing and the role of Nox2 on nitric oxide levels
The nitric oxide levels in the fasting serum were assessed by measuring the 
concentration of its breakdown product nitrite in young (3-4 months), middle aged 
(10-12 months) and ageing (20-22 months) WT and Nox2'^' C57BI/6 mice. There were 
no significant differences found in the serum nitrite levels across all age groups in both 
WT and Nox2 '^ ' mice.
Figure 4.10 The effect of ageing and the role of Nox2 on nitric oxide 
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Legend to figure 4.10
Serum nitrite concentration in young (3-4 months), middle aged (10-12 months) and 
ageing (20-22 months) WT (open bars) and Nox2'^' (filled bars) C57BI/6 mice. Data are 
expressed as mean ± SEM with a number of 5-7 mice per group. Comparisons were 
made by two-way ANOVA with bonferroni post-hoc test.
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4.2.11 The effect of ageing on the morphology of the aorta
The collagen and elastin content in the aorta of young (3-4 months) and ageing (20-22 
months) WT C57BI/6 mice was investigated using the Verhoeff-Van Gieson staining 
technique. Fragmentation of elastin fibres was seen in the ageing mouse aortas but 
not in the young mice. There is also increased collagen content in the vascular wall 
which is much thicker in the ageing mice compared to the young mice.
Figure 4.11 The effect of ageing on the morphology of the aorta
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Legend to figure 4.11
(A) Verhoeff Van Gieson staining images of 10 pM frozen aortic sections from young 
(3-4 months) and ageing (20-22 months) male WT C57BI/6 mice. The elastin in the 
sections is stained black, collagen is stained red and other tissue is stained yellow.
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4.3 Discussion
In this chapter, vascular ageing and ageing-related endothelial dysfunction have been 
investigated with particular focus on the role of Nox2. Wild-type (WT) and Nox2 null 
(Nox2'^‘) C57BI/6 mice were grouped into young (3-4 months), middle age (10-12 
months) and ageing (20-22 months) and vascular function, superoxide production and 
Nox2 expression were assessed.
Firstly vascular function was assessed in young mice starting with investigation of the 
smooth muscle cell contraction response to phenylephrine. There was no difference in 
the contractile ability of the smooth muscle cells in the aorta between the young WT 
and Nox2’ '^ mice. Next the relaxation response of the smooth muscle cells to the nitric 
oxide donor sodium nitroprusside was examined and there was no difference in the 
ability of the aorta to relax between the young WT and Nox2'' ’^ mice. After confirming 
that the smooth muscle function was intact the endothelium-dependent relaxation to 
acetylcholine was assessed. There was no difference in the acetylcholine-induced 
relaxation of the young WT and Nox2'"^ ‘ mice indicating healthy function of the 
endothelium.
Vascular function was then assessed in middle aged mice starting again with 
investigation of the smooth muscle cell contraction response to phenylephrine. There 
was no difference in the contractile ability of the smooth muscle cells in the aorta 
between the middle aged WT and Nox2‘"^' mice. The relaxation response of the smooth 
muscle cells to the nitric oxide donor sodium nitroprusside was then examined and 
there was no difference in the ability of the aorta to relax between the middle aged
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WT and Nox2" '^ mice. After confirming that the smooth muscle function was 
maintained at middle age the endothelium-dependent relaxation to acetylcholine was 
assessed. Middle-aged WT mice exhibited signs of endothelial dysfunction as the 
relaxation of the aorta in response to acetylcholine was reduced compared to the 
response in young mice (figure4.4a). This dysfunction was reversed with elimination of 
Nox2 as evidenced by an improved relaxation response to acetylcholine in the Nox2'^' 
middle-aged mice (figure 4.2c).
Vascular function in ageing mice was then investigated and there was no difference 
between WT and Nox2'^’ ageing mice in the contractile ability of the smooth muscle 
cells in the aorta as assessed by response to phenylephrine or the relaxation ability as 
assessed by sodium nitroprusside. Therefore the smooth muscle function is preserved 
even at old age however endothelial dysfunction is further exacerbated at old age 
evidenced by a decrease in acetylcholine-induced vessel relaxation in ageing mice 
compared with both young and middle-aged mice. In contrast endothelial function was 
preserved even at old age in Nox2'^' mice which demonstrates the importance of the 
Nox2 enzyme in the development of ageing related endothelial dysfunction.
To further elucidate the mechanisms involved in ageing-related endothelial 
dysfunction experiments assessing endothelium-dependent relaxation were carried 
out in the presence of the nitric oxide synthase (NOS) inhibitor Nw-Nitro-L-arginine 
methyl ester (L-NAME). The relaxation response to acetylcholine was completely 
abolished in young and middle-aged WT and Nox2'^' mice in the presence of L-NAME. 
However although the relaxation response in aged mice was significantly reduced it 
was not completely impaired, particularly in the WT mice where the aorta relaxed by
134
over 25 % before the high concentrations of acetylcholine caused a contraction of the 
smooth muscle. This is due to the fact that acetylcholine can cause both relaxation and 
contraction of the smooth muscle and in the absence of nitric oxide due to inhibition 
of NOS by L-NAME contraction is favoured. The ability of the ageing aorta to relax in 
the presence of L-NAME, even by only a small amount, suggests that the involvement 
of nitric oxide in endothelium-dependent vasodilation may be decreased in old age.
To investigate the role Nox2-derived superoxide may have on vascular ageing and 
ageing-related endothelial dysfunction intracellular ROS levels in the aorta were 
detected by DHE fluorescence. There was an ageing-related increase in ROS in the WT 
mice which was attenuated in the Nox2'^‘ mice providing evidence that Nox2 is a major 
source of ROS in the ageing vasculature. Interestingly there was also an increase in the 
levels of ROS with ageing in the Nox2'^" mice although levels were much lower with 
DHE fluorescence in the Nox2'^' ageing mice resembling that of young WT mice. This is 
likely due to the fact that there are other sources of ROS in the vasculature.
To confirm the DHE fluorescence results superoxide production in the aorta was 
assessed by lucigenin-chemiluminescence and there was an ageing-related increase in 
superoxide production in the WT mice that was attenuated in the Nox2'^' mice which 
supports the previous findings. As with the DHE fluorescence results, superoxide in the 
Nox2'^' mice also increased with ageing but to a much lesser extent than in the WT 
mice. Experiments were then carried out in the presence or absence of the superoxide 
scavenger tiron and in WT and Nox2'^' mice at all ages there was a significant decrease 
in the level of superoxide production in the presence of tiron which provides evidence 
that superoxide is being detected rather than any other type of ROS. An inhibitor assay
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was then carried out in the WT young mice to verify that Nox2 is the major source of 
superoxide. There was no difference in superoxide production in the presence of the 
NOS inhibitor L-NAME or the xanthine oxidase inhibitor oxypurinol, however there was 
a significant decrease in the superoxide production in the presence of 
diphenyleneiodonium (DPI) which is a flavoprotein inhibitor and can inhibit NADPH 
oxidase. This further supports Nox2 as a major source of ROS in the vasculature.
The expression of Nox2 in the aorta with ageing was then investigated by 
immunofluorescence and CD31 was used as an endothelial cell marker. There was an 
increase in Nox2 expression in the endothelium with ageing in the WT mice and as 
expected no Nox2 was expressed in the Nox2'^' mice. Western blot was carried out in 
WT mice to confirm these findings and the expression of Nox2 and p22"^ "^ °^  were found 
to be increased with ageing. This provides evidence that the increased superoxide 
production with ageing may be as a result of increased expression of Nox2 in the 
ageing vasculature.
To determine whether the increase in superoxide with ageing led to a decreased 
bioavailability of nitric oxide the level of nitric oxide in the serum was assessed by 
measuring the concentration of its breakdown product nitrite. There was no difference 
in the concentration of nitrite with ageing which was unexpected. This suggests that 
the reduced ability of the vessel to relax is not just due to scavenging of nitric oxide by 
superoxide but due to damage of the endothelium by oxidative stress which then 
reduces the stimulation of endothelial nitric oxide synthase. Another possible 
explanation may be error in the measurement as nitric oxide was not directly 
measured but was assessed by measurement of its breakdown product nitrite and also
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as nitric oxide was assessed in the serum rather than its direct release from the 
endothelium by in situ measurement.
Finally we examined the general morphology of the aorta with ageing and discovered 
fragmentation of elastin in ageing WT aortas and also increased thickness of the vessel 
wall both of which may be caused by increased levels of superoxide and are likely to 
contribute to the vessel stiffening that occurs with ageing.
Taken together these findings suggest that an increased expression of Nox2 with 
ageing leads to increased levels of superoxide and oxidative stress which likely 
contribute to vascular ageing and endothelial dysfunction. Elimination of Nox2 has 
been shown here to protect the vasculature from oxidative stress and ageing-related 
endothelial dysfunction.
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Chapter 5
The effect of ageing and the role of Nox2-derived oxidative 
stress on locomotor activity and dopaminergic neuron firing
5.1 Introduction
Neurodegeneration involves the progressive loss of structure or function of neurons 
leading to dysfunction of the central nervous system and ageing is a major risk factor. 
Although the exact mechanisms behind the damage and loss of neurons with ageing 
remain unknown increasing evidence indicates that an ageing-associated increase in 
reactive oxygen species (ROS) production causes central nervous system oxidative 
stress. Increased ROS production has been demonstrated in ageing (24 months) mouse 
brains compared with young (4 months) mouse brains by dihydroethidium 
fluorescence (Quick et al., 2008) and increased oxidative stress has been found with 
ageing in rat brains as evidenced by increased levels of protein carbonyl content in 
ageing (28 months) compared to young (12 months) rats (Perluigi et al., 2010). This 
increased oxidative stress with ageing is likely to contribute to neuronal dysfunction 
and damage resulting in the development of neurodegenerative disorders.
Dopamine is an important neurotransmitter involved in the mesolimbic and 
mesocortical pathways which transmit dopamine produced in the ventral tegmental 
area (VTA) to the nucleus accumbens, limbic system and frontal cortex. These 
pathways play a vital role in locomotor movement, motivation, reward, learning and 
memory. Dopamine and its markers such as Di and D2 receptors and dopamine
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transporters (DAT) have been shown to be decreased with ageing in various areas of 
the brain including the striatum, frontal cortex, temporal cortex, parietal cortex and 
occipital cortex, hippocampus, amygdala and thalamus (Backman et al., 2006). This 
ageing-related decline in dopamine has been shown to be strongly associated with a 
decline in episodic (long-term) memory in a human study investigating young (18-35 
years) and ageing (63-79 years) participants (Morcom et al., 2010). Decreased 
dopamine levels with ageing has also been shown to be associated with a decline in 
locomotor activity in rats (Salvatore et al., 2009).
Nox2 has been identified as a major source of oxidative stress in the brain and has 
been shown to play an important role in several ageing-related neurodegenerative 
diseases such as cerebrovascular impairment, mild-cognitive impairment, Alzheimer's 
disease and Parkinson's disease (Ansari and Scheff, 2011; Park et al., 2007; Wu et al., 
2003). Additionally, increased Nox2 expression and activity and subsequent increased 
superoxide production were found in the brain of ageing mice in association with 
cognitive decline (Dugan et al., 2009).
The exact mechanisms behind decreased locomotor activity and decreased dopamine 
levels with ageing are unknown therefore this study focuses on elucidating the role of 
Nox2 and oxidative stress in locomotor activity and dopaminergic neuron firing with 
ageing. Groups of young (3-4 months), middle aged (10-12 months) and ageing (20-22 
months) Nox2 null (Nox2’ '^) mice and their wild-type (WT) controls were assessed for 
locomotor activity, dopaminergic neuron firing and superoxide production. Human 
brain samples at young (25-38 years), middle aged (46-60 years) and ageing (75-76 
years) were also assessed for superoxide production.
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5.1.1 Aims and objectives
The aim of this chapter was to uncover the role of Nox2-derived oxidative stress on 
locomotor activity and dopaminergic neuron firing with ageing, therefore the 
objectives were:
1. To investigate diurnal horizontal and vertical locomotor activity with ageing and 
determine the effect of Nox2 deletion
2. To assess dopaminergic neuron firing frequency with ageing and determine the 
effect of Nox2 deletion
3. To measure the level of superoxide production with ageing and determine 
whether it can be attenuated by deletion of Nox2
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5.2 Results
5.2.1 The role of Nox2 on diurnal horizontal activity with ageing
The diurnal horizontal activity of young (3-4 months), middle aged (10-12 months) and 
ageing (20-22 months) WT and Nox2’ ’^ C57BI/6 mice was investigated using motility 
chambers. There was no difference in the diurnal horizontal activity between the WT 
and Nox2'^' young mice which both displayed high activity during the dark 'active' 
period and much lower activity during the light period. There was also no difference in 
the diurnal horizontal activity between the WT and Nox2 '^ ' middle aged mice during 
the first 24 hours, however there was a small difference in activity during the second 
dark 'active' period with WT middle aged mice displaying lower activity than their 
Nox2'^" counterparts. In ageing mice there was a difference in activity between the WT 
and Nox2 '^ ‘ mice during both the first and second dark 'active' periods and also a 
difference in activity from when the mice were first introduced to the cage and were 
exploring their new environment. In both cases WT ageing mice exhibited lower 
activity than their Nox2'^' counterparts.
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Figure 5.1 The role of Nox2 on diurnal horizontal activity with ageing
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Legend to figure 5.1
Horizontal locomotor activity was measured in young (3-4 months), middle aged (10- 
12 months) and ageing (20-22 months) mice using motility chambers. The data was 
collected in 30-minute bins over a 42 hour period beginning immediately after placing 
the animals in the cage which was 3 hours before the start of the dark cycle.
(A) Diurnal horizontal activity profile of young WT (open circles) and Nox2'^‘ (filled 
circles) C57BI/6 mice. Data are expressed as mean ± SEM with a number of 8-9 mice 
per group. The shaded background represents the dark, i.e. active, phase of the mice's 
12:12 hour light dark cycle.
(B) Diurnal horizontal activity profile of middle-aged WT (open circles) and Nox2'^' 
(filled circles) C57BI/6 mice. Data are expressed as mean ± SEM with a number of 11- 
12 mice per group. The shaded background represents the dark, i.e. active, phase of 
the mice's 12:12 hour light dark cycle.
(C) Diurnal horizontal activity profile of ageing WT (open circles) and Nox2'^' (filled 
circles) C57BI/6 mice. Data are expressed as mean ± SEM with a number of 8-10 mice 
per group. The shaded background represents the dark, i.e. active, phase of the mice's 
12:12 hour light dark cycle.
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5.2.2 The role of Nox2 on diurnal vertical activity with ageing
The vertical or 'rearing' activity of young (3-4 months), middle aged (10-12 months) 
and ageing (20-22 months) WT and Nox2'^' C57BI/6 mice was investigated using 
motility chambers. Vertical 'rearing' activities of all the mice were generally much 
lower than horizontal activities. There was no difference in the diurnal vertical activity 
between the WT and Nox2'^' young mice which both displayed higher activity during 
the dark 'active' period and very low activity during the light period. There was also no 
difference in the diurnal vertical activity between the WT and Nox2'^' middle aged and 
ageing mice which also displayed higher activity during the dark 'active' period and 
very low activity during the light period. Initial activity in response to the new 
environment was similar in all mice.
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Figure 5.2 The role of Nox2 on diurnal vertical activity with ageing
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Legend to figure 5.2
Vertical locomotor activity was measured in young (3-4 months), middle aged (10-12 
months) and ageing (20-22 months) mice using motility chambers. The data was 
collected in 30-minute bins over a 42 hour period beginning immediately after placing 
the animals in the cage which was 3 hours before the start of the dark cycle.
(A) Diurnal vertical activity profile of young WT (open circles) and Nox2'^' (filled circles) 
C57BI/6 mice. Data are expressed as mean ± SEM with a number of 8-9 mice per 
group. The shaded background represents the dark, i.e. active, phase of the mice's 
12:12 hour light dark cycle.
(B) Diurnal vertical activity profile of middle-aged WT (open circles) and Nox2'^' (filled 
circles) C57BI/6 mice. Data are expressed as mean ± SEM with a number of 11-12 mice 
per group. The shaded background represents the dark, i.e. active, phase of the mice's 
12:12 hour light dark cycle.
(C) Diurnal vertical activity profile of ageing WT (open circles) and Nox2'^' (filled circles) 
C57BI/6 mice. Data are expressed as mean ± SEM with a number of 8-10 mice per 
group. The shaded background represents the dark, i.e. active, phase of the mice's 
12:12 hour light dark cycle.
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5.2.3 The role of Nox2 on total horizontal and vertical activities with
ageing
The horizontal and vertical activities of young (3-4 months), middle aged (10-12 
months) and ageing (20-22 months) WT and Nox2'" '^ C57BI/6 mice were investigated 
using motility chambers and the sum of the total activity over 42 hours was assessed. 
There was a decrease in the total horizontal activity in middle-aged WT mice compared 
to young mice (85 ± 5 % versus 100 ± 5 % p>0.05) but this was not significant. Total 
horizontal activity decreased further with advancing age and there was a significant 
decrease in the total horizontal activity in WT ageing mice compared to young mice (56 
± 6 versus 100 ± 5 % *p<0.05). There was no difference in the total horizontal activity 
with ageing in the Nox2 '^ ' mice which displayed similar activities in all age groups 
(young: 95 ± 5 %; middle aged: 100 ± 8 %; ageing: 92 ± 3 % p>0.05). In regard to effect 
of genotype there was a significant difference in the total horizontal activity in WT 
ageing mice compared to Nox2’^ ' ageing mice (56 ± 6 versus 92 ± 3 % ^p<0.05).
There was a decrease in total vertical activity in middle-aged WT mice compared to 
young mice (88 ± 10 versus 100 ± 10 % p>0.05) but this was not significant. Total 
vertical activity decreased further in ageing mice compared to young mice (73 ± 13 
versus 100 ± 10 % p>0.05) however this was still not significant. There was no 
difference in the total vertical activity with ageing in the Nox2'^' mice which displayed 
similar activities in all age groups (young: 90 ± 6 %; middle aged: 101 ± 20 %; ageing: 97 
± 7 %).
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Figure 5.3 The role of Nox2 on total horizontal and vertical activity with
ageing
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Legend to figure 5.3
Horizontal and vertical locomotor activity was measured in young (3-4 months), middle 
aged (10-12 months) and ageing (20-22 months) mice using motility chambers. The 
data was collected in 30-minute bins over a 42 hour period beginning immediately 
after placing the animals in the cage which was 3 hours before the start of the dark 
cycle. Total activity was calculated as the sum of the activity over the 42 hour period 
and displayed as a percentage of the young WT value.
(A) Total horizontal activity of WT (open bars) and Nox2'^' (filled bars) C57BI/6 mice. 
Data are expressed as mean ± SEM with a number of 8-12 mice per group. 
Comparisons were made by two-way ANOVA with bonferroni post-hoc test. *p<0.05 
versus young mice **p<0.05 versus age-matched WT mice.
(B) Total vertical activity of WT (open bars) and Nox2“'^ ‘ (filled bars) C57BI/6 mice. Data 
are expressed as mean ± SEM with a number of 8-12 mice per group. Comparisons 
were made by two-way ANOVA with bonferroni post-hoc test.
149
5.2.4 The effect of ageing and the role of Nox2 on brain weight
The brain weight of young (3-4 months), middle aged (10-12 months) and ageing (20- 
22 months) WT and Nox2'^' C57BI/6 mice was measured to investigate any possible 
brain shrinkage with ageing. There were no differences in brain weight across all age 
groups in both WT and Nox2'^' mice.
Figure 5.4 The effect of ageing and the role of Nox2 on brain weight
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Legend to figure 5.4
Brain weight of young (3-4 months), middle aged (10-12 months) and ageing (20-22 
months) male WT (open bars) and Nox2'^' (filled bars) C57BI/6 mice. Data are 
expressed as mean ± SEM with a number of at least 6 mice per group. Comparisons 
were made by two-way ANOVA with bonferroni post-hoc test.
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5.2.5 The role of Nox2 on firing of dopaminergic neurons with ageing
The firing of dopaminergic neurons in the ventral tegmental area (VTA) region of the 
midbrain was investigated by extracellular electrophysiology in young (3-4 months), 
middle aged (10-12 months) and ageing (20-22 months) WT and Nox2'^’ C57BI/6 mice. 
Basal neuron firing frequency decreased with advancing age in WT mice with a 
significant decrease already seen in middle aged mice compared to young mice (1.1 ± 
0.1 versus 1.8 ± 0.1 Hz *p<0.05) which persisted in ageing mice (1.0 ± 0.2 versus 1.8 ± 
0.1 Hz *p<0.05). There was no difference in basal neuron firing activity with ageing in 
Nox2‘'^ * mice which exhibited similar neuron firing frequencies in all age groups (young:
1.7 ± 0.2 Hz, middle aged: 1.6 ± 0.1 Hz; ageing: 1.7 ± 0.1 Hz p>0.05). With regard to 
effect of genotype there was a difference in the neuron firing frequency between WT 
and Nox2 '^ ‘ middle age mice (1.1 ± 0.1 versus 1.6 ± 0.1 Hz p>0.05) and ageing mice (1.0 
± 0.2 versus 1.7 ± 0.1 Hz p>0.05) although these differences were not significant.
AMPA (2-amino-3-(3-hydroxy-5-methyl-isoxazol-4-yl)propanoic acid) stimulated 
neuron firing frequency was found to be decreased with ageing in WT mice. Decreases 
were seen in middle aged mice compared to young (3.3 ± 0.3 versus 3.8 ± 0.3 Hz 
p>0.05) and ageing mice compared to young (2.6 ± 0.1 versus 3.8 ± 0.3 Hz p>0.05) 
however these difference were not significant. AMPA stimulated neuron firing 
remained much more similar with ageing in Nox2‘'^ ‘ mice (young: 3.7 ± 0.3 Hz, middle 
aged: 4.2 ± 0.3 Hz; ageing: 4.1 ± 0.7 Hz p>0.05). There were differences seen between 
the WT and Nox2'^' mice at middle age (3.3 ± 0.3 versus 4.2 ± 0.3 Hz p>0.05) and ageing 
(2.6 ± 0.1 versus 4.1 ± 0.7 Hz p>0.05) although again this was not significant.
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Figure 5.5 The role of Nox2 on firing of dopaminergic neurons with
ageing
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Legend to figure 5.5
Dopaminergic (DA) neuron firing frequency was measured in the ventral tegmental 
area (VTA) of young (3-4 months), middle aged (10-12 months) and ageing (20-22 
months) mice by extracellular electrophysiology. Basal firing frequency was first 
recorded before addition of the glutamate agonist AMPA (2-amino-3-(3-hydroxy-5- 
methyl-isoxazol-4-yl)propanoic acid) to determine the AMPA-stimulated firing peak.
(A) Basal DA neuron firing frequency of WT (open bars) and Nox2'^' (filled bars) C57BI/6 
mice. Data are expressed as mean ± SEM with a number of 14 cells recorded from 5-7 
mice in the young group, 10-11 cells recorded from 6-7 mice in the middle aged group 
and 5-7 cells recorded from 3 mice in the ageing group (N.B. Data from the ageing 
group was collected with the help of Dr Ying Chen). Comparisons were made by two- 
way ANOVA with bonferroni post-hoc test *p<0.05 versus young mice.
(B) AMPA-stimulated DA neuron firing frequency of WT (open bars) and Nox2'" '^ (filled 
bars) C57BI/6 mice. Data are expressed as mean ± SEM with a number of 7-11 cells 
recorded from 5-7 mice in the young group, 10 cells recorded from 6-7 mice in the 
middle aged group and 3-6 cells recorded from 3 mice in the ageing group (N.B. Data 
from the ageing group was collected with the help of Dr Ying Chen). Comparisons were 
made by two-way ANOVA with bonferroni post-hoc test.
(C) and (D) Representative traces of the DA neuron firing frequency of WT and Nox2‘ '^ 
middle aged mice respectively. Basal firing frequency is displayed in the first 10 
minutes before an AMPA-stimulated firing peak which is washed out after 6 minutes to 
allow firing to return to normal.
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5.2.6 The role of Nox2 on ROS production in the ageing brain detected by 
lucigenin chemiluminescence
The reactive oxygen species (ROS) production in mid brain homogenates of young (3-4 
months), middle aged (10-12 months) and ageing (20-22 months) WT and Nox2'^' 
C57BI/6 mice was assessed by lucigenin chemiluminescence. There was a significant 
increase in ROS production in middle aged WT mid brain homogenates compared with 
young WT controls (457.9 ± 53.2 versus 180.5 ± 21.2 MLU *p<0.05). ROS production 
increased further with advancing age with even higher ROS levels in the mid brain of 
ageing mice compared to young mice (643.1 ± 78.4 versus 180.5 ± 21.2 MLU *p<0.05). 
There was no difference in ROS production with ageing in Nox2'^' mice with similar ROS 
levels detected in all age groups (young: 122.6 ± 23.0; middle aged: 138.1 ± 21.5; 
ageing: 128.6 ± 24.3 MLU p>0.05). Regarding effect of genotype there was a significant 
difference in ROS production between WT and Nox2‘ ‘^ mice at middle age (457.9 ± 53.2 
versus 138.1 ± 21.5 MLU ^p<0.05) and ageing (643.1 ± 78.4 versus 128.6 ± 24.3 MLU 
V<0.05).
To confirm that superoxide is the major type of ROS being produced lucigenin 
chemiluminescence was carried out in the presence or absence of 20 mM of the 
superoxide scavenger tiron. There was a significant decrease in ROS production in the 
WT mid brain homogenates in the presence of tiron at young (13.2 ± 2.2 versus 180.5 ± 
21.2 MLU ^p<0.05), middle age (9.8 ± 2.3 versus 457.9 ± 53.2 MLU *^p<0.05) and ageing 
(31.7 ± 4.7 versus 643.1 ± 78.4 MLU ^p<0.05). There was also a significant decrease in 
ROS production in the Nox2'' '^ mid brain homogenates in the presence of tiron at young
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(8.0 ± 2.1 versus 122.6 ± 23.0 MLU **p<0.05), middle age (10.1 ± 1.7 versus 138.1 ± 21.5 
MLU ^p<0.05) and ageing (20.9 ± 5.4 versus 128.6 ± 24.3 MLU *^p<0.05).
An inhibitor assay was carried out to determine the source of superoxide in ageing WT 
mice. Mid brain homogenates were incubated with either buffer, 100 pM of the nitric 
oxide synthase (NOS) inhibitor Nw-Nitro-L-arginine methyl ester (L-NAME), 100 pM of 
the xanthine oxidase inhibitor oxypurinol (oxy), 20 pM of the NADPH oxidase inhibitor 
diphenyleneiodonium (DPI) or 20 mM of tiron. There was a significant decrease in ROS 
production in the presence of L-NAME (432.9 ± 50.5 versus 613.1 ± 14.8 MLU *p<0.05), 
DPI (143.0 ± 7.3 versus 613.1 ± 14.8 MLU *p<0.05) or tiron (1.8 ± 0.5 versus 613.1 ±
14.8 MLU *p<0.05) but not in the presence of oxypurinol.
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Figure 5.6 The role of Nox2 on ROS production in the mouse brain at 
different ages detected by lucigenin chemiluminescence
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Legend to figure 5.6
ROS production in homogenates of the mid-brain region of the mice was detected by 
NADPH-dependant lucigenin (5 pM) chemiluminescence.
(A) ROS production in young (3-4 months), middle aged (10-12 months) and ageing 
(20-22 months) male WT (open bars) and Nox2'^' (filled bars) C57BI/6 mice. Data are 
expressed as mean ± SEM with a number of 6 mice per group. Comparisons were made 
by two-way ANOVA with bonferroni post-hoc test *p<0.05 versus young mice ^p<0.05 
versus age-matched WT mice.
(B) ROS production in young (3-4 months), middle aged (10-12 months) and ageing (20- 
22 months) male WT C57BI/6 mice in the presence (filled bars) or absence (open bars) 
of 20 mM of the superoxide scavenger tiron. Data are expressed as mean ± SEM with a 
number of 6 mice per group. Comparisons were made by two-way ANOVA with 
bonferroni post-hoc test *p<0.05 versus young mice **p<0.05 tiron versus control.
(C) Inhibitor assay in ageing (20-22 months) WT C57BI/6 mice to confirm source of 
superoxide. Homogenates were incubated with 100 pM L-NAME, 100 pM oxypurinol 
(Oxy), 20 pM diphenyleneiodonium (DPI) or 20 mM tiron for 15 minutes before 
measurement of superoxide production by NADPH-dependant lucigenin 
chemiluminesence. Data are expressed as mean ± SEM with a number of 3 
measurements. Comparisons were made by one-way ANOVA with bonferroni post-hoc 
test *p<0.05 versus vehicle.
(D) ROS production in young (3-4 months), middle aged (10-12 months) and ageing 
(20-22 months) male Nox2'^' C57BI/6 mice in the presence (filled bars) or absence
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(open bars) of 20 mM of the superoxide scavenger tiron. Data are expressed as mean ± 
SEM with a number of 6 mice per group. Comparisons were made by two-way ANOVA 
with bonferroni post-hoc test ^p<0.05 tiron versus control.
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5.2.7 The role of Nox2 on ROS production in the ageing human brain 
detected by lucigenin chemiluminescence
The reactive oxygen species (ROS) production in young (25-38 years), middle aged (46- 
60 years) and ageing (75-76 years) human brain samples was assessed by lucigenin 
chemiluminescence. There was a significant increase in ROS production in ageing 
human brain homogenates compared with young controls (120.0 ± 32.0 versus 65.7 ±
11.9 MLU *p<0.05). To confirm that superoxide is the major type of ROS being 
produced lucigenin chemiluminescence was also carried out in the presence of 20 mM 
of the superoxide scavenger tiron. There was a significant decrease in ROS production 
in the human brain homogenates in the presence of tiron at young (19.3 ± 4.2 versus
65.7 ± 11.9 MLU **p<0.05), middle age (20.7 ± 4.1 versus 77.2 ± 8.9 MLU **p<0.05) and 
ageing (33.0 ± 16.0 versus 120.0 ± 32.0 MLU **p<0.05).
An inhibitor assay was carried out to determine the source of superoxide in ageing 
human brain samples. Brain homogenates were incubated with either buffer, 100 pM 
of the nitric oxide synthase (NOS) inhibitor Nw-Nitro-L-arginine methyl ester (L-NAME), 
100 pM of the xanthine oxidase inhibitor oxypurinol (oxy), 20 pM of the NADPH 
oxidase inhibitor diphenyleneiodonium (DPI) or 20 mM of tiron. There was a significant 
decrease in ROS production in the presence of DPI (14.0 ± 3.1 versus 119.7 ± 8.8 MLU 
*p<0.05) or tiron (1.6 ± 0.6 versus 119.7 ± 8.8 MLU *p<0.05) but not in the presence of 
L-NAME or oxypurinol.
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Figure 5.7 The role of Nox2 on ROS production in the human brain at 
different ages detected by lucigenin chemiluminescence
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Legend to figure 5.7
ROS production in homogenates of the ventral tegmental area (VTA) region of the 
human brain was detected by NADPH-dependant lucigenin (5 pM) chemiluminescence.
(A) ROS production in young (25-38 years), middle aged (46-60 years) and ageing (75- 
76 years) human brain samples in the presence (filled bars) or absence (open bars) of 
20 mM of the superoxide scavenger tiron. Data are expressed as mean ± SEM with a 
number of 2-5 brains per group. Comparisons were made by two-way ANOVA with 
bonferroni post-hoc test *p<0.05 versus young samples ^p<0.05 tiron versus control.
(B) Inhibitor assay in ageing (75-76 years) human brain tissue to confirm source of 
superoxide. Homogenates were incubated with 100 pM L-NAME, 100 pM oxypurinol 
(Oxy), 20 pM diphenyleneiodonium (DPI) or 20 mM tiron for 15 minutes before 
measurement of superoxide production by NADPH-dependant lucigenin 
chemiluminesence. Data are expressed as mean ± SEM with a number of 3 
measurements. Comparisons were made by one-way ANOVA with bonferroni post-hoc 
test *p<0.05 versus vehicle.
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5.3 Discussion
In this chapter, the effect of ageing on locomotor activity and dopaminergic neuron 
firing frequency has been investigated with particular focus on the role of Nox2- 
derived oxidative stress. Wild-type (WT) and Nox2 null (Nox2'^') C57BI/6 mice were 
grouped into young (3-4 months), middle age (10-12 months) and ageing (20-22 
months) and were assessed for horizontal and vertical activities, neuron firing and 
superoxide production. Human brain samples were also assessed for superoxide 
production in young (25-38 years), middle aged (46-60 years) and ageing (75-76 years) 
post-mortem brains.
Firstly, horizontal and vertical Tearing' activities were recorded over a 42 hour period 
and initial activities were high in all groups of mice as they explored their new 
environment. The diurnal rhythm of all groups of mice for both horizontal and vertical 
activity was very similar and after the high initial activity the activity of the mice 
decreased until the end of the light Testing' phase. At the onset of the dark 'active' 
phase of the diurnal cycle activities increased rapidly and peaked before a gradual 
decline towards the second half of the dark phase. A secondary peak in activity was 
present in all the groups of mice just before the beginning of the light 'resting' phase 
throughout which activity levels remained low. The second dark 'active' phase 
recorded showed a similar trend with 2 peaks in both horizontal and vertical activities.
The total horizontal activity was not different between the young WT and Nox2'^‘ mice, 
however by middle aged there was a slight decrease in activity in the WT mice which 
was not seen in the Nox2’'^ ’ mice. With advancing age the horizontal activity in WT mice
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decreased further with a significant difference identified in total activity between the 
young and ageing mice. In contrast the total horizontal activity was preserved with 
ageing in the Nox2'^' mice. The total vertical activity exhibited a decreasing trend with 
ageing in WT mice but this effect was not significant. No difference was seen in the 
total vertical activity with aging in Nox2'" '^ mice. Taken together these findings suggest 
that Nox2 plays an important role in horizontal activity with ageing and may be 
targeted to help improve activity with advancing age.
Dopaminergic neuron firing frequency was then assessed and a decreased basal firing 
frequency was displayed in the WT mice with advancing age. In fact a significant 
difference was already present by middle age which persisted with ageing. Elimination 
of Nox2 protected basal dopaminergic neuron firing with ageing with preserved 
neuron firing frequency in middle aged and ageing Nox2'" '^ mice. The brain slices were 
then perfused with the glutamate agonist AMPA (2-amino-3-(3-hydroxy-5-methyl- 
isoxazol-4-yl)propanoic acid) which causes an excitatory response. AMPA-stimulated 
firing was decreased with ageing in the WT mice although this was not significant. In 
the Nox2'^' mice no difference was seen in the AMPA-stimulated neuron firing with 
ageing. This evidence supports a role for Nox2 in the mechanisms behind the ageing- 
related decreases in dopaminergic neuron firing which subsequently is likely to play a 
key role in the phenomenon of reduced dopamine levels with ageing.
To investigate the possible role of Nox2-derived superoxide production on locomotor 
activity and dopaminergic neuron firing, superoxide levels in the mid brain were 
determined by lucigenin-chemiluminescence. There was an ageing-related increase in 
superoxide production in the WT mice which was completely attenuated in the Nox2'^‘
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mice providing evidence that Nox2 is a major source of superoxide in the brain. In the 
presence of the superoxide scavenger tiron superoxide production in WT mice was 
significantly reduced at all age groups. Even in the Nox2'^' mice tiron significantly 
reduced superoxide levels in all age groups which provides evidence that it is 
superoxide that is being detected. An inhibitor assay was then carried out in the WT 
ageing mice to verify that Nox2 is the major source of superoxide. There was no 
difference in superoxide production in the presence of the xanthine oxidase inhibitor 
oxypurinol, however there was a significant decrease in the superoxide production in 
the presence of diphenyleneiodonium (DPI) which is a flavoprotein inhibitor and can 
inhibit NADPH oxidase. This further supports Nox2 as a major source of ROS in the 
ageing brain. Interestingly there was also a significant decrease in superoxide 
production in the presence of the NOS inhibitor L-NAME, although to a much lesser 
extent, suggesting that dysfunctional NOS may also be producing superoxide to some 
degree.
To support that increased ROS and oxidative stress occurs with ageing in humans as 
well as in mice the superoxide production in young, middle aged and ageing human 
brain tissue was investigated. Superoxide production was significantly increased in 
ageing brain samples compared to young controls and the superoxide scavenger tiron 
significantly decreased superoxide production at all age groups confirming specificity 
for superoxide. An inhibitor assay was then carried out in the ageing brain samples and 
there was no difference in superoxide production in the presence of L-NAME or 
oxypurinol. However there was a significant decrease in the superoxide production in
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the presence of DPI which supports that Nox2 is the major source of superoxide in the 
ageing brain.
Overall these findings support a major role of Nox2 in ageing-related oxidative stress 
and deletion of Nox2 has been shown in this study to protect the ageing brain from 
oxidative stress and to prevent a reduction in locomotor activity and a decrease in 
dopaminergic neuron firing frequency.
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Chapter 6 
General discussion and future work
6.1 Discussion
The NADPH oxidase isoform Nox2 has long been recognised as a major source of 
superoxide production in the vasculature and widespread evidence has shown that 
Nox2-derived oxidative stress plays a key role in the development of various 
cardiovascular diseases (Judkins et al., 2010; Li and Shah, 2004; Li et al., 2007, 2002; 
Looi et al., 2008; Colin E Murdoch et al., 2011; Sukumar et al., 2013). Nox2 has also 
been seen to be widely expressed throughout the central nervous system and plays a 
major role in the development of neurodegenerative diseases (Hernandes and Britto, 
2012; Park et al., 2008; Qin et al., 2013; Sorce and Krause, 2009). However the effects 
of Nox2 with ageing are not well understood and therefore this PhD research project 
has focused on investigating the role of Nox2-derived superoxide and oxidative stress 
on ageing-induced metabolic syndrome, endothelial dysfunction and 
neurodegeneration.
Obesity, insulin resistance and hyperlipidaemia are strong risk factors for the 
development of cardiovascular diseases and have all been shown in this study to 
increase with ageing. Obesity was present by middle age in the WT mice and continued 
with ageing which corresponds to other studies in ageing mice which have displayed 
increases in bodyweight at middle age (10 months) and ageing (approx 22 months) 
(Bjursell et al., 2013; Jeon et al., 2006). Ageing related obesity in WT mice was
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accompanied by insulin resistance and hyperlipidaemia, both of which are strongly 
associated with obesity (Akiyama et al., 1996; Casanueva et al., 2010; Kahn et al.,
2006). Hyperlipidaemia and insulin resistance has also been shown with advancing age 
in humans with increased lipid levels in ageing (65 years) compared to young (32 and 
36 years) subjects (James et al., 2006; Singh et al., 2002) and development of insulin 
resistance in ageing (70 years) compared to young (27 years) subjects (Petersen et al., 
2003). Oxidative stress has widely been implicated in the development of obesity, 
insulin resistance and hyperlipidaemia and in diabetic mice increased bodyweight, 
plasma glucose, cholesterol and triglyceride levels were evident alongside increases in 
superoxide production and the lipid peroxidation marker malondialdehyde 
(Pannirselvam et al., 2005). In this study ROS levels were seen to be increased with 
ageing in association with increased expression of Nox2 in the aorta which further 
supports a role for oxidative stress in the development of obesity, insulin resistance 
and hyperlipidaemia and suggests that Nox2 may be an important source. Therefore 
obesity, insulin resistance and hyperlipidaemia were investigated in Nox2'^' mice and 
removal of this superoxide generating enzyme prevented the development of obesity, 
insulin resistance and hyperlipidaemia with ageing. These findings that elimination of 
Nox2 affords protection on the cardiovascular system are supported by other recent 
findings which demonstrated decreased superoxide production and attenuated high- 
fat diet induced obesity, insulin resistance and hyperlipidaemia in Nox2'^' mice (Du et 
al., 2013).
Hypertension is another major cardiovascular disease risk factor and WT mice have 
been shown in this study to develop hypertension with advancing age and in particular
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an increase in systolic and diastolic blood pressure was seen from middle age which 
persisted with ageing. This corresponds to data from human subjects in which blood 
pressure is increased with ageing (Franklin et al., 2001, 1997). Several studies have 
shown that oxidative stress is a major pathogenic factor in the development of 
hypertension (Briones and Touyz, 2010; Ceriello, 2008) but the primary source of ROS, 
particularly with ageing is still unclear. Elimination of Nox2 was found to protect 
against ageing-induced hypertension with both systolic and diastolic blood pressure 
remaining stable throughout all age groups in Nox2'^' mice. These results are in 
agreement with data from other studies investigating different models of hypertension 
where elimination of Nox2 attenuates or prevents the development of high blood 
pressure. In high-fat diet fed mice elimination of Nox2 protected against increased 
systolic blood pressure (Du et al., 2013), and in angiotensin II infused mice elimination 
of p47^ *^ °^  or treatment with the Nox inhibitor gp91ds-tat also prevented the 
development of hypertension (Landmesser et al., 2002; Rey et al., 2001).
There is a strong link between hypertension and endothelial dysfunction however it is 
not fully elucidated which one precedes the other with studies supporting evidence for 
both arguments (Quyyumi and Patel, 2010; Rossi et al., 2004; Shimbo et al., 2010). In 
this study we have observed the presence of both hypertension and endothelial 
dysfunction at middle age (10-12 months) in WT mice, however only the increase in 
blood pressure reached significance which supports that hypertension is a cause rather 
than a consequence of endothelial dysfunction. In very old (20-22 months) mice both 
hypertension and endothelial dysfunction were worsened. Another cause of 
endothelial dysfunction which is widely acknowledged is insulin resistance.
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Accelerated endothelial dysfunction has been demonstrated in insulin receptor knock­
out (IRKO) mice which are a model of mild insulin resistance in comparison to wild- 
type controls in association with an increase in superoxide production (Duncan et al.,
2007). In a more recent study using two in vivo models of human insulin resistance, 
mice with either endothelial-specific mutated human insulin receptor overexpression 
(ESMIRO) or with haploinsufficiency of the insulin receptor (IR^ '^ ') developed 
endothelial dysfunction which was associated with increased levels of superoxide and 
increased Nox2 expression. Treatment with the Nox inhibitor gp91ds-tat in both 
ESMIRO and IR^ '^ mice and knockout of Nox2 in the ESMIRO mice improved endothelial 
function and reduced superoxide levels (Sukumar et al., 2013). The above findings 
strongly support a role for Nox2-derived oxidative stress in the development of 
endothelial dysfunction in a model of insulin resistance, however less is known about 
the role of Nox2 in the development of endothelial dysfunction with ageing. In this 
study we have discovered a crucial role of Nox2-derived superoxide production in the 
development of both insulin resistance and endothelial dysfunction as evidenced by 
reduced superoxide production and a preservation of these cardiovascular pathologies 
in Nox2 '^ ' ageing mice.
To further investigate the mechanisms behind ageing-related endothelial dysfunction 
we assessed the importance of the production of nitric oxide (NO) from endothelial 
nitric oxide synthase (eNOS) in vessel relaxation. Aortic vessels did not generally relax 
in the presence of an eNOS inhibitor which confirms that the relaxation was NO 
dependent. However in ageing mice the vessel did relax moderately in the presence of 
the eNOS inhibitor which suggests that there is a decline in the involvement of NO in
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endothelium-dependent vasodilation with ageing. A study has demonstrated that 
endothelium-derived hyperpolarising factor (EDHF) may serve as a back-up mechanism 
in ageing to help dilate the vessel when the NO pathway is impaired, however it does 
not fully restore function as endothelial dysfunction was still present in ageing mice 
(Gaubert et al., 2007). Decreased bioavailability of NO with ageing has been widely 
reported (Francia et al., 2004; van der Loo et al., 2000) however in this study we did 
not find a difference in nitric oxide levels with ageing. This suggests that the reduced 
ability of the vessel to relax is not just due to scavenging of nitric oxide by superoxide 
but also due to damage of the endothelium by oxidative stress which then reduces the 
stimulation of endothelial nitric oxide synthase. The reason for the difference between 
our results and those reported by Francia and Van der Loo may be due to the fact that 
we indirectly measured nitric oxide in the serum whereas in these reports direct in situ 
measurements of nitric oxide in the aorta were carried out.
In the present study elimination of Nox2 prevented ageing mice from developing 
obesity despite the fact that there was no difference in food intake between the WT 
and Nox2‘ '^ mice at any age. This led us to investigate the activity of the mice with 
ageing and the diurnal rhythm of the mice was found to be similar in both WT and 
Nox2'^" mice at all age groups and followed the rhythm reported in the literature for 
the C57BI/6 strain (Kopp, 2001; Nishi et al., 2010). We discovered that the total 
horizontal activity was decreased in WT ageing mice which is supported by results in 
the literature showing a decrease in activity between young (6 months) and ageing (18 
months) mice (Jeon et al., 2006). Activity of the ventral tegmental area (VTA) 
dopaminergic neurons has been shown to play a role in locomotor activity in
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association with motivational signals (Wang and Tsien, 2011). In our study a decline in 
locomotor activity with ageing in WT mice was accompanied by a decrease in 
dopaminergic neuron firing frequency in the VTA. This decrease in neuron firing was 
associated with an increase in superoxide production which was demonstrated in the 
mid-brain of the WT ageing mice and confirmed in the VTA region of ageing post­
mortem human brains. Ageing Nox2" '^ mice displayed preserved locomotor activity and 
dopaminergic neuron firing with ageing accompanied by a significant decrease in 
superoxide production in the mid-brain. These findings strongly support a role of Nox2- 
derived oxidative stress in the ageing-related decline of locomotor activity and ageing- 
related neurodegeneration in particular dysfunction of dopaminergic neurons in the 
VTA.
In conclusion, the research presented in this thesis provides strong evidence for the 
first time that ageing-related endothelial Nox2 activation and oxidative stress play an 
important role in the development of obesity, insulin resistance, hyperlipidaemia, 
hypertension, endothelial dysfunction and neurodegeneration in old-age. Deletion of 
Nox2 has been shown to protect against these ageing-related abnormalities and 
diseases by reducing levels of oxidative stress and preserving endothelial function. 
Targeting Nox2 activation represents a valuable therapeutic strategy to treat these 
ageing-related diseases.
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6.2 Future work
This research provides a thorough investigation into the role of Nox2-derived oxidative 
stress in the ageing vascular system but has really only touched on the role it plays in 
the central nervous system (CNS). Therefore the next step will be to further elucidate 
the role of Nox2 in the CNS by:
•  Investigating Nox2 expression in the different regions of the brain with ageing 
along with other NADPH oxidase isoforms and subunits
•  Carrying out further behavioural experiments such as those which 
demonstrate reward and motivation
•  Further uncovering the link between vascular oxidative stress and the role on 
neurodegeneration and cerebrovascular disease
Further investigation should also be focused on of the exact mechanisms behind the 
effect of Nox2-derived oxidative stress in the ageing vasculature. In particular it would 
be interesting to elucidate the redox signalling mechanisms involved with focus on the 
most common downstream targets of Nox2-derived ROS including the mitogen- 
activated protein kinases (MARK) such as the extracellular signal-regulated kinase 
(ERK), c-Jun N-terminal kinase (JNK) and p38MAPK.
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